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ABSTRACT 
Background 
Chronic venous disease is a common, distressing and significant cause of health care expense. There have 
been few developments in the treatment of deep venous disease as the understanding of the clinical and 
pathophysiological significance of deep vein reflux and valve failure remains poor. Previous attempts to 
develop a prosthetic vein valve implant have been disappointing. Difficulties with early thrombosis led 
researchers to abandon their efforts many years ago.  Attempts to create a valve implant should be 
revisited. 
Aims 
The aims of this project are to:  evaluate variables around normal deep vein valves, to develop validated 
computational and laboratory flow models for deep venous function, and to develop and investigate a 
novel material to engineer a prototype bioprosthetic deep vein valve replacement.  
Methods     
Functional Anatomy: This is a prospective observational study evaluating subjects with normal deep 
veins.  B and M Mode ultrasound, contrast (microbubble) enhanced ultrasound and dynamic magnetic 
resonance imaging of normal subjects was carried out. This has given the flow, velocity data and 
anatomical images required for the project.   
Modelling: A preliminary computational flow model has been developed using the data obtained from the 
imaging stage of the project.  This is a 2-dimensional model incorprating flexible valve leaflets.  A 
laboratory model of venous function, in the form of a flow rig has been created.   
Materials:  Presently, polymers and polymer coated metal stents, used in the vascular system have several 
problems: they are very thrombogenic and they lack haemocompatibilty and biocompatibility, in addition 
they lack the required mechanical properties.  A novel material that is biocompatible, a copolymer of 
methacrylolyoxyethyl phosphorylcholine (MPC), trimethylsilyl-2-propyl methacrylate (TMSPMA) and 
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Hydroxypropyl methacrylate (HPMA), has been synthesised.  Its properties have been modified by 
electrospinning and crosslinking to change its solubility and mechanical properties, without altering its 
biocompatibility.     
Impact    This project aims to guide the development of a treatment for patients, for whom few options 
are available. Chronic venous disease and venous ulceration are painful and debilitating, potentially 
requiring years of treatment. Effective, minimally invasive treatment options could result in accelerated 
ulcer healing and improvements in symptoms and quality of life as well as reduced costs. 
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ABBREVIATIONS 
ADVT  Asymptomatic Deep Vein Thrombosis 
AIBN  Azoisobutyronitrile 
BMI  Body Mass Index 
BMP  Bone Morphogenic Protein 
BVV  Bioprosthetic vein valve 
BVV2  2nd generation bioprosthetic vein valve 
CCA  Complement Convertase Assay 
CDI  Carbodiimide 
CDT  Catheter Directed Thrombolysis 
CDU  Colour Duplex Ultrasound 
CEAP  Clinical severity, aetiology, anatomy and pathophysiology 
CFD  Computational Fluid Dynamics 
CFV  Common femoral vein 
CJV  Common jugular vein 
CT  Computed tomography 
DFV  Deep femoral vein 
DICOM Digital imaging and communications in medicine 
DS  Deep Superficial 
DVT  Deep Vein Thrombosis 
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ECM  Extra Cellular Matrix 
ECS  Elastic Compression Stockings 
EJV  External jugular vein 
EMS  Electrical muscle stimulation 
FEM  Finite Element Method 
FOV  Field of view 
FSE  Fast Spin Echo 
FSI  Fluid structure interaction 
FV  Femoral vein 
HMDS  Hexamethyldisilazane 
HPMA  Hydroxypropyl methacrylate 
ID  Isolated Deep 
INR  International Normalised Ratio 
IS  Isolated Superficial 
IPC  Intermittent pneumatic compression 
IVC  Inferior vena cava 
LDPE   Low-density polyethylene 
LMWH  Low Molecular Weight Heparin 
MMP  Matrix Metalloproteinase 
MPC  Methacryloyloxyethyl phosphorylcholine 
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MPFF  Micronised purified flavonoid fraction 
MR  Magnetic resonance 
NMR  Nuclear magnetic resonance 
NYHA  New York Health Association  
P  Perforator 
PCL  Polycaprolactone 
PDE  Partial Differential Equations 
PDMS  Polydimethylsiloxane 
PCU  Polycarbonate urethane 
PD  Perforator Deep 
PDS  Perforator Deep Superficial 
PEU  Polyester urethane 
PLLA  poly(L-lactic acid) 
POSS  Polyhedral oligomeric silsesquioxane 
PPMT  Percutaneous Pharmacomechanical Thrombolysis 
PRISMA Preferred reporting items for systematic reviews and meta-analyses 
PS  Perforator Superficial 
PTFE  Polytetrofluoroethylene 
PV  Popliteal vein 
PVA  Polyvinyl Alcohol 
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PVC  Polyvinyl Chloride 
PVVB  Percutaneous vein valve bioprosthesis 
RCT  Randomised Controlled Trial 
REC  Research ethics committee 
ROI  Region of interest   
SEM  Scanning electron microscopy 
SIBS  styrene-block-iso butylenes-block-styrene 
SIS  Small intestinal submucosa 
SFJ  Saphenofemoral junction 
SPJ  Saphenopopliteal junction 
TGF-β  Transforming Growth Factor - beta 
TMSPMA 2-trimethylsilyl-2-propyl methacrylate 
TOF  Time of Flight 
TUS  Triplex Ultrasound 
UV  Ultraviolet 
VEGF  Vascular Endothelial Growth Factor 
VENC  Velocity Encoding 
VKA  Vitamin K Antagonist 
VVP  Venous valve pocket 
WSS  Wall Shear Stress 
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1. INTRODUCTION 
1.1 BACKGROUND 
 
Chronic venous disease is common, distressing and a significant cause of health care expense1. It affects a 
third of the UK adult population and is costs the NHS approximately 2% of the annual budget. The 
cause is failure of the valves in the superficial or deep veins of the legs due to primary or secondary 
failure.  Primary valve failure is caused by weakening of the vessel wall leading to dilatation and separation 
of the valve leaflets.  Secondary valve failure is due to damage to the valves commonly due to venous 
thrombosis.  Both of these result in refluxing disease.  Symptoms include leg swelling, ‘bursting’ pain on 
walking (venous claudication), and venous ulceration.  Although uncommon, amputation may be 
necessary in severe cases.  The prevalence of venous ulceration in the UK and USA in the adult 
population is approximately 0.5-1%, and in patients over 80 years it increases to 3%2, 3.  
Recent advances in the management of venous disease have focused on patients with superficial reflux, 
particularly the use of endothermal technologies to ablate superficial veins4. Treatments can be performed 
in an office-based setting and excellent early outcomes have been reported 5, 6. Duplex studies have shown 
that reflux (or less commonly, occlusion) of deep veins is seen in around 40% of patients with chronic 
venous insufficiency and may be significant in 15-20%7, 8.  Most vascular specialists will have managed 
these challenging patients. There have been few developments in the treatment of deep venous reflux as 
our understanding of the clinical and pathophysiological significance of deep vein reflux and valve failure 
remains poor.  
Attempts to create a valve implant must and are being revisited. Crucially, a non-thrombogenic, 
biocompatible material with the necessary required properties and mechanical integrity for implantation 
into the venous system is essential as well as a design that will minimise turbulence and zone stasis around 
the valve leaflets and valve pocket. 
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1.2 THE AETIOLOGY OF DEEP VENOUS DISEASE 
Veins are thin walled capacitance vessels that return blood from the peripheries towards the heart.  The 
venous system consists of three systems; the deep venous system, the superficial venous system and 
perforating veins. This is divided into 18 segments as described in Table 1 below: 
Table 1: Shows the 18 segments of the deep venous system9 
Superficial veins Deep veins Perforating veins 
1 Telangiectasias/reticular 
veins 
6 Inferior vena cava 17 Thigh 
2 Above knee Great 
saphenous vein 
7 Common Iliac 18 Calf 
3 Below knee Great 
saphenous vein 
8 Internal Iliac   
4 Small saphenous vein 9 External Iliac   
5 Non-saphenous 10 Pelvic, gonadal, broad 
ligament 
  
  11 Common Femoral   
  12 Deep  Femoral   
  13 Superficial  Femoral   
  14 Popliteal   
  15 Tibial (anterior, posterior, or 
peroneal) 
  
  16 Muscular (gastrocnemial, 
soleal, other) 
  
 
Superficial veins drain blood from the skin and subcutaneous fat, then via the perforating veins, this 
blood passes to the deep venous system and is returned to the heart10.  Flow is maintained by the 
movement of the diaphragm during respiration, pressure gradients created by the thoracic and abdominal 
cavities and by peripheral pumps including the foot, calf and thigh pumps.  Unidirectional flow is ensured 
by the presence of valves, which are usually bicuspid, throughout the system preventing retrograde flow, 
and of course patency of the veins ensuring no resistance to flow is essential.  Undoubtedly, the venous 
system is more complex than the arterial system9.  
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The action of the foot, calf and thigh muscle pumps is essential to maintain normal venous function, as 
during ambulation approximately 90% of venous return is attributed to these muscular structures11. The 
calf muscle pump is the most important, as it has the largest capacitance and generates the highest 
pressure, with an ejection fraction (EF) of approximately 65%.  The thigh muscle pump has an EF of 
approximately 15%11. During ambulation there is a pressure increase of 92% in the deep posterior 
compartment of the calf muscle pump, 104% in the superficial posterior compartment, and 18% in the 
anterior tibial compartment12. When the calf muscle relaxes, the venous pressure falls to between 15 and 
30mmHg, when the presence of well functioning bicuspid valves is necessary to prevent retrograde 
flow13. Dysfunction or impairment of either the valves within the venous system or of the muscle pumps, 
particularly the calf muscle pump, can lead to chronic venous disease13.  In addition, any obstruction to 
the flow of blood towards the heart will result in increased resistance to the flow of blood and increased 
pressure within the veins, both during muscle contraction and at rest.  This will also result in the clinical 
manifestation of venous disease.   
It is unclear which of these factors considered to potentially be the cause of venous disease is the 
initiating factor, as many patients with venous disease have all of these conditions.  Some patients have a 
clear trigger, such as a deep vein thrombosis, trauma, an anatomical narrowing or chronic inflammation, 
which is particularly the case in those patients with obstructive venous disease, however for many patients 
none of these is present.  In patients with valve reflux, maybe a valve defect is the primary initiator or 
potentially a condition that affects the vein wall primarily, such as altered collagen composition and 
reduced elastin14. However, whatever the initiating factor, the underlying pathophysiology of CVD is 
chronic venous hypertension, causing oedema, pigmentation, fibrosis and ulceration of the skin and 
subcutaneous tissues13.   
The CEAP classification system, clinical class (C), etiology (E), anatomical (A) distribution of disease and 
underlying pathophysiology (P) is commonly used to sub-classify patients with venous disease.  The 
clinical (C) classification is the most commonly used, which includes patients with no disease (C0) 
telangiectasiae (C1), varicose veins (C2), oedema (C3), liperdermatosclerosis (C4), healed ulcers (C5) and 
active ulcers (C6)15.  This chapter will review the literature to determine if there is a correlation between 
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the anatomical locations of deep venous reflux and obstruction with clinical disease severity and review 
the available literature on the Post Thrombotic Syndrome.  The locations of reflux are divided into its 
presence in the deep, superficial and perforating veins, where as the locations of obstruction are 
specifically assessed as to their location in the deep veins only.   
 
1.2.1 Anatomical locations of deep venous obstruction 
Chronic deep venous obstruction impairs outflow from the lower extremities16, 17.  It can be caused by the 
absence of or incomplete recanalisation of the vein following a DVT, which can be the case in up to 80% 
of patients with an iliac vein thrombosis16, or by anatomical variants such as May-Thurner syndrome, 
venous agenesis associated with conditions such as Klippel-Trenaunay syndrome, trauma, iatrogenic 
causes, and tumours18.   Here, the anatomical location of deep venous obstruction in the deep venous 
system is summarised and correlated with disease severity, from the evidence available in the literature.  
 
Methods 
The review was conducted according to the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines19.  Relevant papers were identified through systematic searches of Pubmed 
(1948 to June 2013). The search terms “chronic venous obstruction”, “chronic venous occlusion”, “deep 
vein thrombosis” AND “lower limbs”, “legs” were used. Article titles and abstracts were screened for 
inclusion. A manual reference list search was also carried out for further appropriate studies to be 
considered for inclusion, ensuring relevant papers published before 1966 were included. Relevant full text 
articles were scrutinised and all studies reporting details of cross-sectional and longitudinal studies 
regarding venous obstruction or occlusion in the lower extremities including the prevalence within the 
deep venous segments were included.  Case studies, reviews and letters were excluded, as were articles 
concerning the arterial system, acute venous occlusion, acute deep vein thrombosis or venous reflux or 
incompetence, and animal studies.  No filters, limits or language exclusions were applied. 
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Results 
The majority of studies used duplex ultrasound to establish the location of venous occlusion.  The results 
of the search are shown in Figure 1.  From 8620 studies identified at the initial search, 2 were included, as 
only 2 allowed correlation between disease severity and the anatomical location in the context of chronic 
obstruction.  Many studies included detailed assessments of the anatomical locations of the obstruction, 
but did not correlate this with clinical severity.  Several studies followed up patients with acute DVT of 
known anatomical location and assessed clinical severity of their ongoing venous disease, however, they 
did not assess the extent of the ongoing occlusion at these follow up visits.   
 
30 
 
Figure 1: Shows the summary of the search strategy for the anatomical locations of chronic deep venous occlusions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
           
 
Records identified through database 
searching  
(n = 8620 publications 
between 1948 and 2013) 
Additional records identified through 
other sources  
(n =5) 
Records screened (title)  
(n = 8625) 
Records excluded  
(n =8589) 
Exclusion criteria: Case studies, 
reviews and letters, arterial 
system, acute venous occlusion, 
acute deep vein thrombosis or 
venous reflux or incompetence 
Abstracts and full-text 
articles assessed for 
eligibility (n = 36) 
Records excluded  
(n = 26) 
Excluded: Articles lacking 
prevalence data 
 
 
 
 
 
Studies included (n = 2) 
Search terms entered: 
“chronic venous obstruction” OR “chronic venous occlusion” OR “deep vein thrombosis” AND “lower 
limbs” OR “legs” 
Records excluded  
(n = 8) 
Excluded: Articles lacking 
clinical severity data 
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The occluded segments in the IVC, IV, FV, and PV relative to the total number of limbs in that group are 
shown as well as these numbers as a percentage of the total number of isolated obstructions depending 
on the severity of chronic venous disease in Figure 2.  All other occluded deep vein segments were 
included in the category of other obstructions, these were occlusions of the tibial and muscular veins.  
Johnson et al20 had 49 patients in the asymptomatic group and 34 patients in the symptomatic group who 
were diagnosed with PTS.  Labropoulos et al21 included 120 limbs of 105 patients all of which were 
followed up with duplex ultrasound at least one year following the acute DVT.  85 limbs demonstrated 
C0-C3 disease and 35 limbs had C4-C6 disease.    
 Table 2 summarises these studies and describes the individual occluded venous segments. The 
summation of these papers is shown in Figure 2. 
 
 Table 2: Shows the clinical severity of venous disease and the occluded deep venous segments from the 
literature 
 
 
 
Reference 
 
Number 
of patients 
(limbs) 
IVC 
obstruction 
IV obstruction FV obstruction PV obstruction Other 
occlusions 
C0-3 ≥C4 C0-3 ≥C4 C0-3 ≥C4 C0-3 ≥C4 C0-3 ≥C4 
Johnson et 
al, 1995 20 
78 (83) - - 5/49 5/34 24/49 18/34 14/49 18/34 5/49 9/34 
Labropoulos 
et al, 2008 21 
105 (120) 10/85 5/35 22/85 15/35 58/85 30/35 50/85 27/35 39/85 17/35 
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Figure 2: Shows the percentage of obstructions at the Inferior Vena Cava (IVC), Iliac Vein (IV), Femoral 
Vein (FV), Popliteal Vein (PV) and other occlusions relative to the total number of obstructions for C0-3 
and C4-6 disease 
 
 
 
 
From the literature, the percentage of occluded segments is higher in patients with more severe CVD, as shown in 
Figure 2.  Labropoulos et al21 were the only group to distinguish between isolated vein thrombosis and multi-
segment occlusions.  They found that patients with multi-segment occlusions had more advanced PTS.  Femoral 
and popliteal veins are the most commonly occluded segments.  
 
Discussion 
This demonstrates that there is a paucity of literature available on the anatomical locations of chronic 
venous obstruction.  There are many studies of acute DVT, its location and ongoing follow up and 
assessment of patients with post thrombotic syndrome, but few perform duplex imaging in the follow up 
assessment to ascertain the ongoing presence of chronic occlusion.  There are several studies which 
describe the locations of chronic occlusions, however, these do not provide any correlation with clinical 
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disease severity.  It would seem logical that the presence of venous obstruction contributes to increased 
venous disease severity and furthermore that the more proximal the occlusion, the more severe the 
venous disease.  This has been demonstrated in the 2 studies here. Multisegmental occlusions appear to 
be more common than isolated obstructions, which result in more severe disease.  It could be argued that 
as one of the causes of chronic venous obstruction is an acute DVT with failure of recanalisation, that it 
the location of the initial DVT correlates well with disease severity, and there are studies which 
demonstrate that the more proximal the DVT, the worse the severity of venous disease22.  However, 
many DVTs may be asymptomatic and development and recanalisation rates for patients in the studies of 
acute DVT that were excluded were not known as duplex imaging was not performed, this data cannot be 
extrapolated for the purpose of chronic occlusions discussed here.  Isolated venous obstruction is rare 
and more commonly obstruction and reflux are present in the same subject.  In patients with 
multisegmental obstructions there is an increased incidence of venous reflux23.  
 
1.2.2 Anatomical locations of deep venous reflux 
 
Venous reflux occurs when the return of blood to the heart flows in a retrograde direction.  This may be 
secondary to valve damage, or an abnormality of the vein wall or if obstruction is present concurrently 
that the occluded veins dilate preventing the valve leaflets meeting and serving as a functional valve, as 
suggested by Van Bemmelen et al24.  By whichever mechanism it occurs, when the valves fail, venous 
insufficiency results.  The available literature is reviewed here to evaluate the anatomical locations of 
venous reflux and correlate this with the clinical severity of venous disease, specifically the presence of 
reflux in the three compartments; the deep, superficial and perforating veins.  
Methods 
The review was conducted according to the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines19.  Relevant papers were identified through systematic searches of Pubmed 
(1948 to June 2013). The search terms “chronic venous insufficiency”, “chronic venous reflux”, AND 
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“lower limbs”, “legs” OR “lower extremities” AND “vein* OR venous” AND “reflux OR 
incompetence” were used. Article titles and abstracts were screened for inclusion. A manual reference list 
search was also carried out for further appropriate studies to be considered for inclusion, ensuring 
relevant papers published before 1948 were included. No filters or limits were applied to the search. 
Relevant full text articles were scrutinised and all studies reporting details of cross-sectional and 
longitudinal studies regarding the prevalence of venous disease in the lower extremities, the severity of 
venous disease and a study population age group of greater than 18 years old were included.  Case studies, 
reviews and letters were excluded, as were articles concerning the arterial system, acute venous occlusion, 
acute deep vein thrombosis or chronic venous occlusion, and animal studies.  The data was grouped 
according to the anatomical location of venous reflux and clinical disease severity according to the CEAP 
classification, as described previously.  
 
Results 
As shown in Figure 3, from 1728 titles screened 14 were included.  The data from these studies was 
extracted, and the presence of reflux in the deep, superficial and perforating veins was compared in those 
patients with C0-C3 disease and C4-C6 disease.  The studies that were excluded at the full text stage 
generally contained data which could not be interpreted, or related only to the superficial system, thus not 
allowing adequate comparison, related only to perforating veins or combined both reflux and obstruction 
which could not be separated.  The patterns of reflux that were considered for this study were isolated 
superficial (IS), isolated deep (ID), deep and superficial (DS), perforator (P), perforator and superficial 
(PS), perforator and deep (PD) and perforator, deep and superficial (PDS).  This resulted in a total of 
6581 patients and 7081 limbs included, with 5244 limbs (74.1%) in the C0-3 and 1837 limbs (25.9%) in 
the C4-6 group.  These results are shown in Table 3. 
 
 
 
35 
 
Figure 3: Shows the summary of the search strategy for the anatomical locations of venous reflux 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching  
(n = 1728 publications 
between 1948 and 2013) 
Additional records identified through 
other sources  
(n =16) 
Records screened (title)  
(n = 1744) 
Records excluded  
(n =1683) 
Exclusion criteria: Case studies, 
reviews and letters, arterial 
system, acute venous occlusion, 
deep vein thrombosis, chronic 
venous occlusion, animal studies 
Abstracts and full-text 
articles assessed for 
eligibility (n = 61) 
Records excluded  
(n = 30) 
Excluded: Articles not relating 
to reflux alone 
 
 
 
 
 
Studies included (n = 14) 
Search terms entered: 
“chronic venous insufficiency”, “chronic venous reflux”, AND “lower limbs”, “legs” OR “lower extremities” 
AND “vein* OR venous” AND “reflux OR incompetence” 
Records excluded  
(n = 17) 
Excluded: Articles lacking 
adequate clinical severity data 
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Authors and publication year CEAP 
Number 
patients 
Number 
limbs 
No 
reflux 
IS ID DS Total S 
Total 
D 
PS PD PDS 
 
IP Total P 
Cornwall et al, 198625 C4-6 100 117 12 40 22 9 49 32 
   
 
 
Darke and Penfold, 199226 C4-6 213 232 
    
90 81 90 
 
81 9 180 
Lees and Lambert, 199327 
C0-3 
153 
202 45 
   
132 17 
   
8 8 
C4-6 98 2 
   
57 39 
   
2 2 
Shami, 199328 C4-6 59 118 
 
42 12 25 67 37 
   
 0 
Labropoulos et al, 199529 C4-6 94 112 4 26 7 13 93 56 23 5 31 3 62 
Myers et al, 199530 
C0-3 
1114 
776 192 429 18 137 566 155 356 107 
 
78 441 
C4-6 166 20 63 13 70 228 142 95 59 
 
20 110 
Labropoulos et al, 199631 
C0-3 
465 
319 168 129 7 12 144 19 3 0 0 0 3 
C4-6 275 10 57 12 48 246 163 42 4 99 3 148 
Welch et al, 199632 
C0-3 
320 
218 80 92 14 14 92 28 
   
 
 
C4-6 282 44 67 30 59 126 89 
   
 
 
Labropoulos et al, 199733 C0-3 110 220 91 108 4 7 125 13 8 0 2 0 10 
Giannoukas et al, 200234 
C0-3 694 
 
537 144 413 16 16 511 48 76 10 6  
 
C4-6 117 
 
11 3 30 92 72 36 24 15  
 
Danielsson et al, 200435 C4-6 83 98 1 3 4 11 84 72 19 6 51 3 79 
Ibegbuna et al, 200636 
C0-3 121 
 
66 
    
44 21 
  
12  
 
C4-6 66 
    
16 50 
  
42  
 
Maurins et al, 200837 
C0-3 3014 
 
2906 
    
406 353 
   
 
 
C4-6 108 
    
74 33 
   
 
 
Kanchanabat et al, 201038 C4-6 41 48 
 
4 8 32 36 40 
   
 
 
Key: Isolated superficial (IS), isolated deep (ID), isolated perforator (IP), deep and superficial (DS), perforator (P), perforator and superficial (PS), perforator and deep (PD) and 
perforator, deep and superficial (PDS) 
Table 3: Shows the clinical severity of venous disease and the distribution of venous reflux
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Once this data is combined as shown in Figure 4, it is demonstrated that in the presence of isolated 
superficial reflux, C0-3 disease, that is the presence of no clinical venous disease, telangiectasia, varicose 
veins or leg oedema, is more common.  However, if deep venous reflux, perforator reflux, or two or 
more of the three venous systems are involved, then C4-6 disease is more likely.   For all stages of venous 
disease, for all CEAP classifications, reflux occurred most commonly in the superficial veins 
compartments (46.3% of the total limbs). The frequency of superficial, deep and perforator reflux was 
higher in all cases for patients with C4-6 disease when compared to patients with C0-3 disease, as shown 
in Figure 5.  For patients with C0-3 disease, only 12% had an element of deep venous reflux and 15% had 
perforator reflux, whereas for patients with C4-6 disease, 49% and 36% had deep and perforator reflux 
respectively.  Only 0.38% of patients with reflux in all 3 lower limb venous system (PDS) had C0-3 
disease, but this was seen in 17% of patients with C4-6 disease.   
 
Figure 4: Shows the anatomical location of venous reflux for C0-3 and C4-6 disease. Isolated superficial 
(IS), isolated deep (ID), isolated perforator (IP), deep and superficial (DS), perforator (P), perforator and superficial 
(PS), perforator and deep (PD) and perforator, deep and superficial (PDS) 
 
 
 
0
5
10
15
20
25
IS ID IP DS PS PD PDS
Pe
rc
en
ta
ge
 o
f t
ot
al
 li
m
bs
 (%
) 
Anatomical  location of reflux 
C0-3
C4-6
38 
 
Figure 5: Shows the total frequency of superficial, deep and perforator reflux for patients with C0-3 and C4-6 
disease.  Superficial (S), Deep (D), Perforator (P). 
 
 
 
 
Figure 6: Shows the relative involvement of the superficial, deep and perforating systems in patients with superficial 
venous reflux.  Isolated superficial (IS), deep and superficial (DS), perforator and superficial (PS) and perforator, 
deep and superficial (PDS) 
 
0
10
20
30
40
50
60
70
80
Total S Total D Total P
Pe
rc
en
ta
ge
 o
f t
ot
al
 li
m
bs
 (%
) 
Anatomical  location of reflux 
C0-3
C4-6
0
10
20
30
40
50
60
70
IS DS PS PDS
Pe
rc
en
ta
ge
 o
f T
ot
al
 S
up
er
fic
ia
l R
ef
lu
x 
(%
) 
Anatomical  location of reflux 
C0-3
C4-6
39 
 
Figure 7: Shows the relative involvement of the superficial, deep and perforating systems in patients with deep 
venous reflux.  Isolated deep (ID), deep and superficial (DS), perforator and deep (PD) and perforator, deep and 
superficial (PDS). 
 
 
Figure 8: Shows the relative involvement of the superficial, deep and perforating systems in patients with perforator 
reflux.  Isolated perforator (IP), perforator and superficial (PS), perforator and deep (PD) and perforator, deep and 
superficial (PDS). 
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 If the involvement of each venous compartment is compared individually, for patients with superficial 
venous reflux, this most commonly (58%) occurs in isolation in patients with C0-3 disease, in 22% of 
patients with superficial reflux and C0-3 disease occurs with perforator reflux and in 9% with deep 
venous reflux.  In contrast in patients with C4-6 disease, of the total patients with superficial reflux 24% 
of patients have an association with either deep or perforator disease and in 25% of patients it occurs in 
isolation or with both perforator and deep venous reflux.  This is shown in Figure 5. 
For patients with deep venous reflux, this most commonly (35%) occurs with both perforator and 
superficial reflux in patients with C4-6 disease, in 33% of patients with deep reflux and C4-6 disease 
occurs with superficial reflux and in 11% with perforator reflux.  It occurs least frequently (12%) in 
isolation in these patients.  In contrast in patients with C0-3 disease, of the total patients with an element 
of deep venous reflux 28% of patients had concurrent superficial reflux.  This is shown in Figure 6. 
For patients with perforator reflux, this most commonly (67%) occurs with superficial venous disease in 
patients with C0-3 disease.  It occurs in isolation in these patients in only 13% of cases.  In contrast, in 
patients with C4-6 disease and perforator reflux, 40% and 42% has an association with either superficial 
or superficial and deep reflux.  This is shown in Figure 8.      
 
Discussion 
This has shown that in CVI of the lower extremities, particularly for patients with less severe C0-3 
disease, the majority of the reflux involves superficial veins only.  Once disease progresses, reflux in the 
superficial veins remains the most common, however, involvement of the deep and perforator veins 
increases in frequency.  There is currently no longitudinal study that demonstrates whether in primary 
venous disease superficial reflux simply progresses to involve more venous segments and clinical disease 
severity increases, or whether the initial underlying abnormality involves all of the systems resulting in 
worse disease severity.  In the case of venous reflux, however, it is clear that although superficial reflux 
remains the most common for all grades of severity, involvement of the deep venous system is apparent 
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more frequently in patients with C4-6 disease.  It is these patients for whom deep venous interventions 
would be potentially beneficial to improve symptoms.  Deep venous reflux does for the most part coexist 
with superficial reflux, and when considering treatment for patients with venous disease, treatment of the 
superficial venous disease will remain the first line of treatment. However, given that the deep venous and 
perforator systems are involved with more severe cases of CVI demonstrates these as potential targets for 
intervention. Treatment options for patients with deep venous disease are limited and this will be 
discussed in greater detail in Chapter 2.    
There are limitations to this limited study reviewing the literature regarding patients with venous reflux.  
There is heterogeneity in the data collected.  The eligibility criteria for patients in each study were variable; 
some papers included patients with C0 disease, which were included here, and others did not, although 
the majority excluded patients with a history of previous varicose vein or other venous intervention, 
others did not.  This may have resulted in the underestimation of the frequency of superficial venous 
reflux. Papers were excluded if they only focussed on patients with reflux in one system, such as the 
saphenous or perforator systems, as this limited the information available on the excluded patients.  There 
were studies that included both patients with reflux and obstruction.  If these could be separated they 
were included but otherwise were not.   
 
1.3 POST-THROMBOTIC SYNDROME 
Introduction 
Deep vein thrombosis (DVT) has a prevalence of approximately 0.2% in the community and up to 25% 
in hospitalised patients39 and is a significant healthcare and socioeconomic burden. Post-thrombotic 
syndrome (PTS) is a frequent complication of acute DVT and occurs in approximately half of patients 
within the first 1-2 yrs40, particularly after more proximal DVT.  Severe PTS occurs in 5-10% of patients 
following iliofemoral DVT and at its worse may result in venous ulceration, which causes significant 
disability and impaired quality of life41.  Not only does it have a significant impact on patients, but it also 
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provides a significant financial burden and societal cost42.  When compared to other chronic diseases, 
patients with PTS have a poorer quality of life than those with chronic lung disease, diabetes or arthritis43 
and the quality of life of patients with severe PTS is in line with patients with congestive heart failure or 
cancer41.  This part of the chapter reviews the pathophysiology, risk factors for developing PTS, as well as 
diagnosis and treatment of PTS, as it is a common cause for secondary venous disease. 
 
Methods 
Relevant papers were identified through systematic searches of Pubmed (1948 to June 2013). The search 
terms “postthrombotic syndrome”, “post-thrombotic syndrome” and “post phlebitic syndrome” in all 
combinations were used. Article titles and abstracts were screened for inclusion. A manual reference list 
search was also carried out for further appropriate studies to be considered for inclusion, ensuring 
relevant papers published before 1966 were included.  An English language filter was applied to the 
search. Relevant full text articles were scrutinised and all studies published in English, with human study 
participants, study data relating to adult (>18 yrs) patients, and relevant data on lower limb post-
thrombotic syndrome were included.  Case studies, non-systematic reviews and letters were excluded.  
Full text articles were obtained if from the title or abstract the inclusion criteria were satisfied.  These 
were then further evaluated for relevance and methodological rigor. 
 
Results 
Although the initial search strategy yielded 1190 results, following exclusion of non-relevant publications 
and the addition of records identified from other sources, a total of 145 articles were included.  This is 
shown in Figure 9. 
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Figure 9: Shows the summary of the search strategy for literature regarding the post-thrombotic 
syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching  
(n = 1190) 
Additional records identified through 
other sources  
(n = 33) 
Records screened (title) 
(n = 1223) 
Records excluded  
(n = 935) 
Excluded: Articles not 
published in English, 
animal and in-vitro trials, 
paediatric trials, upper limb 
PTS, non-systematic 
reviews, single patient case 
reports 
Abstracts and full-text 
articles assessed for 
eligibility (n = 288) 
Studies included (n = 145) 
Search terms entered:  
“posthrombotic syndrome”, “post-thrombotic syndrome”, “post phlebitic syndrome” 
 
Records excluded (n =143) 
Excluded: Data not relevant 
or insufficient, upper-limb 
post thrombotic syndrome 
included in data, review of 
previous material, included 
patients with no history of 
DVT 
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Incidence and natural history of PTS 
The incidence of PTS reported in the literature is widely variable ranging from 20-80%40, 44-48.  However, 
throughout the literature there is marked heterogeneity in the diagnostic criteria, patient populations, 
study designs and time of measurement from the initial insult of acute DVT. Those studies which use 
validated diagnostic criteria consistently estimate the incidence of PTS within the first year following a 
DVT, to be around 50%, even with treatment of the initial DVT with anticoagulation48, 49.  Early studies 
described PTS developed some 5-10 years after the initial DVT, however, current prospective studies 
report that the cumulative incidence of PTS plateaus within 1-2 years of the first presentation40, 49.  The 
incidence and severity of PTS continues to accumulate, however, with up to one-third of patients affected 
at six years49 and in around half of these patients the disease has progressed from mild or moderate PTS 
to severe PTS.  Half of patients have severe PTS at their initial presentation50.  
 
Pathophysiology 
An acute DVT results in a partial or complete occlusion of a vein.  Following this a process of change to 
the size, shape and structure of the thrombus occurs.  This may result in recanalisation of the vein, that is 
the venous outflow is restored.  This can be apparent at 6 weeks following the initial diagnosis of DVT51, 
however, approximately half of all legs at 3 years on imaging still demonstrate some residual thrombus 
causing at least a partial obstruction52.  Within the first three months after an acute thrombus, there is an 
approximately 50% reduction in thrombus load53, but the rate of recanalisation varies.  It appears to be 
related to the initial thrombus load52 and thrombus site, with distal thrombi undergoing more rapid and 
complete resolution54.   The process of recanalisation is less well understood, but seems to involve both 
complex intrinsic mechanisms within the thrombus and systemic activation of fibrinolysis55.  A 
correlation between the presence of fibrinolytic inhibitors and the degree of recanalisation has been 
described55 and it was suggested by Killewich et al suggested that regression of an acute DVT is related to 
an increase in endogenous fibrinolysis56. 
Importantly, the response to an acute thrombosis and recanalisation are inflammatory processes which 
cause damage to the vein wall and venous valves.  As well as the partial or complete obstruction to the 
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vein, this also results in reflux.  This process seems to occur early following a DVT, and at 1 week 
following a DVT 17% of patients demonstrate venous reflux, however, this increases to 69% of patients 
at 1 year following an acute DVT57, and the degree of occlusion is related to the likelihood of developing 
reflux57.  Indeed, rapid resolution of thrombus seems to result in greater preservation of valvular 
function58, 59.  Eventually, the combination of reflux and obstruction results in venous hypertension.  With 
no reduction in the standing pressure during ambulation, chronically elevated deep venous pressure 
adversely affects venous haemodynamics and results in calf muscle pump dysfunction.  These elevated 
pressures get transmitted to the capillary beds.  Large molecules including plasma proteins and fluid are 
forced out of the capillaries to the tissues resulting in tissue oedema, subcutaneous fibrosis and finally 
tissue hypoxia and ulceration60-62.   
 
Risk Factors for developing Post-thrombotic Syndrome 
Recurrent DVTs and DVT location 
Recurrent ipsilateral DVT is the most significant risk factor for the development of PTS, resulting in a 3-6 
fold increased risk46, 50, 63.  This logically follows as it is likely to worsen pre-existing resistance to venous 
outflow and valve damage.   The anatomical location of the DVT seems to have an impact on the future 
development of PTS.  More proximal DVTs have been associated with an increased risk of developing 
PTS in several studies22, 50, and in the acute scenario are generally associated with more severe signs and 
symptoms21, 64.  However, distal thrombi can propagate to more proximal thrombi and in fact, it has been 
observed that approximately 9%-20% of below knee DVTs will involve more proximal veins at further 
imaging65 and over 20% of patients with more distal DVTs will go on to develop PTS66.  More distal 
DVTs do demonstrate improved rates of thrombus regression and recanalisation and reduced rates of 
recurrence, and it maybe this that explains the lower incidence of PTS in these patients23.  
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Age and gender 
There is an unclear association between gender and age on the development of PTS.  Studies performed 
have demonstrated discrepancies.  Several studies failed to find an association with gender63, 67, a large trial 
of 1668 patients identified a 1.5 fold increased risk for women22, and one reported an increase in men54.  
The data from these studies is shown in Table 4.  Similarly with regard to age, there is no definite 
association and further comparison of these studies is difficult due to heterogeneity between the studies.  
As with gender, several studies have failed to find an association48, 67, two studies show a correlation with 
increasing age and PTS development50, 63, but conversely other studies have found a reduced risk of 
developing PTS with increasing age22, 68. 
 
Table 4: Shows the risk of developing PTS in female patients. Pooled analysis of available data. 
Author, Year No. of patients with PTS (n) Relative risk (RR) p-value 
Female 
 [n/N (%)] 
Male 
[n/N (%)] 
Ageno, 200368 * 10/35 (29) 10/48 (21) RR 1.29; 95% CI 0.59, 2.83 0.53 
Kahn, 200369 * 10/17 (59) 9/23 (39) RR 1.32; 95% CI 0.63, 2.76 0.47 
Gabriel, 200448 * 35/57 (61) 49/78(63) RR 0.98; 95% CI 0.70, 1.39 0.94 
Kahn, 200567 * 27/64 (42) 27/81 (33) RR 1.19; 95% CI 0.75, 1.87 0.46 
Stain, 200570 ** 96/246 (39) 80/160 (50) RR 0.84; 95% CI 0.67, 1.08 0.17 
Prandoni, 200571 * 42/97 (43) 25/83 (30) RR 1.31; 95% CI 0.85, 2.00 0.22 
Tick, 200822 * 235/880 (27) 129/788 (16) RR 1.50; 95% CI 1.23, 1.82 <0.001 
Tick, 201054  ** 19/47 (40) 30/52 (58) RR 0.79; 95% CI 0.49, 1.26 0.32 
Latella, 201072 * 85/172 (49) 70/172 (41) RR 1.14; 95% CI 0.88, 1.49 0.32 
Total 559/1615 (35) 429/1485 (29) RR 1.15; 95% CI 1.03, 1.28 0.01 
*Villalta scale used to define presence or absence of PTS 
**CEAP classification used to define presence or absence of PTS 
 
 
 
 
47 
 
Obesity 
Studies that have observed the risk of developing PTS in obese patients are small.  Obesity may be a risk 
factor although the underlying mechanism for this is not clear.  It may be associated with a reduced 
exercise capacity73 and increased venous pressures.  An association was observed in this study of 83 
patients, in that for those patients that developed PTS following an acute DVT, the mean BMI was 
significantly higher73 and Tick et al found a 1.5-fold increased risk of PTS in patients with body mass 
index greater than 30 kg/m222.  
 
Genetics 
Patients with inherited thrombophilias have a predisposition to developing DVT, although this is often 
not discovered until after the initial event.  As such, it would be assumed that inherited thrombophilias 
are associated with the development of PTS, which has been demonstrated with Factor V Leiden in some 
studies74, 75.  However, other studies have failed to find an association63, 70, 76 and some have found that 
there is a reduced risk67.  The data from these studies is shown in Table 5.  The causes for this may be 
related to the duration of anticoagulation therapy, although some studies corrected for this, or may in fact 
represent underlying differences in thrombus biology, as patients with Factor V Leiden mutation may be 
more likely to develop acute DVTs involving the popliteal or calf veins77, rather than more proximal 
DVT and are less likely to embolise78 and are less likely to be recurrent79.  
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Table 5: Shows the risk of developing PTS in DVT patients with proven thrombophilia. Analysis of available data80. 
Table 2: Risk of developing PTS in DVT patient with proven Thrombophilia. Analysis of available data 
Author, Year No. of patients with PTS (n) Relative risk (RR) p-value 
Thrombophilia 
[n/N (%)] 
No Thrombophilia 
[n/N (%)] 
Hafner, 200174  * 16/42 (38) I 2/45 (4.4) RR 6.48; 95% CI 1.57, 26.8 0.01 
Gaber, 200175  *  19/24 (79) I 34/125 (27) RR 2.06; 95% CI 1.32, 3.24 0.002 
Kahn, 200567  13/49 (27) II 38/ 76 (50) RR 0.62; 95% CI 0.36, 1.09 0.10 
Stain, 200570 71/175 (41) II 105/231 (45) RR 0.92; 95% CI 0.72, 1.19 0.53 
Spieza , 201081 63/191 (33) III 110/339 (32) RR 1.01; 95% CI 0.77,1.32 0.93 
Total 182/481 (38) 289/816 (35) RR 1.05; 95% CI 0.90, 1.23 0.55 
*Outcome measure is the development of PTS ulcers. Remainder of studies included all severities of PTS 
classified  using Villalta or CEAP systems.  
Type of Thrombophilia detected:  
I-Factor V Leiden mutation  
II- Factor V Leiden mutation and prothrombin gene mutation 
III-Factor V Leiden, prothrombin gene mutation, lupus anticoagulant, protein C/S deficiency 
 
 
Asymptomatic DVTs 
Asymptomatic DVTs (ADVT) are complex as they are difficult to study in the general population.   In 
post-operative patients, a reduction in ADVT is associated with a reduction in DVT, suggesting the 2 are 
linked82.  A recent meta-analysis pooling 7 clinical trials suggested that ADVT is associated with a 58% 
increased risk of developing late PTS [RR 1.58, 1.24-2.02, p <0.0005]83.  As shown in Table 6, it is not 
conclusive from these studies whether ADVT affects either the incidence or severity of PTS.  
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Table 6: Shows the incidence of PTS in patient with and without asymptomatic deep venous 
thrombosis80. 
 
First Author, Year Villalta ≥5 or equivalent (n) DVT Treatment Treatment Duration 
ADVT 
n/N (%) 
No DVT 
n/N (%) 
RR [95% CI] 
Ginsberg, 200084  ʅ 5/91 (5.5) 7/164 (4.3) 1.27 [0.4,3.9] Warfarin  6-12 weeks 
Persson, 200985  ʃ 3/38 (7.8) 2/45 (4.4) 1.7 [0.3,9.8] Warfarin and ECS 12 weeks 
Andersen, 199186  * 8/25 (32) 0/16 (0) 8.5 [0.5, 138] Warfarin  12 weeks 
Siragusa, 199787  ** 11/46 (24) 2/52 (3.8) 5.2 [1.2, 22] Warfarin 12 weeks 
Schindler, 200588  ǂ 7/42 (17) 0/75 (0) 23[1.3, 390] Warfarin or 
Aspirin  
12 weeks 
Mudge, 198889  * 2/26 (7.7) 1/108 (0.9) 7.8 [0.7, 83] Not stated N/A 
Lindhagen, 198490  
** 
31/137 (23) 135/625 
(22) 
1.0 [0.73,1.48] None N/A 
Total 67/405 147/1085 1.2[0.91,1.56]    
Definition of PTS used in studies:  
*non-validated scoring system based on clinical examination 
** non-validated scoring system based on subjective symptoms and clinical examination 
ǂ CEAP classification 
ʃ Villalta scale 
ʅ non-validated scoring system based on subjective symptoms and evidence of valvular incompetence 
 
 
Diagnosis of PTS 
PTS is complex, and patients’ symptoms vary widely ranging from pain, swelling, restless or heavy legs 
and itching, and these symptoms are often subjective.  In more severe cases they can experience venous 
claudication during mobilisation91.  This makes the diagnosis of PTS difficult, which may explain the 
heterogeneity between studies on PTS.  Signs are more objective and include oedema, telangiectasias, 
venous eczema, hemosiderin deposition and lipodermatosclerosis and in more severe cases leg ulceration, 
which can be slow to heal and can recur92.   The initial symptoms of the acute DVT may be similar to that 
of early or mild PTS, and moreover may take some time to resolve, therefore the timing of diagnosis of 
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PTS is crucial.  If patients are observed 1 month following the initial DVT and classified as having 
moderate or severe PTS, over half are reclassified at 6 months as having mild or resolved PTS, but this 
changes less if patients are diagnosed at 4 or 12 months50.  The standard at present is that a diagnosis of 
PTS is delayed until at least 3 months after the initial acute DVT93.   
There are several imaging modalities that can be used in the diagnosis and ongoing management of 
patients with PTS.  Associated venous reflux, venous obstruction and calf muscle pump function can be 
measured using Doppler ultrasound and plethysmography.  If residual occlusion of the vein is present 
resulting in obstruction to venous outflow, or if venous reflux has developed, then there is an increased 
risk of developing PTS, and if both are present concurrently then this tends to result in more severe 
PTS20, 54, 71.  This has been discussed previously in this chapter.  Roumen-Klappe et al49 used imaging to 
prospectively assess 93 patients and found that if residual thrombus and reflux were present three months 
after an acute DVT, these were the most prognostically important variables with an area under the ROC 
curve of 0.77 [95% CI; 0.65-0.90 p<0.01].  Their presence also seems to be an independent risk factor for 
developing severe PTS21, 72.  As previously discussed, however, not all patients with haemodynamic 
venous disease go on to develop symptoms or signs71.  However, in patients who do not develop PTS, 
venous abnormalities can also be demonstrated.  
Following an acute DVT, inflammatory processes are occurring, but it is not clear whether markers of 
inflammation can predict the development of PTS and indeed, whether this is clinically useful.  There 
may be an association between elevated D-dimer levels 3 months after DVT and the subsequent 
development of PTS70, however, the converse is true for other markers of inflammation such as IL-6 and 
CRP94, 95.  The Bio-SOX study, a randomised prospective trial of 800 patients, aims to further delineate 
the role of inflammatory makers in prediction of PTS96.  
Numerous classification systems have been produced to aid diagnosis, grade severity and enable 
standardisation.  An ideal scoring system for post-thrombotic syndrome should be easy to use, valid, 
specific, have good inter-observer reliability, be acceptable to patients, have a clear association with the 
pathophysiological mechanism, and be able to categorize according to disease severity and identify 
improvement or deterioration in the condition. The Villalta score is able to lay claim to all these features, 
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as shown in Table 7.  It does contain several subjective criteria which could reduce its reliability, and 
perhaps further investigation into inter- and intra-observer reliability would be useful, however, the 
Villalta score appears to be the most commonly used, due to its ease and versatility of use in diagnosis, 
categorisation of severity, and in follow up.  In 2008 it was recommended at the International Society on 
Thrombosis and Haemostasis in Vienna that the Villalta scoring system should be utilised in clinical trials 
as the scoring system of choice for the diagnosis and grading of PTS.  An assessment of the impact of 
venous disease on a patient’s quality of life should also be part of a PTS score. As demonstrated in the 
study by Kahn et al97, patients with PTS have a significantly decreased quality of life, and this in itself is a 
symptom that contributes to the severity of the condition. Consequently, a quality of life questionnaire, in 
combination with the Villalta score, may aid in further clarifying the differences in the categories of 
severity of the condition, and standardise some of the subjective criteria of the Villalta score98.  
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Table 7: Shows the comparison of the properties of the different scoring systems for PTS98 
 
 Villalta Ginsberg Brandjes Widmer 
Inter-observer 
reliability 
Rodger et al 200899 No evidence No evidence No evidence 
Association with 
pathophysiology 
Kolbach et al 
2005100 
Kahn et al 2006101 
Kahn et al 2006101 Kolbach et al 
2001005 
 
Kolbach et al 
2005100 
 
Validity Kahn et al 200297 
Kahn et al 200843 
Kolbach et al 
2005100 
Kahn et al2006101 
Kahn et al 2006101 Kolbach et al 
2005100 
 
Kolbach et al 
2005100 
 
Diagnosis Prandoni et al 
199646 
van Dongen et al 
2005102 
Tick et al 200822 
Kahn et al 200541 
Roumen-Klappe et 
al 200994 
Kahn et al 200567 
Ginsberg et al 
200084 
Kahn et al 200796 
Brandjes et al 
199740 
Widmer et al 
1981103 
Kolbach et al 
2003104 
Categorisation of 
severity 
Kahn et al 200297 
Kahn et al 2011105 
 
No Yes Yes 
Identify change in 
condition 
Yes No No No 
Evaluation of 
treatment for PTS 
O’Donnell et al 
2008106 
Ginsberg et al 
2001107 
No evidence No evidence 
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Prevention of PTS 
Anticoagulation 
In the UK, patients diagnosed with an acute DVT start anticoagulation in the form of Vitamin K 
antagonists such as warfarin, with LMWH until the INR is therapeutic.  In the absence of a triggering 
factor, this is continued lifelong, but if a trigger is identified and can be removed or controlled then 3 
months is usually sufficient, although each case is assessed individually108.  The duration and type of 
anticoagulation should perhaps be studied further, as a longer duration of anticoagulation would reduce 
recurrence of DVT and this has been shown in several studies109-111, but for warfarin therapy no 
additional reduction in PTS was found with patients receiving 6 months versus 6 weeks therapy112.  Trials 
have studied the use of LMWH for the duration of anticoagulation, rather than vitamin K antagonists.  
Patients treated with 12 weeks of tinzaparin reported fewer symptoms of PTS [OR 0.77 95% CI, 0.67-
0.69], fewer venous ulcers [OR 0.12 95% CI, 0.01-0.97] and improved patient satisfaction compared with 
warfarin113.  This could be explained either by the fact that LMWH increases the rate of thrombus 
regression114, 115 or its anti-inflammatory properties116.  Although there is no trial evaluating the effect of 
anticoagulation on the incidence of PTS, logically as its use prevents recurrent DVT, and a subtherapeutic 
INR is predictive of PTS then its use should reduce the incidence of PTS67, 102.    In the peri-operative 
period, bridging anticoagulation reduces the risk of peri-operative recurrent DVT117, 118.  As recurrent 
ipsilateral DVT is a major risk factor for the development of PTS, this will reduce the incidence of PTS in 
the future.  
 
Elastic Stocking Compression Therapy 
There is little consistency between practices on the current use of elastic compression stockings (ECS) 
following an acute DVT, and only around one third of physicians who regularly treat DVT prescribe ECS 
to prevent PTS in asymptomatic patients114, 119.  Their application reduces signs and symptoms during the 
acute episode and by reducing transcapillary filtration, increasing fibrinolytic activity and stimulation of 
collateral formation may reduce the incidence of PTS120.  Following an acute DVT Elastic compression 
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stockings (ECS) are prescribed both to alleviate venous symptoms and to prevent PTS121.    Studies 
performed have demonstrated conflicting results, with several randomised control trials (RCTs) showing 
that daily use of ECS can prevent PTS40, 63, and others failed to demonstrate any benefit107, 122. A meta-
analysis pooling 5 RCTs123 and a Cochrane review124 concluded that ECS reduced the incidence of PTS 
from 46 to 26% [RR 0.54, 95% CI, 0.44-0.67] with the greatest benefit in severe PTS [RR 0.38, 95% CI, 
0.22-0.68]. These results are summarised in Table 8.  A recent study by Kahn el al122, a large multicentre 
randomised trial of patients with a first proximal DVT failed to demonstrate a benefit of wearing ECS for 
the prevention of PTS.
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Table 8:  Shows a summary of elastic compression stocking for the prevention of PTS.  Description of study designs and results 
Author, 
Year 
Participants 
(n) 
Stocking type Scoring System Stocking 
Duration (Yrs) 
Median Follow-
up 
Incidence of PTS (%) 
[RR with 95% CI] 
Mild/Moderate Severe Total 
Brandjes 
199740 
Stocking: 98 
Control : 96 
 
Stocking: Below-
knee, customised, 
30-40mmHg  
Control: No 
intervention 
Villalta Scale ≥ 2 76 months Stocking:  20 
[RR 0.50; 95% 
CI 0.31,0.81; p= 
0.004] 
Control: 47 
Stocking:  11 
[RR 0.54; 95% 
CI  0.28,1.06; 
p=0.07] 
Control: 23 
Stocking: 31 [RR 
0.56; 95% CI 
0.39, 0.80; 
p=0.002]  
Control: 70 
Ginsberg 
2001107 
Stocking: 24 
Control: 23 
Stocking: Below-
knee, 20-30 mmHg  
Control: Placebo 
stocking 
Custom 
definition* 
1.4-4.6 57 months   Below knee: 
Stocking: 0 
[RR 1.04; 95% 
CI 0.46,2.34;  
p= 0.92]  
Placebo: 4.3 
Partsch 
200473 
Stocking: 26 
Control: 11 
Stocking: Thigh 
length, inelastic 
compression (n=13) 
or 30-40mmHg (n= 
13) 
Control: Bed rest 
Villalta Scale Bed rest or 
compression for 
9 days and then 
stockings for 2 
years 
2 yr Stocking: 54 
Control: 82 
Stocking: 0 
Control: 0 
Stocking: 54 
[RR 0.78; 95% 
CI 0.41,1.48;  
p= 0.44] 
Control:82 
Prandoni 
200463 
Stocking: 90 
Control: 90 
Stocking:  
Below-knee,  
30-40mmHg 
Control: No 
intervention 
Villalta Scale 2 4yr Stocking: 22 
[RR 0.66; 95% 
CI 0.41,1.08; p= 
0.09] 
Control: 38 
Stocking: 3 [RR 
0.32; 95% CI 
0.09,1.14; p= 
0.08] 
Control: 11 
Stocking: 26 [RR 
0.62; 95% CI 
0.40,0.96; p= 
0.03] 
Control: 49 
Aschwanden 
2008125 
Stocking: 84 
Control: 85 
Stocking: Below-
knee, 26-36 mmHg 
Control: No 
intervention 
CEAP 
classification 
3.2 3.2 
2.9 
Stocking: 13 
Control: 20 
Stocking: 0 
Control: 0 
Stocking: 13 
[RR 0.69; 95% 
CI 0.34,1.41;  
p= 0.3] 
Control: 20 
*Typical pain plus swelling of > 1 month duration occurring ≥6 months after acute deep venous thrombosis 
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If compression stockings are used, both the type used and duration of therapy are a subject of debate.  
With regard to the duration guidelines recommend the use of ECS for 2 years following an acute DVT108, 
but a study of 169 patients demonstrated that only women had significant benefit from extending 
compression therapy from 6 months to 2 years [hazard ratio 0.11, 95% CI, 0.02-0.91]125. The type of ECS 
used has been studied widely.  Grade II graduated knee length compression stockings are the most 
commonly used in clinical practice and in studies.  With regard to DVT prevention in hospitalised patient, 
above knee ECS do not confer a benefit over below knee ECS126.  Grade III graduated ECS offer greater 
compression and therefore should offer greater benefit in reducing PTS, but no difference between the 2 
has been found for development of PTS107 or recurrence of ulceration, although this may be related to 
patient compliance as patients appear to be more compliant with grade II compression ECS over grade 
III, perhaps due to comfort and ease of application127.  Early application of compression and mobilisation 
has been found to be of benefit in the reduction of PTS in one study73, but this could not be 
corroborated further in this bandaging study128, however, early compression significantly increases vein 
patency the amount of recanalisation at 3 months compared with the application of ECS 2 weeks the 
initial DVT129.  No trials have yet investigated whether other methods of improving venous return, such 
as pneumatic compression devices or electrical muscle and nerve stimulation can prevent PTS, although 
they have been studied for its treatment. 
 
Exercise  
There is no clear correlation between exercise and the development of PTS, and exercise may exacerbate 
symptoms in patients with obstruction to venous outflow of the lower limb.  In one study early 
mobilisation reduced the risk of developing PTS73, however, another found no correlation between the 
reported level of physical activity 1 month after the initial DVT and the subsequent development of 
PTS130, 131.   Although exercise should help the development of a collateral circulation132 structured 
exercise programmes for patients with DVT improve recanalisation rates of occluded veins133.  
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 Thrombolysis 
As early recanalisation of the vein reduces the incidence of PTS, if thrombus is removed early the venous 
outflow would be restored, reducing venous hypertension and reducing PTS59 and patients who 
underwent surgical thrombectomy had improved venous patency and a reduction in PTS  when 
compared with the use of anticoagulation alone134.  In the presence of residual thrombus, the rate of 
recurrent DVT is higher135, and recurrent DVT is a risk factor for developing PTS.  It should therefore 
follow that reducing the thrombus load early is beneficial to the patient.   
Systemic thrombolysis for acute DVT is efficacious136-139.  In a meta-analysis on the use of thrombolysis 
for acute DVT there was a significant improvement in complete clot lysis [RR 4.14; 95% CI 1.22 to 14.01] 
which is maintained [RR 2.71; 95% CI 1.84 to 3.99]140, and this appears to follow through to result in a 
reduction in the symptoms and signs of PTS141, 142, but as expected the risk of major bleeding is increased 
with systemic thrombolysis [RR 2.9; 95% CI 1.1 to 8.1 p=0.04] compared to heparin alone134.  Catheter-
directed thrombolysis (CDT) infuses the thrombolytic agent locally to the affected limb, which reduces 
the overall dose of the drug infused and should reduce the rate of major bleeding complications.  Three 
randomised trials of CDT reported benefit; an improved rate of complete lysis in patients undergoing 
CDT (72% vs. 12% p<0.001)143; a reduction in the rate of PTS development in patients treated with CDT 
compared to anticoagulation alone (3.4% vs. 27.2%, p=0.001) (41.1% vs. 55.6%, p=0.047)144, 145; a 
significant reduction in recurrent VTE (2.3% vs. 14.8%, p=0.003)144; a reduction in haemodynamic 
venous obstruction [20% vs. 49%; RR 29.1% (95%CI:20-38% p=0.004)]145. However, major bleeding 
complications were higher in the treatment than control group (3 vs. 0)145.  
 Percutaneous pharmacological mechanical thrombectomy (PPMT) may be used in conjunction with 
CDT, to further reduce the thrombus load following an acute DVT.  This technique has recently been 
developed and involves mechanical removal of thrombus in conjunction with local delivery of 
thrombolysis medication, further reducing exposure to thrombolytic agents and perhaps improving 
efficiency and effectiveness of thrombus removal. Small studies have shown encouraging results and a 
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recent systematic review confirmed safety and efficacy but highlighted the need for high level evidence 
from large randomised controlled trials146.    
 
Treatment of PTS 
Once the diagnosis of PTS is established, treatment relies on alleviation of patient symptoms.  There is 
little in the way of trial data to guide the treatment of established PTS.   Most physicians recommend the 
use of ECS, however only 1 randomised trial using placebo stockings that were too large for the patients 
has evaluated this and found no significant benefit to active compression, however the numbers were 
small107, however, even large stockings would exert some compression104.  Compression therapy does, 
however, accelerate healing of venous ulceration147.  Intermittent pneumatic compression (IPC) may be 
an alternative to ECS, and appear to improve symptoms in patients with PTS148, however, the 
practicalities of long term use are limiting.   Other pumps such as the VenowaveTM device, a small 
peristaltic calf pump, in small trials have demonstrated an improvement in PTS scores and patients 
quality-of-life106.  Further evaluation of novel electrical calf muscle and nerve stimulation devices, which 
have been seen to improve venous haemodynamics may be of benefit to patients with PTS, but this has 
yet to be further evaluated149-151.   
There are several pharmacological agents that have been evaluated for the treatment of patients with PTS 
and venous ulceration, however, non are currently in widespread use in the UK as trials have been small 
and heterogenous.  Pharmacological treatments which treat the processes of inflammation and venous 
hypertension may be of benefit152.   The use of Aspirin 300mg has been shown to improve ulcer healing 
rates153.  Flavonoid derivatives have both anti-inflammatory and venoactive properties and micronised 
purified flavonoid fraction (MPFF) significantly improved symptoms in a large trial154, as well as in a 
metanalysis155.  Some other flavonoid derivatives including the rutosides156 have improved patients 
symptoms but others have shown no additional benefit over compression therapy alone157.  Horse 
chestnut seed extract158, calcium dobesilate159, 160 and pentoxifylline161 may provide additional benefit over 
compression therapy alone.   
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Surgical treatment options may benefit patients with PTS.  Treatment of superficial veins improves deep 
venous haemodynamics and improves calf muscle pump function162, 163 but is less effective in preventing 
ulcer recurrence in PTS than primary valvular incompetence164, 165.  Deep venous surgery including valve 
repair, transposition or transplantation have been performed and are discussed in more detail in Chapter 
2.  For patients undergoing valve reconstruction in a 25 year follow up study of 51 limbs there was a 
higher rate of symptom and ulcer recurrence in patient with PTS compared with primary venous 
incompetence [43% vs. 73% p=0.029]166.  Surgical167, 168 and percutaneous169, 170 recanalisation of 
chronically obstructed veins improves venous haemodynamics and symptoms of chronic venous disease 
their value in the treatment of PTS has not yet been fully evaluated.    
 
Discussion 
PTS occurs in around half of patients following a DVT.  Patients are often left with residual obstruction 
to venous outflow and venous reflux as a result of the underlying pathophysiological processes. The 
resulting valvular damage and venous hypertension causes severe symptoms and signs, including venous 
ulceration and impairs patients’ quality of life.  Treatment options are limited and the evidence for them is 
lacking.  Compression therapy remains the mainstay of treatment.  Aggressive treatment of the initial 
DVT to restore venous flow and reduce thrombus load may be beneficial in reducing the severity of PTS, 
followed by adequate anticoagulation. Prevention of PTS is more beneficial to patients than treatment 
once it is established, however, once it has been diagnosed symptoms can be further improved by surgical 
and radiological treatment to restore venous outflow and valve function.  These management options are 
discussed further in Chapter 2.   
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2. AIMS 
Venous disease is a healthcare burden with a detrimental effect on the patient’s quality of life.  While 
there have been advances in the treatment of superficial venous disease, there has been very little change 
in the management of patients with deep venous disease over the last few decades.  Currently the only 
management option for these patients is compression or major surgery.  A minimally invasive treatment 
option for this group of patients should be available.    
 
The main aim of this project is to: 
• Design and develop a valve for implantation into the lower limb deep venous system to treat 
patients with deep venous insufficiency 
In order to achieve the main aim of the overall project, each stage of this proposal has a specific objective 
and there is immense potential to generate novel secondary research avenues as the subject of deep 
venous disease remains under researched. These specific objectives are: 
• To further evaluate anatomical and haemodynamic variables in normal subjects  
• To provide data required for the development of computational and experimental flow models 
for deep venous function 
• To develop computer models of venous flow in normal deep venous function and validate this 
using data from duplex ultrasound and MRI scanning 
• To set up and validate a laboratory model of deep vein flow in the form of a flow rig  
• To investigate previously used and novel materials to engineer a prototype bioprosthetic deep 
vein valve replacement 
• To design a valve utilising the models 
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• To test this valve in the validated laboratory model 
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3. DEEP VENOUS DISEASE 
 
3.1 CURRENT TREATMENT OPTIONS FOR PATIENTS 
WITH DEEP VENOUS DISEASE 
 
Introduction 
The treatment options and recommendations for patients with PTS have been discussed, but the majority 
of patients have primary venous disease.  Current treatments for chronic deep venous insufficiency are 
limited, with variable success rates.  The management options for patients with deep venous disease are 
discussed further here. 
 
Conservative Management Options 
Leg Elevation 
Conservative treatments for chronic deep venous insufficiency are limited.  Measures including leg 
elevation, weight reduction, walking, exercise and physiotherapy act to improve venous haemodynamic 
return and reduce venous hypertension.  This alone, however, is invariably not sufficient and it impacts 
significantly on patients’ daily lives.  
 
Compression  
Compression in some form is recommended for patients with venous disease by most surgeons and 
physicians.  Contraindications to compression include concurrent peripheral arterial disease, severe 
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peripheral neuropathy and contact dermatitis, however, for the majority of patients it remains the first line 
of treatment.  Compression may exacerbate symptoms in patients with occlusion, reliant on superficial 
venous channels.  The type of compression used varies between countries, centres and even individuals 
within the same institution and there is little in the way of consensus.  However, a recent Cochrane review 
in 2009 concluded that venous leg ulcers heal more quickly when compression is applied147.   
 
Hosiery 
Graduated compression stockings can be applied and removed by the patient and are therefore the most 
commonly used form of compression.  As with all compression devices, however, the amount of 
compression applied depends upon measurements taken and the individual fitting the stocking, and can 
be reduced over time or indeed as the patients swelling improves, for example.  The pressures indicated 
by the manufacturer can also vary between brands of stocking.  Meissner et al, 2007 recommended that 
the 1st choice for compression pressure for patients with C0-C2 disease is 10-20mmHg (Grade 1), for C3-
C4 disease is 20-30mmHg (Grade 2) and for patients with C5-C6 disease is 30-40mmHg (Grade 3).  For 
patients with deep chronic venous disease, the recommendation is that the compression is lifelong18.  
Although it improves symptoms and prevents ulceration, patient compliance is poor6.  
 
Four layer compression 
Multi-component compression systems improve healing of ulcers compared with single component 
systems147.  However, the recent randomised controlled Canadian Bandaging trial171 involving 424 
individuals failed to show a significant difference in ulcer healing times, recurrence or health related 
quality of life between four layer bandaging and short stretch bandage.  
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Intermittent Pneumatic Compression (IPC) 
A Cochrane review in 2011 of 7 randomised controlled trials concluded that IPC use reduces ulcer 
healing time and increases the number of healed ulcers when compared to dressings alone, but not 
conclusively when compared to other forms of compression172.  The use of IPC is well documented for 
use in venous thromboembolism prophylaxis and for treating lymphoedema and it is known that it 
improves peripheral haemodynamics.   
 
Electrical stimulation of calf muscle pump 
Repeated contraction of the calf muscle pump improves venous velocity and reduces the incidence of 
peri and postoperative deep vein thrombosis.  Dysfunction of the calf muscle pump either due to joint 
immobility or paralysis reduces venous return and worsens chronic venous insufficiency.  Stimulation of 
the calf muscle to contract either by direct stimulation of the muscle or by indirect nerve stimulation may 
improve symptoms and ulcer healing in patients with chronic deep venous disease.  This may be 
especially beneficial for patients in whom external compression is contraindicated due to peripheral 
arterial disease, and others who are not able to tolerate it due to discomfort.  Venous haemodynamics are 
improved as calf muscle stimulation, which generates contraction of the muscle will eject blood from the 
lower limb veins.   
 
Electrical Muscle Stimulation 
An electrical current applied directly to the calf from a conducting pad applied to the surface of the skin 
directly overlying the muscle causes the calf muscle to contract.  A recent study has demonstrated a 
possible added benefit over and above the improvement in venous haemodynamics seen in patients who 
wear this for a short period of time.  Patients who use this system daily over a week may have an 
additional habituation effect which increases ejected venous volume and peak venous velocity173.  As yet, 
there is no data to suggest this improves clinical outcomes.  
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Electrical Nerve Stimulation 
Transcutaneous nerve stimulation to induce calf muscle contraction by stimulation of the peroneal nerve 
has been shown to enhance venous flow including flow volume and peak velocity comparable to EMS 
and IPC174.  In addition when compared to EMS there was less pain and discomfort, however, these 
differences were not significant.  As yet, there is no data to suggest this improves clinical outcomes.  
 
Drug therapy 
There are several drugs available which improve symptoms of venous disease, however, none are 
available in the UK.  Daflon®, for example, is popular in Europe, but trials have been small and 
heterogeneous and it is not available across the UK.  It is a micronized purified flavonoid fraction 
(MPFF) consisting of 90% diosmin and 10% flavonoids expressed as hesperdin.  It improves the 
symptoms reported by patients with venous disease, including reducing calf or ankle circumference and 
improving quality of life, by reducing capillary permeability, improving lymphatic drainage and venous 
tone.  In addition, when combined with standard treatment for lower limb venous ulcers, it has been 
shown to reduce ulcer healing time 175.  The use of other drugs including Oxerutins, rutosides and other 
flavonoid derivatives, which have similar mechanisms of action to MPFF, as well as diuretics, 
naftidrofuryl, Pentoxifylline, calcium dobesilate, and prostaglandin E1 have been shown in trials to either 
improve symptoms or reduce the duration of ulcer healing, but their use remains limited.  
 
Surgery 
Deep venous surgery is performed, but its widespread use is restricted. Valvuloplasty, venous 
transposition, valve autotransplantation and neovalve procedures have all been performed176.  Although 
isolated small studies and case series have shown promising short term results from these invasive 
procedures, consistently good long-term results are lacking.  Moreover, a number of other limitations of 
deep vein surgery have emerged.  
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• Deep vein surgery is highly invasive, involving often long and difficult procedures.  
• Elderly patients with extensive co-morbidity are often unfit or unwilling for such interventions. 
• Long term (often lifelong) anticoagulation therapy is usually required.  
• Deep venous surgery is only offered in a few specialist centres worldwide. 
• Patients are likely to require extensive hospital admission after deep venous procedures, resulting 
in significant health care expenses and time off work. 
Long-term success has not been reliably demonstrated. Consequently, deep venous surgery is performed 
in a small number of centres worldwide and is available for a minority of patients.  A Cochrane review in 
2004 concluded that there is not enough evidence on the effects of surgery for deep venous 
incompetence, but recommended that more well-designed, randomised trials with long term follow up are 
needed177.   The options for the surgical management of deep venous disease are discussed in more detail. 
 
Valve reconstruction 
Valve reconstruction, or valvuloplasty, aims to restore valve competence and is the surgical treatment of 
choice in patients with primary venous insufficiency.  This can either be carried out by the internal 
method178, under direct vision, which was first carried out by Kistner and subsequently modified, or by 
the external method by restoring the diameter of the vein lumen using sutures at the point of insertion of 
the valve cusps179-181.  An alternative to external valvuloplasty is external valve banding, in which an 
external cuff of material is applied, thus avoiding a venotomy.  Many materials have been used including 
PTFE, silastic, Dacron, and live fascia182.  The disadvantage of both of these external techniques is that 
the valve leaflets are not repaired, so remain incompetent if they are damaged, however, the benefits are 
the avoidance of a venotomy which may causing an inflammatory process and possible subsequent 
thrombosis. 
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Venous transplant 
A segment of vein with a competent valve matched for size, for example the axillary vein, is transplanted 
or relocated to the incompetent deep vein.  This procedure is often carried out in combination with an 
external valve banding in an attempt to preserve competence.  These transplanted veins are however, 
prone to failure either due to thrombosis, or more commonly for no identifiable reason.  The reported 
results show a wide discrepancy, ranging from a 75% success rate and a 92% technical success rate at 5 
years183, 184 to 50% at 10 years. 
 
Neovalve formation 
A new valve is constructed from the patient’s own tissue.  The techniques that have been described for 
these procedures are plentiful, but the most commonly employed are Maleti’s technique using the vein 
intima to create the valve leaflets, and Plagnol’s technique using the invaginated termination of the long 
saphenous vein to create the valve.  The patient’s own tissue is used and transposition of a vein from 
another location is not required, thus reducing morbidity compared to venous transplant. The results 
from Italy of autologous valve reconstruction have shown similar success, with a median follow-up of 22 
months demonstrated a clinical improvement in 89% of cases, with an overall vein patency rate of 
83.3%185. Short-term results of cryopreserved vein valves in humans have not been so favourable with 
patency rates of 41% at 2 years and a competency rate of 27%186. 
 
Venous Transposition 
A segment of long saphenous vein or deep femoral vein containing a competent valve is transposed onto 
the incompetent femoral vein, a technique first described by, Kistner and Sparkuhl in 1979187. This 
technique has the appeal of a single anastomosis between the two adjacent segments. Early outcomes for 
the patients were good, but at 3 years many had recurrence of both symptoms and reflux.  Queral et al 
performed venous transposition alone in 12 limbs of 9 patients, early results were again promising, but at 
1 year 9 of the 12 limbs had reverted to the preoperative abnormal venous refilling time, with many 
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having recurrent leg ulceration188, 189.  Between 1983 and 1997, Perrin performed 18 transpositions, with 
the superficial femoral vein transposed onto the great saphenous vein in 11 cases and onto the deep 
femoral vein in 7 cases190, however, concomitant superficial or perforator vein surgery was performed in 
14 of these cases.  Of 9 patients in the study group who had active or previous ulceration, 2 had recurrent 
ulceration.    Of the 17 patient followed up with duplex scanning post operatively, 29% had major reflux 
and 6% had minor reflux.  This procedure is now rarely performed. 
 
Surgical and Interventional treatments for deep vein obstruction 
Occlusive disease causing lower limb outflow obstruction occurs more commonly in the iliac vein.  It can 
also result from more distal segmental occlusions after a failure of recanalisation following a deep vein 
thrombosis.  Correction of the outflow obstruction improves patients’ symptoms, reduces ulcer healing 
times and improves quality of life191.  
 
Venous Stenting 
Venous stenting for occlusion has been proposed, but is only performed in a few centres in significant 
numbers16. However, complete occlusion is present in only a minority of patients with deep venous 
disease, with valvular incompetence responsible for the majority.  In one single centre study, 304 limbs 
with symptomatic chronic venous insufficiency were treated, resulting in primary and secondary stent 
patency rates at 24 months of 71% and 90%, respectively with symptomatic relief in over 70% of patients 
192.  Hartung et al reported they were able to reproduce this with follow up at 36 months demonstrating 
primary and secondary patency rates of 73% and 90%193. 
 
Bypass procedures 
Patients with occlusive disease may benefit from venous bypass procedures, such as femoro-femoral 
crossover bypass (Palma procedure)194 and iliocaval bypass with autologous ipsilateral or contralateral 
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long saphenous vein, or reinforced PTFE195.  Saphenopopliteal bypass is infrequently performed, but 
published results show a 77% functional improvement but variable and often poor patency of 5-
100%196.This does, however, necessitate major surgery and often lifelong anticoagulation, and reported 
outcomes have been variable, and consequently, relatively few procedures are carried out.  
 
Summary of surgical treatment options for patients with deep venous disease 
Deep vein reconstruction procedures are highly challenging, operator dependent surgical procedures, and 
require meticulous surgical technique and comes with it a recognised learning curve. There is no single 
operation applicable to every patient, and every patient requires a thorough clinical and diagnostic 
workup.  Deep vein reconstruction (either by surgery or by radiological intervention) should be 
considered early in the management of selected patients.  The interventional and surgical choices for 
patient management are shown in Figure 10. 
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Figure 10: Shows a summary of the management choices for patients suitable for deep venous surgery197 
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Bioprosthetic valves
Bioprosthetic valves could be implanted to treat patients with both deep venous reflux and obstruction.  
None are currently in clinical use.  Early prototypes which reached the stages of animal studies yielded 
poor outcomes as the majority of stents occluded within a few weeks.  A complete review of previous 
work carried out in there development is considered in the next part of this chapter.  
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3.2 IMPLANTABLE VENOUS VALVES FOR DEEP 
VENOUS INSUFFICIENCY – THE STORY SO FAR  
 
Introduction 
Previous attempts to develop a percutaneous prosthetic vein valve implant have been disappointing198. 
For over 40 years, researchers have attempted to create prostheses. Results from early animal studies were 
poor as the majority of stents occluded within a few weeks199, 200. More recent prostheses involved single, 
double or triple cusp leaflets usually mounted on a self-expanding metal frame. Animal studies showed 
promising early patency rates, but poor long-term results201. Nevertheless, 2 clinical studies have been 
conducted in recent years. In one small series, early occlusion was seen in 4/5 implants, thought to be due 
to inappropriate valve design202. More recent work by Pavcnik et al demonstrated early success and deep 
vein competence in 14/15 studied patients with early clinical improvements. However, stent valve 
occlusion was seen in 4/15 patients by 7 months and by 12 months, all the remaining valves had failed 
and become incompetent203.  
Presently, polymers and polymer coated metal stents, used in the vascular system have several problems: 
they are very thrombogenic, resulting in a deep vein thrombosis and an occlusion of the vein, they lack 
haemocompatibilty and biocompatibility, which causes an inflammatory reaction to occur, their presence 
results in intimal hyperplasia, which subsequently causing vessel narrowing and material failure.  All of 
these would serve to worsen the symptoms and signs of venous disease.  In addition they lack the 
required mechanical properties, as ideally, they should have the ability to expand and contract along with 
the vein, which can double in size with changes in the patient position from lying to standing.   
This review aims to describe previous work that has been carried out and to summarise the reasons for 
failure to guide future work to develop a successful deep vein valve replacement for the treatment of 
patients with chronic venous insufficiency.  
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Methods 
The review was conducted according to the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines19.  Relevant papers were identified through systematic searches of Pubmed 
(1966 to October 2010). The search terms “bioprosthetic vein valve”, “prosthetic vein valve”, 
“implantable vein valve”, “vein valve replacement”, “percutaneous vein valve” and these search terms 
repeated with “vein” replaced by “venous” were used. Article titles and abstracts were screened for 
inclusion. A manual reference list search was also carried out for further appropriate studies to be 
considered for inclusion, ensuring relevant papers published before 1966 were included. Relevant full text 
articles were scrutinised and all studies reporting details of implantable deep vein valves at any stage were 
included. Articles concerning deep vein thrombosis, deep venous valve open surgery or replacement, 
superficial vein valves and cardiac valves were excluded. 
 
Results 
Although the initial search strategy yielded 1486 results, with 13 articles included from elsewhere, 
following exclusion of non-relevant publications, a total of 19 articles were included (Figure 11). All 
selected studies aimed towards developing a minimally invasive technique to implant a natural or synthetic 
valve into the deep venous system to treat patients with deep venous insufficiency.  To highlight the 
development process, the results are categorised into in vitro studies, animal studies and in human clinical 
studies.  The problems encountered with the valves and suggestions for improvement are also 
highlighted.  
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Figure 11: Shows a summary of the search strategy for all studies of implantable deep venous valves 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
           
 
Records identified through database 
searching  
(n = 1486 publications 
between 1963 and 2010) 
Additional records identified through 
other sources  
(n =13) 
Records screened (title)  
(n = 1499) 
Records excluded  
(n = 1445) 
Exclusion criteria: Articles on 
deep vein thrombosis, deep 
venous valve surgery or 
replacement, superficial vein 
valves and cardiac valves, title of 
paper not within scope of 
review 
Abstracts and full-text 
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eligibility (n = 54) 
Records excluded  
(n = 35) 
Excluded: duplicate records, 
open surgical techniques                                                                                                                                                                                                                                                              
cardiac valve studies  
 
 
 
 
 
Studies included (n = 19) 
Search terms entered: 
“bioprosthetic vein valve” OR “prosthetic vein valve” OR “implantable vein valve” OR “vein valve 
replacement” OR “percutaneous vein valve” OR “bioprosthetic venous valve” OR “prosthetic venous valve” 
OR “implantable venous valve” OR “venous valve replacement” OR “percutaneous venous valve” 
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In vitro studies 
Natural Valve material 
Geselschap et al204 in 2006 carried out an in vitro evaluation of an autologous valve-stent device.  They 
used a Palmaz stent, which is a balloon expandable stent made from woven surgical grade steel, initially 
developed for use in arteries.  By sawing half way along the length, so when expanded, half is cylindrical 
and half collapsed, and attaching a segment of vein without valves placed inside the stent and folded back 
to cover both the inside and outside of stent, the valves were made.  During prograde flow the valve 
opened, then reversal of flow caused the unsupported part of vein to collapse against the stent.  The 
major advantages of this design were that it was able to be deployed percutaneously and it is made of 
autologous tissue.  The valve was mounted vertically for testing in a laboratory flow model.  To mimic the 
calf muscle, rapid prograde flow generated by a pump for 3 seconds is followed by allowing 3 seconds to 
allow column to fall back.  Duplex scanning was performed using a solution containing 10 micron 
polyamide microparticles.  Twenty valves were tested.  They demonstrated a closure pressure of 1-3 
cmH2O.  Nine of twelve valves tolerated flow up to 1000ml/min and the closure time was 0.04-0.33s.  
There were however, some issues with the valves tested.  The valve started to deform with repetitive 
cycles in 3 valves due to saline filling between layers which was resolved by eliminating side branches.   
No further results on additional testing of this valve have been published. 
Gluteraldehyde fixing of veins and valves has been considered as an option for the open surgical 
replacement of deep venous valves for many decades.  DeLaria et al205  carried out a haemodynamic 
evaluation of a venous valve implant in vitro, which they aimed to subsequently mount on a stent after 
further testing. They used gluteraldehyde fixation of 9 bovine jugular vein segments containing a valve in 
0.2-0.5% solution and tested in a flow circuit.  When compared to fresh vein segments, the fixed veins 
with valves demonstrated significantly higher opening times, significantly reduced expansion with 
increasing pressures and a significant reduction in orifice area at higher flow rates.  However, they did 
show less reflux when subjected to higher back pressures.  Thrombogenicity and biocompatibility are not 
tested, and the author raises concerns regarding the flexibility of the valve leaflets and their suitability for 
the venous system.   
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Pavcnik and his group to date have the most published literature on the subject of percutaneously 
implantable deep venous valve replacements.  Since 1999, they have developed several bioprosthetic vein 
valves (BVV) and are now in the process of developing a 4th generation valve.  In 2000, the first 
generation BVV1 was developed, consisting of a square stainless steel stent with leaflets of small intestinal 
submucosa (SIS).  SIS is described as an acellular, non-immunogenic, biodegradable, xenogenic, collagen, 
predominantly type 1, based biomaterial from submucosal layer of porcine small intestine, which is pliable 
when wet.  It attracts host cells, is a good bioscaffold and rapidly is remodelled by the host vessel and 
degraded.  Two leaflets of SIS were stretched over the stent and once deployed via catheter, two valve 
sinuses were created206.  The valves were evaluated in vitro using a flow circuit and a back pressure of 
60mmHg created by a column of water, which resulted in valve leaflet closure.  Forward flow was 
generated in a constant manner by a pump, and in a pulsatile manner by a reservoir bag with manual 
compression to simulate the calf pump.  The valve leaflets opened with forward flow and with valve 
closure the pressure below the valve reduced.  Subsequently the valve was evaluated in both a canine and 
ovine model and in a phase I clinical trial as discussed below.  Due to the problems associated with the 
valve a second generation valve (BVV2) was developed.  These in vitro studies are summarised in Table 
9. 
76 
 
Table 9: Shows the in vitro studies utilising a natural valve material 
Reference Materials used  
 
Design Method of testing Results of testing Further improvements 
needed 
Geselschap et al204, 2006 Great saphenous vein on 
surgical steel  Palmaz 
stent 
Stent sawed along half 
way, saphenous vein 
sutures around it to cover 
both the inside and 
outside of the stent 
Mounted vertically, saline 
filled system, 3 second 
prograde flow, 3 second 
fall back, assessed by 
duplex scanning 
Closure pressure 1-
3cmH2O 
Opening pressure 2-
4cmH2O 
Closure times 0.04-0.33s 
 Saline filling between the 
walls – reduced by side 
branches  
DeLaria et al205, 1993 Gluteraldehyde preserved 
bovine jugular vein 
Bileaflet bovine valve Respiratory flow pump in 
circuit with video camera 
and flow meter.  Tested 
before and after fixing 
with gluteraldehyde 
Gluteraldehyde fixing 
results in: 
reduction in orifice area 
at higher flow 
reduced expansion with 
increasing pressure 
prolonged opening times 
 Requires mounting on a 
stent 
 Smaller sizes may 
increase thrombosis 
 Safety and 
biocompatibility need to 
be demonstrated 
Pavcnik et al207, 2000 Stainless steel stent with 
leaflets of SIS (Pavcnik 
BVV1) 
Square based stainless 
steel stent with 2 leaflets 
of SIS sutures with 
prolene, deployed via 
catheter 
In flow circuit , 
retrograde pressure 
60mmHg,  valve closed at 
rest, both pulsatile and 
non pulsatile forward 
flow 
Pressure below valve 
reduced 
Valve closed at rest 
Opening pressures high 
 Further evaluation in 
animal studies carried out 
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Synthetic Valve Material 
Oberdier and Rittgers208 in 2008 designed a prosthetic valve  consisting of a solid frame and flexible 
leaflet, with a circular base and 2 opposing struts, with shoulders for reinforcement,  projecting with an 
anchored flexible leaflet.  In order maintain native anatomy, a bevelled leaflet attachment was created to 
allow the formation of the valve sinuses.  These features evolved over several stages following in vitro 
testing.  Zones of stasis and excessive shear stress were diminished to minimise blood damage and 
thrombus formation.  The resting valve position was open.  The prototype was made utilising a photo-
activated polymer resin of bis-(epoxycyclohexly)-methylcarboxylate and 2,2-dimethoxy-2-
phenylacetophenone (RenShape®) for the frame, cured in an Ultraviolet (UV) oven, for the frame .  The 
leaflets were created using a hand fabrication technique with 0.1270mm thick sheets of ‘Biospan’ 
(segmented polyether urethane), cut with a surgical scalpel and superglued to the flange. The initial 
problems encountered including high closure pressure, leaflet sagging and frame breakage, were corrected 
prior to quantitative testing by bevelling the proximal base edge and by incorporating a supporting 
shoulder on the flange.  Testing was carried out in a flow system209 with pulsatile flow via roller pump and 
two hydrostatic pressure towers, controlled by hydraulic communications to simulate body positions, 
including standing and supine positions with both breathing and ankle flexion.  The results from the flow 
system indicated that testing the valves in the standing, breathing simulation gave the best discrimination 
between the valves.  All valves gave significantly improved haemodynamics compared to “no device” 
controls, including regurgitation, percent reflux, reflux energy loss and energy retention, however, valves 
sized at 2.50 and 3.75mm were significantly superior to 1.25 and 5.00mm suggesting that there were issues 
with scalability. 
Sathe and Ku, in 2006210 developed a flexible prosthetic vein valve designed with the criteria that it must 
be able to withstand 300mmHg back pressure with <1ml/min leakage, the initial and second opening 
pressures  must be less than 5mmHg, and it must be able to withstand 500 cycles opening and closing. 
The valve was fabricated using Salubria, a freeze thawed organic polymer containing poly (vinyl alcohol, 
fixed with polymeric glue, injected into a 2 part silicone cavity mould, fixed and polished.  The tests 
carried out included initial opening pressure, second opening pressure, reflux leakage, burst pressure and 
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cyclic life functionality.  11 valves were tested and 5 showed good competency, but it was discovered that 
valve opening pressures increased after exposures to high back pressures, however, only 5 of the 11 
valves underwent testing of the opening pressures after proximal pressure testing as they demonstrated 
poor competency testing.  Only one valve was tested for cyclic life functionality and was able to withstand 
500,000 cycles and still maintain competency.  Burst pressure testing also yielded results that were well 
above physiological pressures.  Further studies have not yet been published, however, this valve is 
undergoing testing in an animal model. 
Most recently in 2011, Moriyama et al211 produced fibre scaffolds by electrospinning polyurethane over 
cobalt-chromium stents. This material has previously been shown to support endothelial cell growth212. 
Electrospinning is a technique whereby a voltage is applied across a solution in a syringe in a syringe 
pump.  The needle is positively charged, and the collecting plate is grounded, drawing out a fibre of 
polymer from the solution.  They developed an in vitro model to simulate standing, standing with ankle 
flexion and supine positions.  In the standing positions, both open and biomimetic bicuspid polyurethane 
valve prevented the increase in distal pressure with small amounts of leakage, however, the open valve 
had greater, 0.514ml/s against 0.034ml/s, leakage than the biomimetic valve.  It was noted however, that 
large stagnation zones were present between the leaflets of the valves and the tubing walls.  This could 
represent a potential site for thrombus formation.  These are summarised in Table 10.  
79 
 
Table 10:  Shows the in vitro studies utilising a synthetic valve material 
Reference Materials used  
 
Design How tested Results of testing Further improvements 
needed 
Oberdier and Rittgers208, 
2008 
Frame – photo-activated 
resin RenShape® 
Leaflet – polyether 
polyurethane 
Circular base with 2 
opposing shouldered 
struts, projecting with an 
anchored flexible leaflet 
Pulsatile flow pump, 
pressure towers, 3.45% 
dextran fluid.  Standing / 
supine / breathing /ankle 
flexion included. 
Compared to “No device” 
Improved haemodynamic 
compared to “No device” 
Intra-design variability 
Valve size had effect on 
performance 
Authors suggested drug 
reservoir incorporation 
Thickness scaling for 
different sizes 
 
Sathe and Ku210, 2006  Poly(vinyl alcohol) 
hydrogel, “Salubria” 
Polymer injected into 
mould 
Bicuspid valve with 
leaflets open in resting 
position 
Withstand back pressure 
300mmHg with leakage 
<1ml/min, initial and 2nd 
valve opening pressure 
<5mmHg, withstand 
500,000 cycles 
5/11 good competency 
opening pressures 
increased after high back 
pressures 
Good cyclic functionality 
Additional flow testing 
needed to determine 
optimum valve shape 
Moriyama et al211, 1993 Electrospun polyurethane 
Cobalt-chromium stent 
Bicuspid valves with 
leaflets in closed 
(biomimetic) and open 
resting positions 
In vitro model to simulate 
3 positions, flow fields 
visualised and recorded by 
video 
Valves withstood 
150mmHg pressure with 
minimal leakage 
Open valve regurgitation 
> closed valve in 
standing position 
 
 
Additional studies 
needed to characterise 
material 
Large stagnation zones 
noted between leaflets 
and tubing 
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Animal studies 
Natural Valve material 
By far the most extensive work has been carried out using natural valve material in animal studies.  As yet, 
no results have been published using synthetic material in animal studies.  De Borst et al213 from the 
Netherlands used a percutaneous venous valve bioprosthesis (PVVB), from VenPro Inc., USA,  and 
implanted it into the porcine venous system, 18 valves into the iliac systems of 10 pigs.  PVVB is a 
gluteraldehyde preserved valve bearing venous xenograft from segment of bovine jugular vein containing 
competent bicuspid native valve sutured inside laser cut memory-coded nitinol frame, sutured in place 
with prolene.  In order to maintain the position within the frame, it was relatively oversized, and when 
inserted to common iliac vein, it was deployed endovenously to 2mm larger than the vein itself.  The 
valves were tested in vivo at 4 weeks to assess patency and competence with antegrade and retrograde 
phlebography, the animal was sacrificed and the valves underwent histological examination to assess 
thrombus formation and venous wall. They were graded 0 (no changes) to 4 (severe changes).  In pigs 
receiving vitamin K antagonists, sacrificed at 2 weeks due to bleeding complications, 7 of 8 valves were 
patent and 3 of 8 valves were competent.  In pigs receiving aspirin and clopidogrel, sacrificed at 4 weeks, 
5 of 10 valves were patent and 3 of 10 were competent.  Clearly long term patency and competency of 
these valves needs to be improved.  Gomez-Jorge et al201, also studied a gluteraldehyde fixed segment of 
bovine EJV with valve sutured in a self expanding nitinol stent from Boston Scientific.  They deemed the 
procedure to be technically feasible, however of the 11 valve-stent devices implanted either into the 
inferior vena cave or external iliac veins, 2 were unsuccessful immediately due to deployment in the renal 
vein and rupture of the inferior vena cava.  Animals were sacrificed immediately or at 1 week or 2 weeks..  
Of the 5 successful deployments which were sacrificed immediately, all were patent and competent, and 
of the 4 sacrificed at 1-2 weeks, of which 1 died in the cage, all were patent and competent, however, they 
all showed granulomatous change and foreign body reaction, and one showed bacterial contamination. 
Boudjemline et al214 did a similar study in 2004, again assessing a segment of bovine jugular vein 
containing a valve, preserved in gluteraldehyde and fixed in a platinum-iridium stent from Numed Inc.  
The gluteraldehyde was removed prior to use by soaking in saline solution.  They focussed on the longer 
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term outcomes, in contrast to Gomez-Jorge et al.  The valve stent devices were deployed endovenously 
into the IVC of 6 lambs and assessed 2 months after implantation.  In all 6 cases, the valves and IVC 
were completely occluded.  They questioned appropriateness of the use of the IVC to site the valve as the 
pressure gradient is so low, but in addition the material itself needs improvement as it is thrombogenic.  
Kucher et al215 made a direct comparison between segments of jugular vein containing valves from dogs 
implanted into canine femoral veins, either by open surgical technique or by a percutaneous technique 
after  mounting on a nitinol stent. In total, 7 dogs each had open surgery on one side, and the valve stent 
device inserted to the contralateral side, intraoperative venograms confirmed patency in all cases.  6 valves 
in each category remained patient at 120 days, reflux pressure was slightly higher in the stent grafts than 
the transplanted side.  This did not demonstrate that stenting was superior as expected, but it showed it as 
an alternative to valve transplant. Ofenloch et al216 in 1997 performed a similar study in goats, taking a 
segment of external jugular vein and valve and mounting it, by suturing with polypropylene,  within a 
Wallstent device, a self expanding stent made of stainless steel.  The terminal 1-2mm of the stent was not 
covered by EJV in the 1 week study, leaving exposed metal, however, for the 6 week study the stent was 
completely covered with tissue.  The devices were deployed endovenously back into the same animal, into 
the contralateral EJV.  The 5 animals tested at 1 week, which had exposed metal from the device, all had 
thrombus on the stent struts, however, the valves themselves remained both patent and competent.  
Those tested at 6 weeks, which had no exposed metal remained patent in all cases, however, 1 of the 6 
valves was incompetent.  Autologous valves clearly have good compatibility, however, may not be 
practical in clinical terms.  Dalsing et al217, 1996 carried out a feasibility study assessing 5 valve-stent 
devices  of canine external jugular vein over a stainless steel stent, deployed into the same animals iliac 
venous system.  Of the 5 devices placed, 1 migrated to the lung and only one that was placed in the 
common iliac vein was patent at 4 weeks, with 2 showing clot and all valves showing scarring. 
Pavcnik et al’s first generation valve, BVV1, was tested in both a long and short term animal model, 
inserted into canine and ovine Inferior vena cava (IVC) for the short term studies and into the external 
jugular veins (EJV) bilaterally of 12 sheep for longer studies with 3 animals receiving an extra BVV1 in 
the common jugular vein (CJV).  All were implanted via the percutaneous route.  In the short term 
study207, all venous valves implanted showed good patency for 6 weeks and good valve function and 
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histologically, SIS was incorporated smoothly into the vessel wall and a good covering of vascular 
endothelial cells covered the valve leaflets.  The longer term study demonstrated tilting on deployment in 
3 of the 25 valves in total implanted, but no reflux in 24 of the 25 valves, and 22 of the 25 valves were 
functioning at the time of animal sacrifice on venographic assessment, only one valve was thrombosed218.  
All valves demonstrated complete endothelialisation and neovascularsation histologically, one animal 
showed dystrophic calcification at 6 months.  Subsequently the BVV1 was inserted into 3 patients, as 
discussed below.  Following problems with tilting, Pavcnik et al developed the second generation BVV2.  
This consisted of 2 different stent designs and 2 different materials, implanted as a short term study in 
sheep EJV.  In total, 16 Z-stents with SIS were placed, 8 of the stents were stainless steel and 8 were 
nitinol.  All were placed without tilt and were competent and patent at 6 weeks.  Histological analysis was 
not carried out on the Z-stents.  32 double stents were sited, 4 stainless steel and 28 nitinol.  All were 
patent at 6 weeks.  However, 2 of 4 stainless steel double-stents became incompetent and had severe 
intimal hyperplasia on histological analysis and 2 of 28 nitinol double stents became incompetent.  
Histology of 4 of the valves showed endothelial cells and remodelling of the SIS.  Pavcnik et al219 also 
carried out studies in autologous venous valves harvested from sheep jugular veins, mounted in a stainless 
steel double stent and deployed into the contralateral jugular vein of the same animal. The outcomes were 
very good, and at 3 months 8 of 9 were competent, and the only incompetent valve showed immediate 
reflux due to a technical problem, 2 of 9 had perivalvular leak immediately.  However, the sutures and 
wires all showed extensive foreign body reaction and chronic inflammation.  These results are 
summarised Table 11.
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Table 11: Shows the animal studies utilising a natural valve material 
Reference Materials used / valve 
 
Animal Model used How did it work How tested Results of testing Further improvements 
needed 
Gomez-Jorge et al201 Gluteraldehyde fixed 
bovine EJV with valve 
sutured in self 
expanding nitinol stent 
(Boston Scientific) 
Porcine External iliac 
vein or Inferior vena 
cava 
Bicuspid valve in 
nitinol stent deployed 
endovenously  
Animals scarified 
immediately, at 1 week 
or at 2 weeks, 1 animal 
died in the cage 
Venographic for reflux 
Histopathology post 
mortem 
 
All had granulomatous 
change and foreign 
body reaction 
Immediate sacrifice – 
5/5 patent and 
competent 
1-2 week sacrifice 4/4 
competent and patent 
2/11 unsuccessful 
immediately after 
deployment, 1 had 
bacterial 
contamination 
Technically feasible 
but issues with 
deployment, vein 
rupture and 
inflammatory response 
De Borst G et al213, 
2003 
Gluteraldehyde 
preserved bovine 
jugular vein valve 
inside nitinol frame, 
VenPro USA 
Porcine iliac veins Bicuspid valve in 
nitinol frame, deployed 
endovenously 
Venography to assess 
patency and histology 
after animal sacrifice 
12/18 patent, 6/18 
competent., no 
inflammation and 
slight fibrosis in all 
valves 
Long term patency and 
competency 
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Boudjemline et al214, 
2004 
Gluteraldehyde 
preserved bovine 
jugular vein valve in a 
platinum-iridium stent 
from Numed Inc 
Porcine inferior vena 
cava 
Tricuspid valve in 
platinum-iridium stent 
deployed 
endovenously 
Venography to assess 
patency and histology 
after animal sacrifice 
6/6 completely 
occluded at 2 months 
Improvements in 
material 
thrombogenicity 
needed 
Kucher et al215, 2005 Jugular vein over 
nitinol stent 
Canine femoral vein Jugular vein harvested 
from dog, stretched 
over nitinol frame, 
native bileaflet valve 
contained in segment 
Venography to assess 
patency, histology and 
electron microscopy to 
assess valve structure 
6/7 patent at 120 days 
Valve structures intact 
Endothelial lining 
intact 
Further testing needed 
as model does not 
subject valves to blood 
column 
Ofenloch et al216, 1997 Goat external jugular 
vein over stainless steel 
stent 
Autologous goat 
external jugular vein 
Jugular vein harvested 
from goat, sutured in 
stainless steel stent, 
native bileaflet valve 
contained in segment 
Venography to assess 
patency and histology 
after animal sacrifice 
1 week –  5/5 patent 
and competent with 
thrombus on struts 
6 weeks – 6/6 patent, 
5/6 competent 
Autologous transplant 
not practical for 
clinical use 
Dalsing et al217, 1996 Dog EJV over 
Stainless steel stent, 
Cook Company 
Autologous dog 
common or external 
iliac vein 
Jugular vein harvested 
from dog, stretched 
over stainless steel 
stent, native valve 
contained in segment, 
placed endovenously 
Venography to assess 
patency and histology 
after animal sacrifice 
Animal sacrificed 
between 1-4 weeks 
1/5 migrated to lung 
5/5 Scarring 
1/5 patent at 4 weeks 
Needs to improve 
scarring and prevent 
migration 
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Pavcnik et al206, 2001 BVV1 (See above) Canine IVC 
Ovine IVC 
BVV1 as above Venography and 
pressure measurement, 
and histological 
assessment after 
sacrifice` 
Good valve function 
and patency in all 
animals for 6 weeks, 
SIS incorporated into 
vein wall, histology – 
leaflets covered with 
endothelial cells 
Longer term studies 
needed 
Pavcnik et al218, 2002 BVV1 Ovine EJV BVV1 as above Venography in live 
animals, and histology 
when animals 
sacrificed at 1, 3 and 6 
months 
1/25 thrombosed 
22/25 good function 
25/25 endothelialised 
1/25 dystrophic 
calcification 
Issues with valve tilting 
need addressing 
Pavcnik et al220, 2004 SIS membrane  on Z-
stent or double stent 
of nitinol or stainless 
steel (BVV2)  
Ovine EJV SIS membrane sutured 
over square nitinol 
stent , with additional 
stent to prevent tilting 
Venography in live 
animals immediate and 
at 6 weeks, and 
histology when animals 
sacrificed 
All stents placed no tilt 
16/16 Z stents 
competent and patent 
at 6 weeks 
28/32 Double stents 
competent and patent 
at 6 weeks 
Longer term study 
needed 
Pavcnik et al219, 2007 Jugular vein from 
sheep into double 
square stainless steel 
stent 
Ovine Jugular Vein Autologous bicuspid 
valve from jugular vein 
sutured in double 
square stent 
Venography at 3 
months, competence 
tested in vitro after 
explants, histology of 4 
samples 
2/9 immediate 
perivalvular leak 
8/9 competent at 3 
months 
 
The use of autologous 
tissue difficult in 
clinical practice 
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In Human Clinical studies 
Three clinical studies have been conducted in recent years. The phase I clinical trial in the first 2 patients 
was published by Gale et al202.  They observed that with their percutaneous venous valve bioprosthesis 
(PVVB), consisting of gluteraldehyde  preserved bovine venous bicuspid valve on a nitinol frame, 
implanted into the femoral vein by a percutaneous method, 1 patient had a successful competent and 
patent valve with ulcer healing.  However, the second patient developed post insertion thrombosis and 
required a second procedure to restore patency, but most importantly also had a healed ulcer at 2 months. 
Suggestions were made for a second generation device for the future, including a shorter device, with less 
tissue, 3 cusps, made with porcine pericardium and increased radial strength to reduce compliance.  There 
are no further publications, however, data has been presented that the complete series consisted of 5 
patients, however, early occlusion was seen in 4 of the 5 implants, thought to be due to inappropriate 
valve design202, 221.  According to investigators reports, 1 valve embolised to the pulmonary artery198. 
Pavcnik et al, tested their early first generation BVV1 in human studies222, by implanting the valve by the  
percutaneous method via a right internal jugular approach into 3 patients with severe deep venous 
insufficiency.  Valves were assessed by descending venography in the first instance and at 2 months, then 
subsequently by duplex ultrasound up to 12 months.  Clinical assessment was also carried out.  All 
patients were fully anticoagulated.  1 patient had a significant perivalvular leak, no reflux through the 
valve, but importantly, complete ulcer healing, 1 patient had an oversized BVV with valve leak and 
persistence of clinical symptoms and 1 patient had good improvement in clinical symptoms, but due to 
tilting had valve leak.  The issues with tilting were addressed resulting in the development of second and 
third generation valves. 
More recent work by Pavcnik et al demonstrated early success and deep vein competence with early 
clinical improvements in 12 of 15 studied patients into whom the BVV3 was implanted.  The BVV3 was 
deployed percutaneously by the transjugular approach into the femoral vein. However, stent valve 
occlusion was seen in 4 of the 15 patients by 7 months and by 12 months, all the remaining valves had 
failed and become incompetent198, 203.  These are summarised in Table 12. 
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Table 12: Shows the in human clinical studies 
Reference Materials used / valve 
 
How did it work How tested Results of testing Further improvements 
needed 
Gale et al202, 2004 
Serino221, 2002 
Gluteraldehyde fixed 
bovine valve in nitinol 
self expanding stent 
(PVVB, VenPro) 
Bileaflet valve in nitinol 
stent, functioning as 
native valve, implanted 
percutaneously 
Patency and competency 
assessed by venous 
duplex and ulcer healing 
rates noted 
Thrombosis in 4/5 
valves 
1 embolised to 
pulmonary artery 
Improved valve design 
Improved 
thrombogenicity 
Pavcnik et al223, 2003  
Pavcnik et al222, 2005 
BVV1 as above BVV1 as above Percutaneous 
implantation to 
proximal femoral vein, 
assessed by venography 
and duplex ultrasound 
2/3 patient improved 
clinical symptoms 
3/3 valve leak 
Issues with tilting need 
addressing 
Pavcnik et al198, 2008 Square stent with frame 
of nitinol tubing, round 
geometry, valve leaflets 
of SIS (Pavcnik, BVV3) 
As previous BVV but 
with geometry altered to 
prevent contact of 
leaflet with venous wall 
Clinical examination, 
Intravascular US, duplex 
US, venography, air 
plethysmography 
4/15 occluded – at 12 
months non functional 
due to incompetency 
due to thickening and 
rigidity of leaflets 
Geometry needs 
optimising 
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Discussion 
Deep vein valve replacement by the open surgical technique with autologous or allogenic vein grafts has 
been considered a viable option for the treatment of patients with deep venous insufficiency for many 
decades.   Results from early animal studies were poor as the majority of stents and grafts occluded within 
a few weeks199, 200. There have been attempts to develop a prosthetic vein valve implant over 40 years, 
with many prelimary models being developed. These include methods to create a new in situ valve, to 
create an artificial valve with stainless steel and platinum, the use of a cryo-preserved pulmonary heart 
valve, and attempts to transplant cryo-preserved vein valves. More recent developments have seen vein 
prostheses involving single, double or triple cusp leaflets mounted on a self-expanding metal frame to 
develop a percutaneous method of insertion. Animal studies showed promising early patency rates, but 
poor long-term results201.  Nevertheless, 2 clinical studies have been conducted in recent years, but again 
problems with thrombosis and valve competency resulted in the studies being abandoned202, 203.  In 
addition to the published works, there are reports of conference proceedings and a plethora of patents for 
artificial vein valves, however, the evidence for how these were developed and evaluated is lacking.   
Presently, the use of polymers and polymer coated metal stents, used in the vascular system is receiving 
much attention, however, there are several problems, particularly for use in the venous system: they are 
very thrombogenic, resulting in a deep vein thrombosis and an occlusion of the vein, they lack 
haemocompatibilty and biocompatibility, which causes an inflammatory reaction to occur, their presence 
results in intimal hyperplasia, which subsequently causing vessel narrowing and material failure.  All of 
these would serve to worsen the symptoms and signs of venous disease.  In addition they lack the 
required mechanical properties, as ideally, they should have the ability to expand and contract along with 
the vein, which can double in size with changes in the patient position from lying to standing.   
 
The scope of this review excluded valves and experimental models using open surgical techniques using 
autologous valves without stents for both animal and in human studies as this would not further 
contribute to the development a deep vein valve replacement, however, it is important to consider some 
of the tissue engineering techniques employed to study valve transplantation for use in the future 
development of a percutaneous deep vein valve replacement. 
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The long term aims must be to develop a material that is non-thrombogenic, biocompatible, 
haemocompatible, is flexible, does not fatigue and avoids intimal hyperplasia.  The valve design itself 
should minimise the zones of stasis of blood, reduce turbulent flow and have low shear stress, as well as 
remain patent and competent over time.  The method of implantation should ideally be via a minimally 
invasive percutaneous technique and additional thought must be given to the number of valves and their 
location.  Attempts to create a valve implant should and are being revisited here.  
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4. THE ANATOMY OF DEEP VEIN VALVES 
 
4.1 REVIEW OF THE LITERATURE 
4.1.1 Introduction 
The deep veins of the lower limb accompany all major arteries and their branches.  Blood flows  from the 
peripheries towards the heart and from the superficial to the deep veins, maintained by unidirectional224, 
usually bicuspid225, 226, valves which close passively as the valve leaflets move towards the centre of the 
vein 227.  Early anatomists including Charles Estienne (1539), Giovanni Battista Canano (1551) 
demonstrated venous valves, but were ridiculed as their work could not be repeated 228 and now, their 
discovery is generally attributed to Fabricus ab Aquapendente in 1579.  
The number, location and consistency of deep vein valves in normal subjects are poorly understood. As 
an understanding of these details is essential to inform and guide the development of novel interventions 
and treatments for patients with deep venous disease, a literature review was performed229.    
 
4.1.2 Methods 
Relevant papers were identified through systematic searches of Pubmed (1966 to October 2010). The 
search terms “femoral vein valve”, “popliteal vein valve”, “femoral vein”, “venous valves” and “venous 
valve AND lower limb” were used. English language and human limits were applied and article titles and 
abstracts were screening for inclusion. A manual reference list search was also carried out for further 
appropriate studies to be considered for inclusion. Relevant full text articles were scrutinised and all 
anatomical studies reporting details of deep vein valves were included. Articles concerning deep vein 
thrombosis, the treatment of deep venous disease, deep venous valve surgery or replacement, superficial 
vein anatomy and cardiac valves were excluded. 
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4.1.3 Results 
Although the initial search strategy yielded 7472 results, following exclusion of non-relevant publications, 
a total of 7 articles were included.  The junction of the femoral vein (FV) and Deep Femoral vein (DFV) 
was chosen as the reference point for valve positions for several reasons: 
• It is readily identified on colour duplex ultrasound imaging, in contrast to the inguinal ligament 
• It is unlikely to have been surgically altered or removed, in contrast to superficial venous 
reference points 
In the studies, if other venous reference points were used, for example, the saphenofemoral junction 
(SFJ) and saphenopopliteal junction (SPJ), the distances and locations obtained from the publications 
were adjusted, using the average values: from the mouth of DFV to the inguinal ligament is 9cm and 
from the mouth of the long saphenous tributary to the inguinal ligament is 5cm226. A summary of the 
studies is shown in Table 13 and Table 14 which show the number and location of valves within the 
femoral and popliteal veins respectively.   
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Table 13: Shows a summary of the number and location of valves within the femoral veins 
Reference Number 
of subjects 
(limbs) 
Age of 
subjects 
Sex of 
subjects 
Number 
of valves 
in femoral 
vein 
Location of valves in femoral vein 
(distance from Deep Femoral vein) 
Genovese, 
circa 
2002230 
1(2) Not 
known 
Not 
known 
3-4 - 
Muhl-
berger et 
al, 2008231 
32(63) 56.5-
103.25 
17 male 
15 female 
1-6 0-2 valves proximal 0-9cm 
1-3 valves distal 1.9-11.2cm 
Powell 
and Lynn, 
1951225 
 
27(54) Still born 
foetus - 84 
14 male 
13 female 
2-6 1-2 valves proximal 44 limbs, last at 
inguinal ligament 9cm 
50 limbs valve "just below" 1-3cm 
distal, then  every 2.5-16cm 
Banjo, 
1987232 
92(184) 
(study in 
black 
Africans) 
All adults 73 male 
19 female 
Not 
stated: 
All had a 
least 1 
valve 
169 limbs ≥1 valve proximal at 5-
9cm 
13 limbs ≥1 valve proximal at 0-5cm 
184 limbs ≥1 valve distal at 0-3cm 
Basmajian, 
1952226 
38(76) 31-94 38 male 0-6 51 limbs 1 valve 5-9cm proximal  
2 limbs 1 valve 0-5cm proximal 
68 limbs 1 valve 1-3cm distal 
Kwakye, 
1971233 
25(50) 60-85 20 male 
5 female 
2-6 Most constant sites: 5-9cm proximal 
and 1-3cm distal. 
6cm distal often 2nd valve (exact 
figures not given) 
Eger and 
Wagner, 
1949234 
100(200) 91 adults, 
4 children, 
5 infants 
Not stated Not stated 138 limbs ≥1 valve at 4-9cm 
proximal 
62 limbs no valves at 4-9cm 
proximal 
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Femoral vein valves 
Muhlberger et al 231 used the saphenofemoral junction as a reference point and investigated 63 limbs (32 
patients), of which 83% of legs had at least one valve proximal to the junction of the DFV and FV and 
distal to the inguinal ligament within the common femoral vein (CFV).  Distally, 76-100% of legs had a 
valve distal to the junction between DFV and FV.  A further cadaveric study of 54 legs from Powell, 1951 
reported that a valve in the common femoral vein (CFV) was present in nearly three quarters of patients. 
The CFV valve was located consistently at the level of the inguinal ligament. The FV contained 1-4 valves 
in all cases, with at least two valves seen in over 90% of cases.  The most common site for a valve was 
just distal to the junction of the DFV and FV (93% of cases). 
Fifty legs were studied by Kwakye233, who found that a mean of 4 valves were present in the FV, ranging 
from 2-6. Consistently, a valve was seen just distal to the DFV opening, and just proximal to the SFJ. 
This may correspond to the valve just below or at the inguinal ligament, consistently reported in other 
papers. The femoral vein was more likely to contain valves proximally than distally, unlike the popliteal 
vein, where valves were more frequently cited in the distal part. Using a reference point of the inguinal 
ligament, a further study reported that 76% of the 76 legs studied had a valve in the five centimetres 
inferior to the inguinal ligament and a valve immediately distal to the DFV / FV junction was present in 
nearly 90% of legs226.  One limb had no valves throughout the femoral vein, the median number 
identified was 3 with a maximum of six. 
Banjo et al232 divided veins into 7 segments in a study of 92 black African subjects.  In keeping with other 
reports, all patients in this study had a valve in the 3cm distal to the DFV junction of the FV and a valve 
was present in the CFV in 93% of legs.  
Eger and Wagner, 1949234, carried out the largest study of 200 limbs (100 cadavers) by dissection and 
found that 69% of the 200 limbs studied had valves present within the common femoral vein proximal to 
the saphenofemoral junction, that is within 9cm proximal to the junction of the FV and DFV.  There was 
complete absence of valves within this region in 31%.  This study did, however, only focus on the region 
above the saphenofemoral junction, excluding the 4cm immediately proximal to the FV and DFV 
junction, which is a limitation, as well as not discussing the exact locations of these valves.  
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 Popliteal vein valves 
The popliteal vein (PV) is defined as the segment of vein between the adductor hiatus and confluence of 
anterior and posterior tibial veins.  Studies previously discussed including, Powell, 1951225 and Kwayke, 
1971233, have consistently reported the presence of a valve just distal to the adductor hiatus. A second 
valve was commonly seen in the very distal segment of the PV, just proximal to anterior and posterior 
tibial veins, Santilli, 2000235 and Kwayke, 1971233.  
 
Table 14: Shows the summary of number and location of valves within the popliteal veins 
Reference Number 
of subjects 
(limbs) 
Age of 
subjects 
Sex of 
subjects 
Number 
of valves 
in 
popliteal 
vein 
Location of valves in popliteal vein 
(distance adductor hiatus) 
Genovese, 
circa 
2002230 
1(2) Not 
known 
Not 
known 
1-2 - 
Santilli et 
al., 2000235 
39(47) Not 
known 
13 male 
26 female 
1.8+/-0.5 1st valve: 7.0 +/-5.0cm  
Last valve: 14.1+/-3.0cm  
Powell 
and Lynn, 
1951225 
27(54) Still born 
foetus - 84 
14 male 
13 female 
1 in upper 
1/3 (rest 
not 
visualised) 
Just distal to adductor hiatus (1-3cm) 
Kwakye, 
1971233 
25(50) 60-85 20 male 
5 female 
0-4, 
average 1-
2 
Most constant sites: above junction 
anterior and posterior tibial veins 
and near adductor ring 
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4.1.4 Discussion 
The validity of these finding is, however, limited by the small number and heterogeneity in reporting of 
studies.  Fixed anatomical reference points, including the inguinal ligament and DFV tributary, have been 
used to amalgamate with some confidence, the studies, although as the distances used to adjust the 
distances used were average values this will have caused some inaccuracy. Moreover, many of the reports 
were of cadaveric studies in patients without venous disease or the presence or absence of venous disease 
was not discussed, so the application of these data to a patient population with deep venous disease is 
suboptimal.  
In summary, in the studies included, venous valves are consistently located in specific sites in the 
common femoral, femoral and popliteal veins of the leg.  This is summarised in Figure 12. 
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Figure 12: Shows the most constant locations of valves within the femoral and popliteal veins  
 
The most consistently reported sites of valves are: 
• in the CFV, near the inguinal ligament 
• in the FV just distal to the DFV tributary 
• in the PV near the adductor hiatus  
 
As a result of these findings the clinical studies in this report, including the ultrasound and magnetic 
resonance (MR) imaging of deep vein valves and their function has specifically target these anatomical 
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locations.  In addition, this information may also be of value once a minimally invasive treatment for 
patients with deep vein valve failure has been developed, these are sites that should be considered for 
location of the device.  
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5.  DAMAGED VENOUS VALVES 
 
5.1 A SURVEY ON THE MANAGEMENT OF PATIENTS 
WITH COMPLEX VENOUS REFLUX AND 
OBSTRUCTION 
5.1.1 Introduction 
As discussed in the previous chapters, the management of venous disease is variable both between 
centres and even between different specialists within the same institution.  This often depends on their 
personal expertise and experience.  Large trials are difficult and due to the heterogenous nature of 
patients the exclusion rates are often high236 and therefore often not applicable to the patients that we see 
in daily practice.  For these patients, the underlying haemodynamic abnormalities are variable and similar 
underlying disease patterns do not results in the same signs and symptoms33 in different patients.  For this 
reason patients are treated on an individual basis, and assessed by each lead physician.  Many patients 
have complex underlying venous disease with mixed venous reflux and obstruction, and many patients 
have had intervention, particularly to their superficial veins previously237.  Following this they will have 
different degrees of recurrence of their superficial venous disease and different effects on deep venous 
haemodynamics.  Vascular specialists manage patients such as this with complex deep venous reflux and 
obstruction in their everyday practice.  Therefore, by performing a survey of venous experts, this study 
aims to guide the management of these challenging patients.  
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5.1.2 Methods 
Eight patient scenarios with descriptions of their symptoms and signs as well as their vascular and 
imaging demonstrating complex venous reflux (5 patients) and obstruction (3 patients) or mixed disease, 
were developed. Questions were on the preferred choice for the management of these patients, and the 
experts were asked to rank the choices given in the order in which they would choose them.  The 
questionnaire was sent to 10 venous experts for their review.  Each of them gave feedback on the 
questions and requested changes.  These were made and the same 10 specialists were given the 
questionnaire again for their review.  This was to ensure all possible management options that would be 
considered in clinical practice were listed and that the questionnaires were easy to understand and 
complete.   Of the ten complex cases selected, all five patients in the reflux cases had C5-6 disease and 
mixed superficial and deep reflux with or without chronic deep venous obstruction, and of the 
obstruction cases, 3 were relating to the lower limbs, and 2 to the upper limbs.  The upper limb cases are 
not discussed further in this paper as they are not relevant to the management of lower limb deep venous 
disease.  The cases are described in complete detail in the results section for ease of understanding.  An 
online survey program, www.freeonlinesurveys.com, was employed and the anonymous surveys were 
distributed by e-mail to vascular specialists.  The surveys sent can be seen in Appendix 1.  This was done 
through the administration staff of each society to member of the American Venous Forum, the 
European Venous Forum, the UK Venous Forum and the Vascular Society of Great Britain and Ireland.  
The first and second preferred management options were taken and the results are shown below.  
 
5.1.3 Results 
For the deep venous reflux survey, to date, there have been 77 responses, including 38 Consultants.  For 
patients with deep venous obstruction, there have been 35 responses, including 25 Consultants.  Each 
individual case is discussed below along with the preferred first and second choice management options 
for patients with these conditions. 
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Reflux 
Case 1 
A 64 year old female, who is currently taking HRT presents with a one year history of an aching, painful right leg, 
with heaviness and swelling in right leg, despite adequate compression dressings.  On examination she has C6 
disease with lipodermatosclerosis and an active 7x3 centimetre ulcer present in the medial gaiter area, which has 
been non-healing despite wearing compression for 6 months.  Her ABPI was greater than 1 bilaterally.  Her duplex 
ultrasound imaging is shown in  
Figure 13, and the thrombus in the iliac vein appeared chronic.  The options for the initial management of this 
patient were; compression only, anticoagulation with warfarin, anticoagulation with treatment dose heparin alone, 
open surgery, iliac vein stent, treatment of the superficial veins or pharmacomechanical thrombolysis.  The results 
are shown in Figure 14 and Figure 15.  The preferred first choice management option by over half of respondents 
was to proceed with an iliac vein stent and the second choice was to treat the superficial venous reflux. 
 
Figure 13: Shows the duplex ultrasound imaging for Reflux Case 1 
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Figure 14: Shows the results for Reflux Case 1 - 1st Choice of management 
 
 
Figure 15: Shows the results for Reflux Case 1 – 2nd Choice of management  
 
Case 2 
A 53 year old female, who had previous had bilateral great saphenous vein ablation GSV ablation 3 years ago, 
presented with a 6 month history of cramping, aching, heavy, throbbing legs with healed a ulcer on the right and an 
active 5x4 centimetre venous ulcer on the left.  Her symptoms were persisting despite compression stockings.  Her 
ABPI was greater than 1 bilaterally.  Her duplex ultrasound imaging is shown in Figure 16.  Respondents were ask 
whether they would carry out any further investigations to further guide the management of this patient; no 
19% 
10% 
1% 7% 53% 
3% 3% 4% 
Reflux Case 1 - 1st choice Compression only
Anticoagulation
Anticoagulation Heparin
Open surgery
Iliac vein stent
Treatment superficial veins
Pharmacomechanical thrombolysis
Other
15% 
23% 
4% 
10% 
13% 
29% 
4% 2% 
Reflux Case 1 - 2nd choice Compression only
Anticoagulation
Anticoagulation Heparin
Open surgery
Iliac vein stent
Treatment superficial veins
Pharmacomechanical thrombolysis
Other
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additional investigations; CT Venography; MR Venography; conventional venography.  The results of this are 
shown in Figure 17.  Although the majority (31%) preferred to perform MRV to guide further management of this 
patient, 22% opted for CTV, and 26% did not require any further imaging of this patient.  Further they were asked 
how they would best manage the patient’s left leg, that is the leg with active venous ulceration.  The options given 
were compression only, drug therapy such as daflon, open surgical options including transposition, valve transplant, 
external valvuloplasty, internal valvuloplasty, or another preferred option.  The results of this are shown in Figure 
18.  68% of respondents recommended continuing with compression therapy despite the fact that the patient had 
not responded to it in 6 months, and 32% of respondents recommended surgery, of which valve transposition was 
the preferred option.  With regard to the right leg, that is the leg without ulceration present, 76% of respondents 
recommended continuing with compression therapy, and 13% recommended the use of medication, only 11% in 
this case opted for any surgical treatment options.   
 
Figure 16: Shows the duplex ultrasound imaging for Reflux Case 2 
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Figure 17: Shows the results for Reflux Case 2 - Investigations 
 
Figure 18: Shows the results for Reflux Case 2 - Management of the patient’s left leg 
 
Figure 19: Shows the results for Reflux Case 2 - Management of patient’s right leg 
 
 
26% 
22% 31% 
14% 
7% 
Reflux Case 2 - Investigation 
No Investigations
CTV
MRV
Venography
Other
68% 
8% 
15% 
3% 3% 
3% 
Left leg Compression
Daflon
Transposition
Transplant
External valvuloplasty
Internal Valuloplasty
76% 
13% 
2% 0% 
7% 
2% 
Right leg Compression
Daflon
Transposition
Transplant
External valvuloplasty
Internal Valuloplasty
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Case 3 
A 69 year old gentleman with a high BMI of 40 and heart failure with a poor performance status NYHYA grade III 
and limited mobility due to shortness of breath presents following a DVT 20 years ago with a 3 month history of 
worsening pain and swelling of the left leg and ankle.  He has tried compression, but this worsens his symptoms and 
so has not been compliant with its use.  On examination he has lipodermatosclerosis in left leg and a non healing 
ulcer over the medial gaiter area which is 6x6 centimetres in size, and has been present for 1 year.  He has bilateral 
ABPIs greater than 1 and his duplex ultrasound assessment is shown in Figure 20.  The further options for the 
management of this patient that were offered included compression therapy, anticoagulation with warfarin, 
anticoagulation with treatment dose heparin alone, open surgery, treatment of the superficial veins, or 
pharmacomechanical thrombolysis.  The preferred first choice management option for this patient was to persist 
with compression therapy (45%) as far as the patient could tolerate, and several respondents stressed that this was 
their preferred and most conservative management option due to the patients multiple comorbidities.  34% of 
respondents did suggest treating the superficial veins as either the first or second preferred treatment option, but 
others commented that if compression exacerbated his symptoms then treating the superficial veins would be ill 
advised.  This is shown in Figure 21 and Figure 22. 
 
Figure 20: Shows the duplex ultrasound imaging for Reflux Case 3 
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Figure 21: Shows the results for Reflux Case 3 - 1st Choice of management  
 
 
Figure 22: Shows the results for Reflux Case 3 – 2nd Choice of management 
 
 
Case 4 
A 49 year old lady with a history of breast cancer and left sided DVT 4 years ago, and previous ablation 
of the left great saphenous vein 2 years ago presented with a 1 year history of left leg pain, itching, 
oedema and recurrent leg ulceration.  She had multiple recurrence of the same ulcer in the left, totaling 4 
45% 
17% 5% 
8% 
19% 
6% 
Reflux Case 3 - 1st choice Compression
Warfarin
Heparin
Open surgery
Treatment Superficial Veins
Pharmacomechanical
29% 
32% 
9% 
9% 
15% 
6% 
Reflux Case 3 - 2nd choice Compression
Warfarin
Heparin
Open surgery
Treatment Superficial Veins
Pharmacomechanical
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ulcers in the last year despite wearing compression stockings continually.  On examination in clinic, there 
was evidence of a healed ulcer around the left medial malleolus which was 2x2 centimetres.  Her ABPIs 
were greater than 1 bilaterally.  Her duplex ultrasound assessment is shown in Figure 23.  The options for 
the management of this patient that were offered were compression only, anticoagulation with warfarin, 
anticoagulation with treatment dose heparin alone, open surgery to treat the venous reflux, open surgery 
to treat obstruction, stenting of the iliac vein or pharmacomechanical thrombolysis with one of the novel 
devices such as Trellis®.  The results are shown in Figure 24 and Figure 25.  50% of respondents 
considered that the preferred first choice management option was to stent the iliac vein to treat the 
obstruction in the first instance.  A further 35% recommended continuing compression therapy only, and 
7% opted for open surgery to treat the obstruction as a first line treatment.  As a second choice option, all 
of the given choices were considered to be possible options. 
 
Figure 23: Shows the duplex ultrasound imaging for Reflux Case 4 
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Figure 24: Shows the results for Reflux Case 4 - 1st Choice of management 
 
 
 
Figure 25: Shows the results for Reflux Case 4 – 2nd Choice of management 
 
 
 
 
35% 
4% 
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50% 
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Warfarin
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Surgery - reflux
Surgery - obstruction
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Case 5 
A 30 year old gentleman, who was a lifelong heavy smoker of 40 cigarettes per day presented with a 9 
month history of heaviness and throbbing pain in the right leg with oedema, and a 6 x6 centimetre ulcer 
in gaiter area.  This had failed to heal despite 9 months of well applied 4 layer bandage therapy.  He had a 
previous right femoral vein DVT 5 years ago following flight from Australia.  He took warfarin at that 
time for 6months, and had not been followed up with regard to this since.  Bilaterally his ABPIs were 
greater than 0.9.  His duplex imaging is shown in Figure 26.  A total of 79% of respondents preferred to 
continue with compression therapy alone as a first or second choice option, despite this having failed to 
heal the ulcer for 9 months.  A total of 58% of respondents treated the superficial veins as a first or 
second line for this gentleman, and only 23% of respondents thought that open surgery to treat the deep 
venous obstruction would be the best option for this patient management. 
The options offered to those taking the survey for the ongoing management of this patient were: 
continuing compression therapy, anticoagulation with warfarin, anticoagulation with treatment dose 
heparin alone, open surgery, treatment of his superficial veins or pharmacomechanical thrombolysis.  A 
total of 79% of respondents preferred to continue with compression therapy alone as a first or second 
choice option, despite this having failed to heal the ulcer for 9 months.  A total of 58% of respondents 
treated the superficial veins as a first or second line for this gentleman, and only 23% of respondents 
thought that open surgery to treat the deep venous obstruction would be the best option for this patient 
management.   
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Figure 26: Shows the duplex ultrasound imaging for Reflux Case 5 
 
 
 
Figure 27: Shows the results for Reflux Case 5 - 1st Choice of management 
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Figure 28: Shows the results for Reflux Case 5 – 2nd Choice of management 
 
 
Obstruction 
Case 1 
A 34 year old lady, who is 13 weeks pregnant presented with an 8 day history of acute, painful left lower 
leg swelling.  She had no history of a previous DVT, although her mother had a DVT while she was 
pregnant and now has a post phlebitic limb and venous ulceration.  The patient’s only history was that of 
mild asthma.  Her duplex imaging is shown in Figure 29.  Respondents were asked to rate the following 
management options in their order of preference: Compression, anticoagulation with warfarin, 
anticoagulation with treatment dose heparin alone, open thrombectomy, catheter directed thrombolysis 
or pharmacomechanical thrombolysis with one of the novel devices such as Trellis®.  The preferred first 
choice management option was anticoagulation with heparin, in two thirds of respondents.  All of the 
other options were considered as possible methods of treatment as a second line therapy including 
interventional treatment, such as pharmacomechanical or catheter directed thrombolysis and open 
surgery.  Several commented that they would only perform this, however, if heparin therapy failed.  These 
results are summarized in Figure 30 and Figure 31. 
 
28% 
23% 
5% 
10% 
31% 
3% 
Reflux Case 5 - 2nd choice Compression
Warfarin
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Open surgery
Treatment Superficial Veins
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Figure 29: Shows the duplex ultrasound imaging for Obstruction Case 1 
 
 
Figure 30: Shows the results for Obstruction Case 1 – 1st Choice of management 
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Figure 31: Shows the results for Obstruction Case 1 – 2nd Choice of management 
 
 
Case 2 
A 48 year old male rock singer with a 3 year history of a painful swollen left leg after a DVT 10 years before has 
recurrent left leg ulceration.  Wearing compression stockings does improve his symptoms slightly, but do not 
prevent ulcer recurrence.  On examination he has left leg swelling, evidence of a recently healed ulcer in the left 
gaiter area and lipodermatosclerosis.  He has palpable pedal pulses and his ABPIs bilaterally are greater than 1.  The 
results of his CT venograms and duplex ultrasound are shown in Figure 32 and Figure 33 respectively.  As shown in 
the imaging, the patient had developed collaterals to bypass the obstruction in the iliac vein, this could be called a 
“self-Palma” procedure.  The management options that were offered for consideration included compression, 
anticoagulation with warfarin, anticoagulation with treatment dose heparin alone, open surgery such as a Palma 
procedure or in line bypass or an interventional procedure such as an iliac stent.  66% of respondents preferred iliac 
stenting as a first or second choice for the preferred management of this patient.  37% considered that open surgery 
should be considered as a first or second choice, and 29% would continue compression alone as the first line 
treatment. 
0% 
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Obstruction Case 1 - 2nd Choice Anticoagulation - warfarin
Anticoagulation - heparin
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Figure 32: Shows the CT Venogram for Obstruction Case 2 
 
 
 
Figure 33: Shows the duplex ultrasound imaging for Obstruction Case 2 
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Figure 34: Shows the results for Obstruction Case 2 – 1st Choice of management 
 
Figure 35: Shows the results for Obstruction Case 2 – 2nd Choice of management 
 
 
 
Case 3 
A 55 year old male suffered a subdural haematoma following a road traffic accident 4 months ago, which 
was treated with craniotomy and surgical evacuation.  Subsequently the patient had a thrombosis of the 
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IVC managed with an IVC filter.  Initially, the symptoms resolved for a week then recurred.  On 
examination the patient had bilateral lower extremity oedema with varicose veins. The duplex imaging of 
this patient is shown in Figure 36.  The options offered for the management of this patient included 
anticoagulation with warfarin, anticoagulation with treatment dose heparin, pharmacomechanical 
thrombolysis, open surgical thrombectomy, open surgical bypass, stenting or catheter directed 
thrombolysis.  56% of respondents considered that anticoagulation with heparin or warfarin was the 
preferred first line management despite the head injury.  28% considered interventions such as catheter 
directed or pharmacomechanical thrombolysis or stenting to be more appropriate in the first instance.  
These results are shown in Figure 37 and Figure 38. 
 
Figure 36: Shows the duplex Ultrasound Imaging for Obstruction Case 5 
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Figure 37: Shows the results for Obstruction Case 3 – 1st Choice of management 
 
 
Figure 38: Shows the results for Obstruction Case 3 – 1st Choice of management 
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5.1.4 Discussion 
The majority of cases had a clear preferred option for initial management.  For patients with a 
combination of reflux and obstruction, if the obstruction is proximal, such as in the iliac, this survey 
found that the majority of venous specialists would treat the obstruction in the first instance.  If the 
obstruction is more distal, such as in the femoral or popliteal veins, the majority of respondents treated 
the superficial venous reflux first.  For patients with combined superficial and deep venous reflux, the 
preferred option was to treat the superficial venous system first before considering any treatment of the 
deep venous disease.  Compression was considered a reasonable option for all cases of venous disease, 
and all combinations of obstruction and reflux.  In the presence of deep venous reflux and leg ulceration, 
surgical management options were considered.  In the presence of malignancy or pregnancy heparin was 
the preferred method of anticoagulation and surgical or interventional management options were less 
popular.   For a patient 4 months following a head injury, anticoagulation was considered a safe option by 
more than half of those taking the survey.   
Preferred management options for patients with complex deep vein reflux, deep venous obstruction or 
mixed reflux and obstruction are variable across the world.  A consensus would be valuable to determine 
the best management options for these patients.  In general, anticoagulation and more conservative 
management options are the preferred options.  Interventional and open surgical procedures were 
considered second or third line.  
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6. IMAGING THE VENOUS SYSTEM TO 
DEVELOP A COMPUTATIONAL MODEL 
OF A DEEP VEIN VALVE 
 
6.1 INTRODUCTION 
6.1.1 Venous Haemodynamics 
 
The circulatory system moves blood around the body and the venous circulation is responsible for 
returning blood back to the heart for recirculation.  For the most part, the veins carry deoxygenated 
blood from the peripheries to the right side of the heart, except the pulmonary vein, which bring 
oxygenated blood from the pulmonary circulation to the left side of the heart.  In order to maintain 
antegrade flow from the peripheries towards the heart, there are several requirements: 
• A pressure gradient  
• A venous pump, that is a muscle pump or respiratory pump 
• Competent unidirectional venous valves 
The venous system has deep, superficial and perforating veins. The deep veins run below the muscular 
fascia, the superficial veins run above the muscular fascia and the perforating veins which link the two 
systems and perforate the fascia.  The direction of blood flow in the normal circumstances is from 
superficial to deep veins and from distal to proximal, that is from the limbs towards the heart, in a 
prograde fashion.   
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Blood flow in veins is regulated by several different mechanisms, including gravity, peripheral muscular 
pumps, the respiratory pump and ultimately, venous return must equal cardiac output in homeostatic 
conditions, therefore, this will also have an effect on flow. However, veins are compliant and have the 
capacity to pool blood for a short time.  Venous capacity can be controlled passively by gravity, causing 
an increase in transmural pressure, resulting in expansion of the veins.  There is also a hormonal and 
neural control of veins which is regulated both centrally and at a local level.   
The sympathetic nervous system innervates the smooth muscle in the vein wall via α1-adrenoceptors.  An 
increase in activity of these receptors causes venoconstriction, and a decrease below the baseline tonic 
level of activity causes venodilatation.  At the general level, and increase in circulating hormones such as 
adrenaline or angiotensin II also cause venoconstriction.   
 
6.1.2 Flow Direction 
Blood flow in healthy veins the blood flow in veins is directed towards the heart. In general that means 
from superficial to deep veins and from foot to groin. This flow direction is called antegrade or 
retrograde. Normally functioning valves in the lower limb veins prevent retrograde flow.  Reflux is the 
flow in the opposite direction to physiological flow. 
Antegrade flow in the vasculature is generated by the pumping of the heart, which generates a pressure to 
propel blood through the arteries.  This pressure is dissipated gradually as blood flows through the 
arteries and capillaries, vein and right atrium, therefore, in the supine position, antegrade flow will 
continue down this pressure gradient, in the veins and return to the right side of the heart.  In the lower 
limb venous system, the return of blood to the right atrium is augmented by the work of respiration and 
the lower limb muscle pumps, most notably the calf muscle pump.  Retrograde flow is prevented by the 
presence of unidirectional valves.  These mechanisms ensure that in the normal healthy state, the flow of 
blood in the lower limbs is from the superficial to the deep system and from the feet towards the heart, 
maintaining antegrade flow. 
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The pressure gradient between the capillaries and the right atrium is the dominant driving force for the 
venous blood flow.   In the supine position, at the venous end of the capillary, the pressure is 
approximately 12-18mmHg238.  The pressure in the larger veins, such as the femoral vein in approximately 
8mmHg and in the right atrium is 4-7mmHg, therefore, in the supine position, antegrade flow will 
continue down this pressure gradient, in the veins and return to the right side of the heart.  In the 
standing position, the gradient between the artery and vein at any level is maintained as the gravitational 
pressure affects both the artery and vein to the same hydrostatic pressure value.   At the entrance to the 
right atrium the pressure is also pulsatile. As blood enters the right atrium, it is subjected to a pulse as the 
right ventricle contracts against the closed tricuspid valve.  This augments the entry of blood from the 
vena cava to the right atrium.  It is possible that this pulsatile pressure wave is transmitted throughout the 
venous system239, however, this would have only a very weak effect on the flow and remains a 
controversial issue. 
 The respiratory pump has an effect on venous return.  During inspiration and expiration, changes in 
intrathoracic and intra-abdominal pressures are transmitted to the right atrium, vena cava and intra-
abdominal vessels and have an effect on venous return.  During inspiration, intra-thoracic pressure falls 
and this is transmitted to the right atrium.  In turn, the venous pressure gradient along which blood flows 
back to the heart is increased, promoting venous return.  When the diaphragm contracts and descends, 
the intra-abdominal pressure increases, compressing the inferior vena cava, driving blood into the thorax, 
but as inspiration continues and intra-abdominal pressure increases further, the IVC can collapse and 
cause a reduction or complete cessation of flow from the lower limbs240-244.  During expiration the reverse 
is true.  An example of the velocity of blood flow in the femoral vein in the supine position during quiet 
respiration in a normal subject demonstrated using ultrasound is shown in Figure 39 below. 
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Figure 39: Show the velocity of blood flow in the femoral vein during quiet respiration in the supine position of a 
normal subject 
 
  
 
The muscle pumps of the lower limb are also a major driving factor for venous return.  These include the 
calf muscle pump, the foot pump and the thigh pump.  Contraction of the surrounding skeletal muscle 
compresses the vein, forcing blood out of he vein and towards the heart, as in the healthy state, reflux is 
prevented by bicuspid valves.  During relaxation, the pressure is reduced in the deep veins, causing blood 
to flow from the superficial veins, via the perforating veins, to the deep venous system along a pressure 
gradient.  Again, reflux back to the superficial system is prevented by valves in the perforating veins238.  
The calf muscle pump, consisting of the gastrocnemius and soleus muscles, is the most effective of these 
muscle pumps14 and in the normal subject should expel more than 60% of the volume of blood in the 
calf veins as determined by air plethysmography245.  During a normal ambulation, the pressure is 
approximately at 20 – 30 mmHg in normal subjects246. The Cockett perforators (posterior tibial 
perforating veins) contain valves which close during muscle systole to prevent high pressure from the 
deep system being transferred to the superficial, low pressure chamber. This is the reason why the system 
is sometime referred as the “peripheral heart”. Conversely, in muscle diastole, the valves prevent 
backflow and allow drainage from superficial to deep chambers via the perforating veins aided by 
122 
 
temporarily lowered pressure in the deep veins14.  The foot pump also make a contribution expelling 
approximately 25 millilitres of blood during each step in ambulation247.     
There have been many studies to establish which is dominant, and as such, muscle contractions during 
varying respiratory exercises have been investigated 242, 243, 248, 249. This remains controversial and is 
obviously dependent on position, activity and respiration of the subject, however, Miller 243 concluded 
that respiration maintains a persistent effect during both mild and moderate calf contraction. 
Retrograde flow occurs if the blood flows from deep to superficial veins, or from the direction central to 
peripheral.  Pathological reflux is considered to be occurring if the duration of retrograde flow is more 
than 0.5s.  There was a suggestion by Labropoulos et al that the cut off value for reflux in the superficial 
and deep calf veins should be 0.5s, but the cut off value for the femoropopliteal veins should be greater 
than 1s250.  However, a more recent study by Lurie et al concluded that a universal cut off of 0.5s 
throughout the venous system to describe pathological reflux would improve reliability251.   These 
measurements were all performed using duplex ultrasound which offers information about  venous flow 
patterns and reflux, it is safe, reliable and readily available in the clinic setting.  Reflux time itself, however,  
does not correlate well with clinical severity 252.   The cause is failure of the valves, which should maintain 
unidirectional flow, present in the superficial, perforating and deep veins of the legs.  This may be due to 
primary or secondary failure.  Primary valve failure is caused by weakening of the vessel wall leading to 
dilatation and separation of the valve leaflets.  Secondary valve failure is due to damage to the valves 
commonly due to venous thrombosis.  Both of these result in refluxing disease.  Duplex studies have 
shown that reflux (or less commonly, occlusion) of deep veins is seen in around 40% of patients with 
chronic venous insufficiency and may be significant in 15-20%7, 8.  
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6.1.3 Venous Pressure (Normal, supine, stationary, walking) 
Introduction 
Vascular haemodynamics is governed by blood flow, pressure and vascular resistance. Veins are thin 
walled capacitance vessels which contain approximately two-thirds of the total circulating blood 
volume253, depending on the tone of the vein wall smooth muscle.  Their function is to return blood to 
the heart.  The return of this large reservoir of blood to the heart is carried out by a combination of: 
• peripheral muscle pumps which squeeze blood from the veins during muscle contraction 
• gravity, which assists venous return in the raised upper limb and cerebral circulation and opposes 
return from the lower limbs in the standing position 
• respiration, which changes intra-thoracic pressure, contributing to a pressure gradient from the 
peripheral to the central veins  
Uni-directionality from peripheries towards the heart and from superficial to deep veins is ensured by the 
presence of many, mostly bicuspid, venous valves.  Valves are more frequent in the more distal veins and 
are not present in the vena cava229. Pressure in the venous system, in contrast to the arterial system in 
which it is generated by the heart, is determined by forces which oppose venous return and forces which 
promote venous return.    
 
Factors opposing venous return from the lower limbs 
The pressure generated by gravity, known as the hydrostatic pressure, is the weight of the column of 
blood from the right atrium.  In the standing position, in the lower limbs, this opposes the return of 
blood to the heart from the peripheries, in the raised upper limb it promotes it.  It is calculated by 
measuring the vertical distance from the right atrium to the point under consideration254, 255.  The pressure 
is calculated by taking into consideration the density of blood (1.056g/cm3) and the acceleration of gravity 
(980cm/s2) and expressed in mmHg238, according to the following equation: 
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 Hydrostatic Pressure  = Density of blood (g/ml) x Acceleration of gravity (cm/s2) 
(mmHg)     Hg constant (dynes/cm2) 
Hydrostatic Pressure  = 1.056 x 960 
     1333 
Hydrostatic Pressure  = 0.77 mmHg (per cm below the right atrium) 
 
Therefore the effect of gravity increases the pressure by 0.77mmHg/cm below the level of the right 
atrium.   
As the pressure increases, the volume of the vein increases.  Between 0 and 10 mmHg, the pressure-
volume curve for the vein is steep as the vein wall distends easily.  Above 10 mmHg the curve flattens as 
the vein resists further distension.  In addition, the change in shape of the vein can be observed, at very 
low pressures (<1 mmHg) the vein adopts a dumbbell shape, and as the pressure increases it becomes 
more elliptical, and then spherical to accommodate a larger volume of blood.  This is shown in Figure 40 
below. 
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Figure 40: Shows the venous pressure-volume curve, reproduced from Katz et al, 1969256 
 
 
This increase in pressure does not occur instantly, but gradually increases over 30-60 seconds during 
standing as blood from the arterial system passes into the venous system254.   
Importantly, the effect of gravity cannot and must not be explained simply because there is less flow in 
the veins in the standing position in the lower limbs or the lowered arm position in the upper limbs.  In 
fact, the flow volume itself must remain the same in both the arteries and veins as the system is closed 
and gravity will have an equal effect on both veins and arteries in the peripheries, so that in the mean the 
inflow will be equal to the outflow in any position.  The pressure in the veins and velocity of flow will 
however demonstrate changes.  Any overall changes in flow volume must occur in both the arteries and 
the veins simultaneously due to changes in cardiac output, which can be altered by venous return, 
according to the Starling law.   
In the supine position, without the effect of the muscle pump, the pressure in the lower limb veins is 0-
10mmHg as there is little or no vertical difference between the peripheral veins238 and the right atrium.  
The venous pressures in the supine position are summarised in the Figure 41 below. Any pressure 
gradient is generated by changes in intra-thoracic and intra-abdominal pressures due to the work of 
respiration, which is discussed further later in the chapter.  
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Figure 41: Shows the venous hydrostatic pressures in the supine position (adapted from Meissner et al238) 
Supine Venous Pressures (mmHg)
4.6 7.5 10
In the standing position, if no muscle contraction is taking place, the pressure at the distal calf is 
94mmHg in an average 174cm man257, which is generated by the hydrostatic pressure alone.  Venous 
pressures in the standing position are summarised in Figure 42 below.  During calf contractions, either 
during walking or heel raising, the pressure decreases to a mean of 22mmHg within 7-12 steps254.  This is 
the ambulatory venous pressure which ranges from 0-25mmHg.  Once static, the pressure increases again 
to resting hydrostatic pressure in 14+/-11 seconds after tiptoeing or 19+/-13 seconds after knee 
flexion258.  
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Figure 42: Shows the venous hydrostatic pressures in the standing position (Adapted from Meissner et al238) 
Standing Venous Pressures (mmHg)
-32
-15
0
15
44
59
94
 
Factors promoting venous return in the lower limbs 
Muscle Pumps 
At the venous end of the capillaries, there is a pressure generated by the pumping action of the heart, 
called vis a tergo. Most of the energy is absorbed by the arteries, but in the supine state, this pressure, 
usually 12-18mmHg, is sufficient to generate a pressure gradient, so blood flows to the right atrium.  In 
the standing position, however, the pressure is used in the work of dilating the veins so that blood 
progression is delayed until a maximal volume, just before producing an appreciable progression. The role 
of the muscle pumps is to work in the lower part of the curve of compliance, with low volume and low 
transmural pressure. (Work=Energy=Transmural Pressure x Volume change). 
In the limbs, contraction of the skeletal muscle squeezes the veins within it and expels the blood towards 
the heart.  The veins are emptied, decreasing the volume in the veins, the pressure decreases, then the 
veins fill from the more distal veins during muscle relaxation.  The presence of venous valves, which are 
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more frequently located distally229 where the muscle pump has more effect on the venous return, prevent 
reflux of blood.  If the valves are incompetent, the muscle pump becomes ineffective259, the veins distend 
and the pressure increases in the vein (venous hypertension).  The pressure is transmitted to the capillary 
beds, fluid moves out of the vessels into the surrounding tissues, causing oedema.  If this is persistent, 
skin changes occur including pigmentation and ulceration.   
The lower limb muscle pump, or “the peripheral heart” as it is sometimes known, consists of the calf 
muscle pump, the foot pump and the thigh pump.  The calf muscles, consisting of gastrocnemius and 
soleus on one contraction expel over 60% of the volume they contain260, 261, which can be up to 100-
150ml in the normal limb.  During walking, repeated contractions of the calf muscle will reduce the 
pressure in the dorsal veins of the foot from resting hydrostatic pressure to the ambulatory venous 
pressure, which is in the range of 5 to 30mmHg254.  These values can be measured invasively or indirectly 
by foot volume, air or strain gauge plethysmography.  The calf muscle pump can also be augmented 
extrinsically using either intermittent pneumatic compression, in which applies a direct squeeze to the calf, 
or using electrodes applied to the skin which either stimulate the calf muscle to contract, known as 
electrical muscle contraction, or in which a skin electrode stimulates a peripheral nerve which cause 
contraction of the calf muscle indirectly262.  In addition, the thigh and foot pumps make a contribution to 
venous return from the lower limb, but to a lesser extent than the calf muscle pump.  The thigh has been 
shown to have an ejection fraction of 20% using plethysmography260, this is likely to be because the deep 
veins are not compressed as much by each muscle contraction.  Compression of the plantar venous 
plexus on weight bearing forces blood from the plantar venous arch of the foot to the calf263.  
The muscle pump fills the veins with distal blood when relaxing (diastole) and propels it upwards when 
contracting (systole) thanks to the upstream and downstream valves that alternately open and close 
ensuring unidirectional antegrade flow.  This creates Gravitational Hydrostatic Pressure Fractioning 
(GHPF)264, 265.  In the upright position, the GHPF generates a pressure which is lower below the knee 
than above, or a retrograde PG.  This causes a retrograde flow in both the superficial and deep veins.  
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Muscle Pump Tests 
There are several muscle pump tests that have been suggested in research and clinical practice.  Muscle 
pump tests are designed to measure both the rate and direction of venous flow during the systolic and 
diastolic phases of MP activity, particularly the calf pump, which is the most important of the lower limb 
muscular pumps. The ideal test conditions which mimic daily activities such as walking and running are 
not readily available in daily practice. Some manoeuvres try to recreate these conditions in a reproducible 
fashion.   
• The Parana manoeuvre consists of a slight push-pull at the waist of the patient triggering a 
proprioceptive isometric reflex contraction of the calf to restore balance and has been used in 
different studies to detect deep and superficial vein incompetence266, 267.  
• The oscillation manoeuvre consists of accompanying a forward slight oscillation of the body with 
a hand on the patient’s waist.   
• The Wunstorf manoeuvre consists of a voluntary flexion of the toes, causing the calf muscle 
veins  to empty passively268. It has been the basis for different studies to investigate venous 
insufficiency 
• A calf squeeze is commonly used and can be performed manually or by inflation of a cuff. It is 
considered that this is less likely to mimic physiological conditions as the MP is not stimulated.  It 
may compress veins not physiologically squeezed by the muscles, for example the superficial 
veins and in addition, may not be feasible due to pain, lipodermatosclerosis, skin changes or 
ulceration. However, it can be useful in the supine and sitting positions when the manoeuvres 
described above are not possible.  A calf squeeze by insufflations of a cuff would, however, be a 
consistent and reproducible method of applying the same squeeze for repeated reproducible 
measurements.  
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Muscle Pump Diastolic Reflux Grading 
A reliable grading of the muscle pump diastolic reflux would improve the diagnostic reproducibility of 
reflux and allow a means of quantifying haemodynamic outcomes of different treatments. However the 
haemodynamic pathological significance of the reflux should be interpreted according its cause. So far, 
various methods have been proposed to define pathological: 
• Refluxing time: As a little retrograde flow is necessary to allow veins valves to close269, it was 
considered that “The cut-off value for reflux in the superficial and deep calf veins is greater than 
500 ms. However, the reflux cut-off value for the femoropopliteal veins should be greater than 
1000 ms. Outward flow in the perforating veins should be considered abnormal at greater than 
350 ms. Reflux testing should be performed with the patient standing”250.  However, more 
recently it has been considered that in order to improve reproducibility in the diagnosis of reflux, 
a uniform cut-off value of 500ms should be used.  This was used in the studies later described to 
ensure subjects did not have significant reflux.   
• Reflux ratio: Psatakis proposed a ratio, known as the Psatakis Index (PI)270, calculated by dividing 
the amount of diastolic reflux by the amount of systolic antegrade flow. RT doesn’t take into 
account the amount of reflux and PI doesn’t take in account the reflux time. The Reflux 
Dynamic Index (RDI) which uses the calculation:  
 
RDI =      (mean reflux velocity² x reflux time) 
(mean systolic velocity² x systolic  time)  
 
takes into account both reflux time and amount. The reflux can be “total” when all of the valves above 
the measured reflux are absent or incompetent, “partial” when valves are not completely incompetent and 
“segmental” when the valves overlying the incompetent one store part of the systolic outflow.  
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Respiration 
Normally, spontaneous respiration activates the respiratory pump that affects intrathoracic pressure, 
which is transmitted to the blood in the vena cava, meaning that venous blood flow varies according to 
breathing depth and strength. Its effect is maximal proximally and decreases distally. The flow variation 
induced by breathing changes with the posture. In the upright position, this flow is antegrade and persists 
only during the inspiratory phase, whilst in the supine position; it persists for the complete respiratory 
cycle, with a peak at the end of the expiration, as shown diagrammatically in Figure 43.   
 
Figure 43: Shows the femoral vein flow variation according the respiratory pump and posture.  Solid line: 
Supine position, dotted line: upright standing position.  (This image is adapted from an unpublished 
image provided by Claude Franceschi) 
 
 
During inspiration, the intrathoracic pressure decreases, and due to diaphragmatic contraction, 
intrabdominal pressure increases.  This increases the flow from the central veins in the abdomen to the 
thorax.  The reverse happens during expiration.  This is transmitted to the veins in the limbs in addition.  
Figure 44 below shows the fluctuation in the velocity of blood moving through the femoral veins 
associated with respiration in the supine position in a healthy subject. 
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Figure 44: Shows the velocity in the femoral vein in the supine position during respiration 
 
 
 
In the presence of a venous obstruction, in the distal patent vein, the amplitude of the respiratory 
variation in the flow decreases and the minimum velocity increases proportionally to the resistance caused 
by the obstruction.  This is particularly evident at the groin in the case of iliac vein or caval obstruction. 
The valsalva manoeuvre is a forced expiration against a closed glottis, or blocked expiration. This 
manoeuvre compresses the right atrium and the vena cava so that it reverses the antegrade venous 
pressure gradient. This effect is proportional to the strength and the speed of the manoeuvre, which is 
difficult to standardise and measure unless the patients blow into a gauge.  In daily practice, the patient 
can blow into a blocked straw or for improved reproducibility; the valsalva could be quickly performed 
after a deep inspiration resulting in a fast and strong retrograde gradient.  The blocked expiration (BE) is 
followed by a release (BR). In normal individuals, the blocked expiration reverses the pressure gradient, 
dilates the veins, closes the valve leaflets and can produce a short and low flow.  The release restores the 
antegrade pressure gradient and triggers a consecutive antegrade flow (Figure 45). In the presence of valve 
incompetence, blocked expiration induces a longer and faster pressure gradient than below the competent 
valves (Figure 46).  
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Figure 45: Valsalva manoeuvre (normal individual): The blocked expiration (BE) reverses strongly the pressure 
gradient that induces only a negligible short and small reflux thanks to the correct competence of the underlying 
valve.  (This image is adapted from an unpublished image provided by Claude Franceschi) 
 
Figure 46: Valsalva manoeuvre: pathological reflux (valsalva positive).  Valsalva is Positive when valves are 
incompetent. Reverse Flow appears when blowing (BE) and at release (BR).  (This image is adapted from an 
unpublished image provided by Claude Franceschi)   
 
 
The rate of flow during BE also depends on the capacitance of the underlying venous bed. Therefore, a 
VM will be more demonstrative when the distal venous volume is first reduced. However, if competent 
valves are interposed between the RP and the incompetent veins, a VM will not demonstrate reflux 
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during BE, as is the case for incompetent superficial veins in the presence of competent perforators, SFJ 
and SPJ. 
 
Venous Diameters 
In general vein size is related to transmural pressure, which is derived from the inner hydrostatic pressure 
and outer interstitial or tissue pressure. Measurements are taken in the standing position and with the 
probe transversely to the long axis of the vein271.   GSV diameter measurements may correlate with 
clinical severity272, with terminal valve competence or incompetence273, as well as with ilio-femoral valve 
competence, incompetence or absence. Vein wall compliance, defined as the ability of vein wall to change 
diameter between the lying and standing positions, is another factor that plays a role in changes in vein 
diameter.  In addition their changes after treatment are a tool to observe vein disease evolution.  
For the deep veins, the diameter of the common femoral vein is usually measured immediately below the 
confluence with GSV. The femoral vein may be measured at the mid thigh or just distal to the confluence 
with the deep femoral vein. The popliteal vein measurement is conditioned by the anatomical variability 
of the popliteal fossa and no consensus is available yet.  
For the superficial veins, there is still no consensus about the optimal place to measure the great and 
small saphenous vein diameters. The UIP Consensus 2006274 proposes the levels of the groin and mid-
thigh for GSV and at the proximal and mid calf levels for the SSV. Most published data in interventional 
studies use measurements at the groin (stripping, endovenous procedures or foam) or at the proximal 
thigh275. Furthermore when comparing measurements of the GSV at the groin and proximal thigh level, 
there is a higher correlation between diameter and presence of reflux; similarly proximal thigh GSV 
diameter measurements correlate with the clinical condition of the limb272.  
For the perforator veins, the diameters of perforators are usually taken at the fascial level271. 
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6.2 IMAGING IN VENOUS DISEASE 
 
6.2.1 Introduction 
Detailed evaluation of the venous system providing information on the location, presence and extent of 
valvular incompetence or obstruction is important to choose appropriate percutaneous procedures and 
assess haemodynamic improvement. Conventionally, in the past, ambulatory venous pressure 
measurement and descending venography have been the methods of choice complementing the 
localisation and haemodynamic assessment. These treatments are largely superseded by less invasive 
techniques. Continuous wave Doppler (CWD) examinations have little accuracy on identifying specific 
incompetent or obstructed vein segments and differentiating duplicated or collateral veins however can 
provide segmental physiology. Duplex ultrasound on the other hand is the most useful modality for 
measuring valvular incompetence and venous obstruction276. Other haemodynamic investigations include 
air Plethysmography (APG) and photo-plethysmography (PPG) these tests are used to compliment 
duplex ultrasound to obtain more detailed measurements of haemodynamic severity.  These along with 
computed tomography and magnetic resonance imaging of the venous system are discussed in more detail 
here. 
 
6.2.2 Ultrasound 
Ultrasound, from the continuous wave (CW) doppler that first allowed a live,  non-invasive and 
repeatable blood flow velocity and direction  measurement almost 40 years ago, to today’s  pulsed wave  
Doppler and CDU that simultaneously shows the flow (colour and B-Flow) and the vessels (B-Mode) 
have advanced our understanding of venous anatomy and physiology. It is a tool which has improved 
both our understanding of the haemodynamics and diagnosis of the venous disease, which is yet to be 
surpassed, and is increasingly considered to be the gold standard in the evaluation of the morphology, 
haemodynamics and surrounding tissues limb veins.  
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 Continuous Wave Doppler 
Continuous Wave Doppler (CWD) is commonly used to complete a clinical examination. Deep veins are 
ideally studied with lower frequencies (5MHz) and superficial veins have low velocity blood flow thus are 
better heard with higher frequencies (10MHz). At each specific location the presence of a spontaneous 
signal is documented. Small veins with low flow may require manoeuvres to hear the signal by 
compressing the leg above or below the Doppler probe.  
Flow reversal in a segment demonstrates valvular incompetence. Presence of a signal during the Valsalva 
manoeuvre diagnoses the presence of common femoral vein incompetence. More distally compression 
techniques are commonly used. The patient in an upright position gives a better indication of the 
physiological conditions that are normally present and is ideal for assessing venous reflux. The presence 
of perforator vein incompetence can be demonstrated by the presence of bidirectional flow in the medial 
calf when the calf is compressed above the Doppler probe277.  
Duplex 
Duplex ultrasonography is a safe and reliable diagnostic imaging which assesses the venous system 
effectively. In the last ten years many alternatives to duplex ultrasound have been investigated with 
potential to replace this established modality. Duplex ultrasound with compression is commonly regarded 
as highly sensitive and specific in the determination of acute DVT. In chronic DVTs, with patients who 
are obese and oedematous it is less effective. It is also considered more challenging to visualise the iliac 
veins and inferior vena cava278. 
Duplex ultrasonography has many advantages over continuous wave doppler. B-mode imaging visualises 
the vein directly and accurate image guided placement of the probe. This results in better identification of 
non axial veins, paired veins and distinguishes collateral veins from major veins more easily274, 279.  
Coleridge-Smith et al, 2006271 outlined in a consensus report that patient with chronic venous disease 
should routinely have the following evaluated with duplex ultrasound:  
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• The saphenous junctions to assess which are incompetent, their locations and diameters.  
• The extent of reflux in the saphenous veins of the lower limbs and their diameters.  
• The number, location, diameter and function of incompetent perforating veins.  
• Other relevant veins that show reflux.  
• The source of filling of all superficial varices if not from the veins already described.  
• Veins that are hypoplastic, atretic, absent or have been removed.  
• The state of the deep venous system including competence of valves and evidence of previous 
venous thrombosis.  
This information is then used to determine the type of treatment offered. Those with sapheno-popliteal 
junction or sapheno-femoral junction incompetence can be offered ultrasound guided sclerotherapy, 
endothermal ablation including laser or radio frequency ablation, tumescent free ablation techniques, or 
surgery.  However, others with isolated incompetence of saphenous tributaries maybe offered 
sclerotherapy or phlebectomy. Inadequate identification of all areas of venous filling can lead to early 
recurrence271, 280.   
 
Colour Duplex Ultrasound 
Colour spectrum analsysis enables visualisation of presence, direction and patterns of blood flow. Colour 
coded flow maps can be added to simplify this281.  Colour duplex also distinguishes between veins and 
arteries and flow in multiple simultaneous vessels. It shows the flow over long vessels so a larger area can 
be seen more easily compared with continuous wave doppler. Colour immediately shows disturbance of 
flow by a thrombus and the presence of reflux by inverting the colour pattern.  Conventionally, the 
direction is set so that blue indicates antegrade venous  blood flow back to the heart and red indicates 
arterial blood away from the heart281.  
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In cases of venous obstruction the whole venous system from the iliac to the ankle can be assessed by 
duplex scanning.  On identification of a vein, compressibility assesses its patency. A complete thrombosis 
of the lumen will be non compressible. Chronic obstruction will be evident by the presence of marrowed 
lumina with thick walled veins that can be echogenic with fibrosis. Calcification can be present and will 
also contribute to decreased compressibility238.  
The diagnosis of venous valvular incompetence is undertaken with the patient standing, similar to the 
continuous wave doppler examination.  Manoeuvres described in the previous section to induce 
antegrade venous flow are performed. The veins are imaged using B-mode imaging and character of the 
Doppler signal is audible. Subsequently colour flow velocity can be used to visualise the long axis view 
and a colour flow map or inverted spectrum can demonstrate retrograde flow thus venous incompetence.  
Many clinicians use compression above or below the probe to identify suspected distal reflux disease. 
However others prefer the distal cuff deflation method, when the velocity spectrum is monitored during 
inflation and for 4 seconds after deflation as they consider this to be more of a reliable method to identify 
reflux disease282. The variability of venous reflux patterns complicate the management of venous disease, 
they are best assessed by complete whole leg venous duplex mapping283. 
Much literature is available on the quantification of reflux and its relationship with clinical symptoms in 
chronic venous insufficiency. This has included investigating factors including: the number of 
incompetent valves, mean flow rates, duration of reflux. Although mean reflux times correlate well with 
clinical disease severity they provide unreliable evidence or prediction of ulcer healing or clinical 
improvement post treatment284. 
Generally incompetence of the deep veins is associated with worse clinical symptoms and signs of venous 
insufficiency285. In contrast incompetent distal superficial veins are associated with lower risk of ulcer 
development. Two thirds of patients with C4-6 disease have incompetent perforator veins. Concomitant 
obstruction with reflux disease can lead to patient’s complaining of both venous claudication and 
superficial ulcers286.  Adopting a standardised protocol of clinical and duplex assessment can ensure that 
the underlying aetiology of the leg ulcer can be established in 97% of cases287. 
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 In each case the clinical question that needs to be answered should be clear. In situations when non-
operative management is considered duplex may be employed to exclude co-existing arterial disease prior 
to the use of compression stockings. In contrast, if surgical management is being considered a more 
thorough knowledge of the anatomical location and extent of the underlying venous disease may be 
required to plan the optimum surgical approach. Valvular incompetence, wall abnormalities and 
perforator incompetence should be examined. Multiple sites of reflux can exist and if the patient has 
symptoms of venous claudication, further investigations should be carried out to exclude venous 
obstruction18.  In general DUS is a more accessible modality than other forms of imaging278. Venous 
reflux is measured by distal manual compression and rapid release. A reflux time of more than 0.5 s is 
generally accepted as the definition of venous reflux38. 
 
CDU and Haemodynamic Changes  
The velocity and direction of the flow are valuable hemodynamic data because they are related to the 
variations in the pressure gradient. The changes in calibre of the vein correlate with the variations of the 
transmural pressure and the wall compliance. According to the location of the obstruction and 
incompetent valves, specific patterns of each pathological haemodynamic configuration can be classified.  
CDU gives an accurate and detailed evaluation of vein dimensions and haemodynamics in deep and 
superficial veins, but is limited by both current ultrasound device technology, and the venous 
haemodynamics model that defines the imaging protocol. It is obvious that improving the quality of the 
CDU protocol will improve the treatment strategy259, 264, 288. Unlike arteries, veins do not have a consistent 
regulated pump that drives blood flow. In the static standing position very little blood flow may be 
registered at DUS, and a totally immobile standing subject would have almost zero flow in the lower limb 
veins. Manoeuvres which affect blood flow include respiration and muscle pump activation, particularly 
the calf muscle pump. Different manoeuvres, to deliver reproducibility, have been developed to allow 
investigation of blood flow, as has been discussed previously. 
CDU and haemodynamic changes 
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Normal subjects 
Altered venous haemodynamics can be found in asymptomatic individuals and can be normal in 
symptomatic patients.  Obese individuals, prolonged standing, high levels of physical activity and patients 
with cardiac insufficiency can have a normal CDU examination, but have a functional impairment of their 
venous drainage.  
 
Venous obstruction 
Obstruction increases the resistance to flow. It increases the residual pressure and consequently the 
transmural pressure. The resistance depends on its extent and location and decreases proportionally to the 
number and calibre of the collateral pathways.  B-mode imaging can demonstrate the obstruction and its 
cause, the dilated underlying veins and the overloaded collateral veins while colour doppler imaging can 
visualize the stenotic lumen.  
Pulsed wave and continuous wave doppler measure the direction and velocity of the flow upstream, in the 
collaterals and in the stenosis. Distal to the obstruction, the effect of the respiratory pump is reduced in 
proportion to the resistance. The pressure measurement at the ankle is performed in the horizontal 
supine position in order to select the respiratory pump value, independently of the gravitational 
hydrostatic pressure, assumed to be 0mmHg in this position. The normal values are around 20 mmHg.  
An upright posture is necessary to assess the flow activated by the muscle pump systole.  
 
Valve incompetence   
Valvular incompetence can be seen in B-mode imaging, when the leaflets are seen to reverse. The grade 
can be assessed by the reflux time.  Colour Doppler shows the changes of the flow direction but not its 
grade.   
 
Lower limb deep venous incompetence  
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Deep veins are assessed directly in the upright position from the ankle up the groin while the iliac 
incompetence is assessed indirectly by observing reflux at the proximal common femoral vein during 
valsalva manoeuvre. The incompetence grade is assessed by various tests and measured according to the 
elected measurement method described above.   A thorough assessment can allow delivery of an efficient 
therapeutic strategy: the best location for valve repair or transplant, prosthetic valve or deep venous shunt 
disconnection.  
 
Lower limb superficial venous incompetence 
An incompetent valve will not cause any reflux if there is no refluxing tributary or any entering perforator 
interposed with an underlying competent valve. On the other hand, reflux can occur between two 
competent valves if an interposed perforator or a tributary is incompetent.  Two different types of 
superficial venous incompetence are discussed here: with and without competent connections, including 
the SFJ, SPJ and perforators.  
 
Superficial venous incompetence with competent connections with deep veins 
The connections between superficial and deep veins are competent when the incompetent superficial 
veins reflux during muscle pump diastole down to the deep veins through perforators, but do not reflux 
during the valsalva manoeuvre.  This may occur when the SFJ valve is competent, meaning the superficial 
veins are not overloaded by the deep veins. When saphenous trunk reflux is not induced by valsalva 
manoeuvre, the re-entry perforators are often located on the same saphenous trunk or distant from the 
trunk were it connects through a tributary289.   Sometimes, reflux at the SFJ terminal valve can be 
triggered by the valsalva and not present during muscle pump diastole.  This is because the pressure 
gradient produced by the valsalva is higher than that of the muscle pump test. This phenomenon has 
been named “terminal valve dissociation”.   
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Superficial venous incompetence with incompetent connections with deep veins  
Superficial venous incompetence with incompetence of one or more of the SFJ, SPJ and perforators 
demonstrate reflux during diastole with the muscle pump dynamic tests and the valsalva manoeuvre.  
 
Perforator vein incompetence 
Perforators have often been considered the cause of varices, ulcers and recurrence.  However, the 
assumption that all perforators need ablating in these circumstances is haemodynamically contradicted in 
both studies using invasive methods of assessment290, 291 and more recent CDU data264, 265, 292.   Two 
combined conditions must exist to produce perforator reflux, both valve incompetence and pressure 
gradient reversal. CDU can show clearly inflow and outflow through the perforators during valsalva, 
dynamic muscle pump and squeezing tests, and allows the understanding of their significance according 
to the normal and abnormal functioning of the deep and superficial veins.  
 
Combination of deep and superficial venous incompetence in the same limb   
Both superficial and deep venous incompetence can be responsible for increased transmural pressure and 
its clinical consequences and their relative contributions can be determined by CDU.  The specific 
haemodynamic effects of each condition have been described above, however, their combination can 
change the haemodynamics. Deep venous competence is a necessary condition for a proper functioning 
muscle pump, and can activate superficial venous reflux, however if the pump is not efficient, superficial 
reflux may not occur. The most demonstrative case of “deep venous competitive reflux” is the absence of 
Doppler observable diastolic reflux in a large incompetent GSV, in which the valves have been destroyed, 
when the deep venous incompetence is severe. More than a century ago, Perthes asked his patients to 
walk with a tourniquet at the proximal end of the varicose GSV, stating that the deep veins were 
competent when the GSV collapsed and incompetent when it did not. Therefore, in such cases, GSV 
reflux that becomes apparent or increased after a deep valve incompetence repair, attests for the success 
of the operation. It only remains to treat the GSV reflux.  
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 Combination of valve incompetence and obstruction in the same limb 
The combination of obstruction and valve incompetence in the same limb is most commonly found in 
the postphlebitic disease. The findings on CDU are a combination of those described above for both 
conditions. The clinical challenge is to determine the proportion of increased transmural pressure they 
produce respectively, in order to predict the positive effect their respective treatment.  Therefore, an 
additional CDU challenge is to recognize their common and independent contribution in order to treat 
the patient effectively.   
 
Common Challenges in Duplex US Imaging  
Many studies have shown the sensitivity and specificity of venous ultrasound to be between 90-100% 
however all three set of calf veins are seen in only 60-90% of studies293. Other challenges in duplex 
imaging are correct identification of the vein, for example, in the lower limb the great saphenous can be 
mistaken for the femoral vein. However this is reduced with identification of anatomical landmarks and 
experience. Image quality can also be a problematic with obese subjects and those with soft tissue 
oedema, however transducer selection, identifying imaging planes and optimal instrumentation setting are 
needed to optimise this. Areas of poor visualisation are often eluded to in ultrasound reports (N 
Labropoulos, Kang, et al., 1999).  
Venous compression is difficult in certain anatomical positions: iliac veins, adductor area of the femoral 
vein and the calf veins, and this can lead to false positive results when assessing for compressibility. This 
is generally overcome by the use of colour flow Doppler. In addition unusual anatomy, such as venous 
duplications may cause a DVT to be overlooked within the duplicated segment. This should be 
considered particularly when the vein is of smaller calibre or is in an atypical position. 
Colour flow Doppler is a useful technique but it too has diagnostic problems. If the colour Doppler 
settings are too high colour artefacts may arise leading to masking of small to moderately sized thrombi. 
The opposite may occur, that is false positives will arise, if the Doppler angle is incorrect, the wrong 
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velocity range is set or if examination is in a cool room. A higher incidence of false negatives has also 
been reported in patients with a lack of venous distension secondary to hypovolaemia or systemic illness.  
Characterising acute from chronic thrombus can be difficult with the use of many modalities but generally 
heterogeneity and echogenicity of the thrombus increase with time since onset. Chronic occlusions are 
also more likely to have reduced vein diameters, venous collateral development and flow channels within 
the lumen compared with acute thromboses which have a more dilated appearance.  The presence of a 
free floating edge also suggests a new thrombus.  
 
6.2.3 Laser Doppler 
Laser Doppler flowmetry is a technique which can be used to assess the haemodynamics of blood flow.  
A laser is directed at an area, and the beam is scattered by the presence of red blood cells, and returned to 
a detector.  It is most useful in superficial areas, such as the skin and superficial muscle, and is 
predominantly used to assess a change in blood flow in these areas in response to an intervention.  A 
study comparing laser Doppler fluximetry (LDF) and laser Doppler imaging (LDI) demonstrated that 
both can be used to assess the microcirculation by different methods, where LDF electrodes measure a 
small area with electrodes applied directly to the skin and  LDI measures a large skin surface, but does not 
directly touch the skin294. LDI provides an image of a perfusion end point whereas LDF provides a 
constant measure of blood flow. Previous studies have struggled with reproducibility of the two 
techniques295. 
 
6.2.4 Plethysmography  
Plethysmography provides a non-invasive global evaluation of lower limb vein physiology, including 
venous capacity and outflow, providing an assessment of both reflux and obstruction and their impact on 
venous function and a measure of calf muscle pump function296, 297.  Veins are compliant vessels and in 
response to changes in circulating volume and central haemodynamics can pool volumes of blood.  In 
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normal conditions, there is a large reserve capacity, but in the presence of venous obstruction this reserve 
is reduced and resistance to flow increases. Plethysmography assesses the degree of venous obstruction by 
measuring capacitance and resistance within the venous system. In the case of chronic obstruction, 
collaterals may have formed that can increase the resistance which can affect the results298.  There have 
been issues with reproducibility, due to inter-observer differences, but results are also affected by changes 
in environmental temperature and pressure, the presence of cool peripheries, and more proximal 
obstructions. 
 
Strain gauge plethysmography  
Strain gauge plethysmography (SGP) measures changes in the calf in response to different conditions.  
The plethysmograph consists of a compliant tube containing a liquid, which is placed around the widest 
part of the calf, which will detect a change in volume and circumference of the calf, which translates to a 
change in electrical resistance of the gauge, picked up by a detector.  It makes the assumption that the leg 
is a cylindrical shape with a uniform distribution of volume change.  A tourniquet placed proximal to the 
gauge can be inflated above venous pressure, but lower than arterial pressure, and deflated to halt and 
restart blood flow.  The rate the limb swells is a measure of arterial flow.  Release of the venous 
tourniquet will cause the limb swelling to decrease, and based on the principle that arterial blood supply 
and transcapillary fluid exchange are constant, the change in extremity volume is due to emptying and 
filling of veins.  
 
Air plethysmography  
Air plethysmography (APG) measures changes in cuff pressure standardised to reflect volume changes.   
In one study, for patients with a venous filling index of more than 7, it showed a 73% sensitivity and 
100% positive predictive value of identifying pathological venous reflux299 and it has been shown to have 
some correlation with CEAP classification300. Both SGP and APG give quantitatively different 
information, however, it has been shown to be qualitatively similar301.  The diagnosis of chronic venous 
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insufficiency by venous duplex correlates well with the diagnosis by air plethysmography302.  APG has 
been shown to be useful in the diagnosis of complex congenital anomalies cases, such as Klippel- 
Trenaunay Syndrome with advanced venous disease303.  Inconsistencies of results can be due to many 
factors; systemic changes in central venous pressure, changes in arterial supply to the leg, variability in 
performing exercises, changes in posture and weight distribution, as well as temperature changes which 
alter vein lumen size and venous capacitance. For these reasons care must be taken when analysing the 
results18.   
 
Photoplethysmography  
An alternative form of this method is photoplethysmography (PPG).  This measures the changes in tissue 
density by quantifying the amount of light reflected from the extremity.  Although skin is opaque, in the 
infra-red spectrum it transmits a small amount of light, which can be detected by a light sensitive diode.  
Red blood cells absorb the most light when pressure in the veins is higher and they are full.  The probe if 
fixed to the leg either close to the medial malleolus or dorsal foot.   In some studies it has been shown to 
be relatively unreliable technique as there is low specificity and difficulties in calibration with poor light 
penetration through the skin304 but he VRT measured by PPG correlates well with direct pressure 
measurements305.  When PPG is used with a tourniquet, it can distinguish limbs with and without venous 
pathology, and limbs with superficial and deep venous incompetence, however, it is not considered to be 
a good indicator severity of deep venous disease306 . 
 
6.2.5 Venography 
Ascending venography 
Contrast venography has been considered historically the gold standard for defining venous anatomy, and 
making the diagnosis of DVT venous incompetence, since it was first described by Berberich and Hirsch 
in 1923.   It is usually carried out and observed in real time in a fluoroscopy suite.  Contrast injected into 
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the dorsum of the foot allows good visualisation of the deep veins of the calf and thigh, improved by the 
use of a tourniquet around the thigh to slow the movement of the contrast.  Preferential filling of the 
deep veins can be aided through compression, a tilt table and the Valsalva manoeuvre. Iliac veins and the 
IVC are best visualised by injecting contrast into the femoral vein238.  It has now largely been replaced by 
the use of duplex ultrasound as venography is less reproducible, difficult to interpret in 9-14% of patients, 
associated with inter-observer disagreements in up to 10% of studies and is invasive, and it does not give 
quantitative information on the collateral circulation307-310.  Nevertheless it is still used in situations when 
the duplex is equivocal or if the duplex is negative but the clinical suspicion for DVT remains high, 
particularly if atypical venous anatomy is suspected, with one study demonstrating that 12% of the 
patients had a truncular venous malformation of the femoral vein311.  However, for the investigation of 
new techniques for the diagnosis of DVT, ascending is still widely considered the gold standard for 
comparison312, 313  and the diagnosis of a DVT is demonstrated by the presence of a lack of opacification 
of a vessel also known as a filling defect312.  More recently, however, with the increased use of 
interventional procedures to treat DVTs, including chemical thrombolysis and pharmacomechanical 
thrombectomy, the se of venography is again on the rise.  
 
Descending venography 
Descending venography is used to demonstrate reflux in the superficial, deep and pelvic vein, as well as 
determine the location of venous valves.  Contrast is injected through either the brachial vein or the 
ipsilateral or contralateral femoral vein or, for assessing for distal disease, the ipsilateral popliteal vein.  
The patient is usually tilted towards the upright position, and injection is performed during a forced VM 
to determine the extent and site of venous reflux.  This is graded accorded to Kistner’s classification, with 
4 grades of abnormal reflux according to the amount of leakage and the distal extent of leakage in each of 
the SFV, DFV and GSV314, as below: 
• Normal – No reflux occurs through any valve during VM 
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• Grade 1 – A wisp of reflux through one or more valves during VM, which is not sufficient to 
affect the direction of flow in the iliac veins 
• Grade 2 – Considerable reflux in the thigh veins, which does not extend to the calf due to the 
presence of a competent valve in the distal thigh, with some effect on flow direction in the iliac 
veins 
• Grade 3 – Considerable leakage, as grade 2, but with extension into the calf, with an effect on the 
iliac vein flow 
• Grade 4 – Cascading reflux in the thigh and calf and complete reversal of flow in the iliac veins 
 
Although it may still have a role in situations such as venous reconstruction, it is an invasive test with 
recognized limitations.  There are associated complications including a risk of contrast allergy or 
extravasation, thrombosis, and nephrotoxicty, therefore, its use has largely been replaced by duplex 
ultrasound.     
 
 
6.2.6 Intravascular Ultrasound (IVUS) 
IVUS is an invasive imaging modality whereby a catheter with an ultrasound probe is inserted into the 
vein to be assessed.  The vein can be visualised from the inside allowing an accurate assessment of any 
stenosis or obstructions present.  There have been several studies into its use in the venous system, 
particularly for IVC filter placement and the assessment of iliac vein stenosis or obstruction.  In one 
study, the insertion of IVC filters using transabdominal DUS, fluoroscopy and IVUS were compared, 
IVUS was only used if DUS was inadequate.  Of the 28 procedures performed with IVUS, 26 were 
successful at the time of placement and 24 confirmed to be correctly located post-procedure315.  Other 
studies have looked at the use of IVUS for assessing iliofemoral veins for stenosis, caused either by a 
partial obstruction, or extravascular compression.  One study assessing the role of IVUS in endovascular 
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surgery for the treatment of iliac vein obstruction, suggested that IVUS should be used generously in both 
the diagnosis and treatment as venography was unreliable, as the venograms significantly underestimated 
the degree of iliac vein obstruction by 20% in patients with post-thrombotic syndrome and 28% in 
patients with May-Thurner syndrome170.   
The advantages of IVUS over other imaging modalities are that it can be used at the bedside, which 
contrast venography cannot, and it allows improved visualisation and assessment of stenoses, which 
cannot always be detected haemodynamically on DUS.  It will also show intraluminal features, such as 
webs and trabeculations, which other modalities will not.  However, its disadvantage over other 
modalities is that it can only detect collateral vessels close to the imaged vessel.  The complications of 
IVUS include thrombosis at the insertion site, pulmonary embolism, infection,  
 
 
6.2.7 Computed Tomography Venography (CTV) 
The advent of spiral-computed tomography (CT) has greatly extended the range of venous imaging. 
Intravenous contrast administered though an arm vein is usually necessary for optimisation of evaluation. 
Within a matter of second large areas of the body can be imaged rapidly. In addition different scans can 
show opacity of various veins depending on their filling time based on the organ, blood flow and 
proximity to central veins. However these factors (blood and contrast flow) themselves can cause 
artefacts. Furthermore if homogenous mixing of the contrast within the vessels does not occur filling 
defects may appear. This is more of a pitfall imaging the thoracic region when filling of central veins 
occurs unilaterally – therefore bilateral infusions in each ante-cubital vein is preferred18.  
CT venography is shown to be as accurate as duplex ultrasound (DUS) for detecting DVTs below the 
inguinal ligament and more accurate than DUS for detecting thrombus that extends above into the pelvic 
veins and inferior vena cava316, 317. 
Colour Doppler ultrasonography is an easy to use, widely available and robust screening tool for 
diagnosing DVT. It is particularly more accurate in patients who are symptomatic. The benefits of CT 
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venography over Duplex are that there is less operator variability, shorter investigation time, and better 
imaging of the pelvic veins. CT venography does however require a large volume of contrast and subjects 
the patient to high dose radiation making it inappropriate for use in patients with impaired renal function 
and those who are pregnant.  
Marston et al 2011318 retrospectively reviewed 78 patients with CEAP 5-6 to look at the incidence of ilio-
caval obstruction.  They found that DUS is a useful screening tool however 23% of patients with high 
grade ICVO confirmed on US and MRI had a normal DUS. The study did acknowledge that CT and 
MRI are limited in visualising intraluminal webs and chronic abnormalities that may contribute to venous 
obstruction.  
Some studies show that magnetic resonance venography is more accurate than Duplex or conventional 
venography for identifying pelvic extension of DVT319-321.  Both MRA and CT have been proven 
effective in helping clinician’s make decisions and accurately plan further interventions. Data from CT 
and MR can be further manipulated in a multi-planar and 3D fashion to give exacting detail.  CT results 
are generally equivocal to MR, and both compare favorably with contrast invasive imaging. Ultimately the 
individual use of different imaging modalities depends on experience of operator, local availability and 
cost322. 
6.2.8 Magnetic Resonance Venography (MRV) 
 
Although duplex ultrasonography is a well-established standard of care and an excellent screening test for 
the detection of venous disease its accuracy of displaying the venous system is limited, in particular when 
imaging the pelvic veins323.  Duplex has a high sensitivity and specificity in the popliteal and femoral veins 
however is operator dependent and its accuracy is reduced in the distal extremities due to low velocity and 
volume of blood324. 
Magnetic resonance imaging has been employed to detect obstruction in both upper and lower 
extremities over the last decade325. It provides high-resolution images and decreases the need for ionising 
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radiation.  It has been shown to be capable of detecting DVTs in the upper leg, pelvic and abdominal 
regions278. 
Other modalities, such as time-of-flight (TOF) and phase contrast MR venography have been extensively 
investigated and considered reliable for the assessment of the deep venous system324. Despite this, these 
techniques are limited in the identification of paired veins and valves, are time consuming and can be 
prone to artefacts326. 
Flow-enhanced multi-shot TOF echo-planar imaging results in improved imaging of the calf veins by 
exploiting transient flow-augmenting with venous occlusion, but this method is prone to edge blurring 
due to T2 decay and poorly differentiates arterial-venous circulations327.  
Small veins with slow flow can be difficult to image, however fast-spin-echo (FSE) techniques have a high 
sensitivity for these but have a low sensitivity for large veins with high flow rates328.  In the presence of 
oedema, a high signal occurring in flow dependent MR venography can lead to suboptimal visualisation 
of venous anatomy329. 
Contrast-enhanced MRV is a more recent investigation used for the assessment of venous anatomy330-332, 
which involves the injection of contrast material. On injection of the bolus the arterial system is enhanced 
then subsequently venous structures are displayed. In the lower limbs diluted contrast can be injected by 
the pedal veins and evaluated by single phase, which enhances the lower limbs and pelvic veins330.  
Multi-phase MR can show a difference in arterial and venous systems, by using a subtraction algorithms; 
the early arterial phase can be subtracted to show a selective venogram331. Most dynamic imaging 
produces time resolved imaging that can give poor temporal resolution. Higher temporal resolution is 
better to illustrate contrast dynamics. High contrast may also assist with image processing, filtering and 
correlation analysis. This can help generate higher quality venograms. 
Venous contrast dynamics are effective at visualising venous structures particularly in areas where the soft 
tissue enhancement can obscure the vasculature325. Time resolved data in this modality can help the 
identification of areas of subclinical tissue injury with contrast dynamics333.  
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Du et al, 2006325 demonstrated the feasibility of performing three-dimensional DCE-MRV in the distal 
extremities. Time-resolved hybrid PR scanning resulted in images with high temporal and spatial 
resolution. This gave good delineation of venous valves and separation from background tissue 
enhancement. They also effectively were able distinguish veins and arteries by using contrast BAT 
thresholds. Region-specific arterial and venous CATs can be automatically generated with an iterative CE 
and CAT threshold algorithm.  
Magnetic resonance venography (MRV) has the advantage over CT in avoiding the need for nephrotoxic 
contrast. It gives high-resolution images of adjacent structures and allows for a variety of views, both 
coronal and sagittal,  of the area. The radio-frequency generated by the magnetic resonance allows for 
increased contrast between the venous system and its surrounding structures.  MRV is particularly 
advantageous in determining thrombus in smaller branched vessels. It is useful in the diagnosis of pelvic 
vein thrombosis and Kippel-Trenaunay Syndrome334. It is also the preferred modality for the identifying 
the venous drainage of other soft tissues. 
Unique to DUS is the dynamic manipulation of the patient’s position to assess flow and valve patency in 
the deep venous system.  Arnoldussen found that twice as many collateral systems were identified with 
DUS compared with MRV which was more difficult to ascertain their patency.  However their anatomical 
position was more easily detected with MRV278. 
MRV is also advantageous for the reviewing of images by multiple radiologists and allows comparison 
between cases.  It gives excellent information of the anatomical location and size of vessels this is 
particularly important in the abdominal and pelvic regions where no valves are present so there is less 
emphasis on hemodynamic information. Both DUS and MRV identified the majority of deep veins and 
analysis was performed using the LOVE score278.  
Edelman et al, 2009323 describe a pilot study in a cohort of healthy subjects with lower limb venous 
disease, to assess the clinical feasibility of a new method to image the deep and superficial veins of the 
lower extremities. The signal targeting using alternative radiofrequency and flow-independent relaxation 
enhancement (STARFIRE) is a flow-independent method for performing MR angiography that can 
selectively depict arteries or veins. The technique preferentially suppresses signal intensities of fat and 
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muscle whilst preserving that of blood.  STARFIRE can be used in patients at risk of developing 
nephrogenic systemic fibrosis, as it does not require the use of paramagnetic contrast agents. The 
technique has potential in the evaluation of acute and chronic deep venous thrombosis and venous 
mapping for the planning of varicose vein treatment. The vessel detail was competitive with MR 
angiography however as with MRA is prone to high signal defects from fluids and oedema. Subcutaneous 
and joint fluid can be edited out however the deep tissue fluid cannot. In the case of DVT, the thrombus 
was low intensity and the oedema surrounding was high intensity. 3D MRA has been used to image 
recurrent varicose veins, STARFIRE may provide potentially, equivalent diagnostic information without 
the need for contrast administration. However this needs to be further evaluated with larger studies. 
 
6.2.9 Image Guidance for venous interventions  
Often various clinical scenarios require the need to ‘road map’ the venous system by CT or MRI imaging 
prior to an intervention. As in some cases DUS alone may not be sufficient. This is particularly pertinent 
in the pelvic area, for obese subjects or the presence of bowel gas or if atypical anatomy is suspected. 
These modalities can further guide the approach to treatment as well as giving detailed information on the 
location and extent of disease. This includes feasibility of the proposed intervention, puncture site, the 
need for IVC filters, other devices or the requirement for further medical therapy335.  In the case of 
placement of IVC filters, methods of image guidance include intravascular ultrasound336, trans-abdominal 
ultrasound337, venography338 and fluoroscopy. Aberrant venous anatomy that can affect filter placement 
include duplicated IVC, accessory renal veins, intra-caval thrombus, caval tortuosity, caval compression 
and mega or micro cava. CT and venography together are able to reliably identify these anomalies. 
However if venography is not undertaken, careful review of CT scans must be undertaken. A large review 
of abdominal CTs by showed that there was a 5.6% incidence of major venous anomaly339. 
Ultrasound is a modality that is well established for the guidance of various interventions in venous 
disease, for example ultrasound guided sclerotherapy is a minimally invasive procedure that is well 
established for the treatment of perforator vein incompetence340. 
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 6.2.10 Venous Malformations 
As MRI provides the most comprehensive information of the anatomical distribution of venous 
malformation and it has become the ‘gold standard’ in these clinical situations. These problems can be 
complex and planning of interventions from radical surgery to micro embolisation is crucial for 
satisfactory outcomes. MRI is also superior at visualising high flow malformations, arteriovenous 
shunting and communications between the deep and superficial systems. CT in comparison can 
underestimate the extent of soft tissue and bony involvement in venous malformations238.  
 
6.2.11 Other techniques 
Capillary microscopy is effective in showing capillary convolution is associated with lipodermatosclerosis 
and ulceration in severe chronic venous disease341 (Howlader & Smith, 2003).  
 
6.3 ULTRASOUND IMAGING OF DEEP VEIN VALVES 
6.3.1 Background 
As previously discussed, ultrasound duplex imaging offers information about deep venous flow patterns 
and reflux, it is safe, reliable and readily available in the clinic setting.  Importantly for this study, velocity 
data can be obtained, and the movement of the valve leaflets visualised in real time, giving essential 
information for understanding the venous haemodynamics and modelling the deep venous system.  
Contrast enhanced ultrasound  has been well documented in its use in the vascular system, including the 
assessment of hepatic haemodynamics342 and atherosclerosis in carotid arterial disease343.  This may 
provide additional information on the flow through in the deep vein and through the valve.  Normal 
subjects were selected as the aim is to develop a model of a normal vein valve with a view to developing a 
deep vein valve replacement, although this will be implanted into patients with venous disease.  
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The aims of this part of the project are to use ultrasound and contrast enhanced ultrasound imaging343 to 
evaluate anatomical and haemodynamic variables in patients with normal deep veins and to compare this 
data with that obtained from magnetic resonance imaging20 of the same segment of vein, which is 
discussed in Section 6.4.  This ultrasound data will then be used for the development of the 
computational and experimental flow models for deep venous function, which are described in Section 
6.5 and Chapter 8 respectively. 
 
6.3.2 Methods 
Ethical approval, study registration and regulation 
Ethical approval for this study to carry out ultrasound and magnetic resonance imaging of normal 
subjects has been obtained from the West London Research Ethics Committee 2, REC Reference 
Number 10/H0711/79 (Appendix 2).  
The research has been registered with Imperial College Joint Research Office.  Informed written and 
verbal consent has been obtained from all patients and volunteers involved in this study.  A prospective 
observational study to evaluate patients with normal deep veins has been carried out.   
 
Volunteer and patient recruitment 
The target study population is 1 group, containing 7 patients. In view of little previous research in this 
area, it has not been possible to calculate a target sample size using power calculations. The chosen target 
provides a plausible, realistic sample size within the clinical setting in order to achieve the study aims.   
Volunteers have been recruited from the Department of Vascular Surgery, Charing Cross Hospital.  
Clinical assessment was performed to ensure that either no venous disease was clinically evident or the 
presence of telangiectasia only. A medical history and clinical evaluation is carried out.  Subjects were 
eligible and approached for recruitment if they had no clinical evidence of venous disease and no deep 
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venous reflux or obstruction evident on ultrasound imaging.  They are then given an information leaflet if 
they are willing to consider participating.   
Inclusion Criteria  
• C0 or C1 venous disease 
• Ankle brachial pressure index >0.85 
• Age >18 years 
 
Exclusion Criteria 
• Patients under the age of 18 years 
• Those unable to consent 
• Subjects with significant peripheral arterial disease, ankle brachial pressure index <0.85 
• Previous allergy to sulphur or contrast media used for MRI (gadolinium) 
• Subjects who are pregnant, planning pregnancy or breastfeeding 
• Subjects who have had a myocardial infarction within the last week, have an artificial heart valve, 
cardiac pacemaker or defibrillator or have had a recent coronary angioplasty. 
• Subjects with cerebral aneurysm clips, metallic shards in their eyes, cochlear implants, other 
electronic implants or nerve simulation units. 
 
Image storage 
All images taken are immediately anonymised and stored on a “WD My Book Essential” 2 terabyte 
external hard drive in a locked drawer in a locked office. 
 
157 
 
Ultrasound Imaging 
Ultrasound scans are performed using the standard Venous presets on a Philips iU22 scanner.  A 12-
5MHz 3D linear array probe is used.  Contrast imaging is obtained with non-linear imaging contrast 
mode.    
The patient is positioned standing with the weight on the left leg, the right hip externally rotated to 30° 
and the right knee flexed to 30°. The exact location of the first visible valve distal to the confluence of the 
right DFV and FV is marked on the surface of the patient’s skin while the patient is standing.   The 
distance from the base of the valve leaflets to the junction of the DFV and FV is recorded.  A device that 
can apply a standard calf squeeze, the Kendall SCD express system, which inflates to a pressure of 
45mmHg, is applied with the bladder that is first to inflate around the widest section of the calf.  The 
following images and videos are then acquired. 
• B-mode / 30 second video / standing at rest 
• M-mode / Standing / 2cm Proximal to valve / No calf squeeze / Normal respiration 
• M-mode / Standing / within valve / No calf squeeze / Normal respiration 
• M-mode / Standing / 2cm Distal to valve / No calf squeeze / Normal respiration 
• M-mode / Standing / 2cm Proximal to valve / calf squeeze / Normal respiration 
• M-mode / Standing / within valve / calf squeeze / Normal respiration 
• M-mode / Standing / 2cm Distal to valve / calf squeeze / Normal respiration 
• M-mode / Standing / 2cm Proximal to valve / calf squeeze / No respiration 
• M-mode / Standing / within valve / calf squeeze / No respiration 
• M-mode / Standing / 2cm Distal to valve / calf squeeze / No respiration 
 
The patient is then positioned supine on the couch, with a leg-torso angle of 15°, right hip externally 
rotated to 30° and right knee flexed to 30°.  With the patient in this position, the same images and videos 
were acquired as described above.   
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1ml of “SonoVue” microbubbles is then injected into the right antecubital fossa of the patient through a 
20 Gauge cannula.  The following images are then obtained. 
• Video / semi recumbent, at rest 
• Video / semi recumbent, calf squeeze 
• Video / standing, at rest 
• Video / standing, calf squeeze 
 
B and M Mode images of the same segment are acquired for use subsequently to build the geometry of 
the venous valves and to assess wall compliance and motion. “SonoVue” microbubbles are typically of 
the order of 2 to 6 microns consisting of a lipid shells filled with a high molecular weight gas, sulphur 
hexafluoride. They are true intravascular agents and remain within the vascular system, and have been 
used in both non-targeted and targeted forms for clinical diagnostic, prognostic and therapeutic purposes 
in oncology and cardiovascular diseases. Their resonance frequency, at which compression and expansion 
occurs most readily, is within the range of frequencies used for clinical ultrasound, therefore detectable 
signals are returned from the microbubbles.  
All images are recorded to allow subsequent validated assessment and extraction of geometric and flow 
parameters.  The Digital Imaging and Communications in Medicine (DICOM) videos are converted to 
AVI and JPEG format for review.  Image analysis is carried out using ImageJ analysis software.  The 
curve depicting the velocity of blood within the vein is traced manually by one observer on the software 
program, and measurements including the maximum velocity, mean velocity and duration of increased 
flow during calf compression can be calculated.  This was then repeated by a second observer, and again 
by the first observer to establish inter and intra observer reliability.   For clarity, the locations that were 
considered distal (a), within (b) and proximal to (c), valve leaflets are considered anatomically.  This is 
demonstrated in Figure 47.  
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Figure 47:  Shows the measurement of venous velocity with ultrasound distal (a), within (b) and proximal to (c), 
valve leaflets and the velocity curve traced by one observer on ImageJ (d). 
 
 
6.3.3 Results 
Seven normal subjects have been studied, of which 6 were male.  The mean age was 31.85.  Three 
subjects had C1 disease, with mild asymptomatic telangiectasia, 4 had C0 disease, that is no signs of 
venous disease.  None of he subjects had any evidence of deep venous reflux or incompetence. In the 
case of subject 4, the 2nd valve distal to the confluence was used as the first was less than 1cm distal, 
making velocities difficult to measure as distal to the valve they were taken in the CFV.   Examples of the 
ultrasound images of deep venous valves are shown in Figure 48 and Figure 49.  In Figure 48, the 
difference between the flow waveforms and velocities within the vein in both the standing (A) and lying 
(C) positions can be observed.  Image B demonstrates the flow waveform and transient increase in 
velocity during a calf squeeze to 45mmHg which simulates walking. 
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Figure 48: Shows the ultrasound images of venous valves.  A - Normal respiration, standing position, B - Standing 
position, calf squeeze, C - Semi recumbent position, normal respiration, D - Still of B mode video image showing 
valve leaflets. 
 
 
 
 
 
 
 
 
Figure 49: Contrast enhanced ultrasound of venous valve 
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Figure 49 shows still images of the contrast enhanced microbubble ultrasound using SonoVue 
microbubbles.  In image A, behind the valve leaflet is a flow void, and image B demonstrates that the 
microbubbles can adhere to the valve leaflet and highlight its shape. 
The maximum velocities obtained in both the lying and standing positions for each subject are shown in 
Table 15 below.  The maximum and mean velocities and the duration of increased flow following calf 
squeeze are shown for each subject in Appendix 3 for observer 1 and Appendix 4 for observer 2.  These 
show the maximum and mean velocities over the total duration of the recording as well as the mean 
velocity during the calf squeeze only, if one was applied. 
 
Table 15: Shows the position of the valve measured and summary of the maximum velocities obtained in both 
recumbent and standing positions for each subject 
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Subject Distance of valve 
from DFV/FV 
junction (cm) 
Maximum velocity 
standing position 
(cm/s) 
Maximum velocity 
recumbent position 
(cm/s) 
Mean duration of 
calf squeeze (s) 
1 4.8 59.00 91.05 2.08 
2 5.0 40.35 71.93 2.42 
3 15.0 41.68 76.50 2.6 
4 6.0 54.9 105.88 1.63 
5 12.0 41.11 93.23 2.88 
6 2.9 29.37 51.43 2.52 
7 2.7 52.94 127.06 2.14 
     
 
The intra and inter observer reliability data is demonstrated by Bland-Altman analysis.   
 
Figure 50: Shows the Bland-Altman analysis of the inter-observer reliability between observer 1 and 
observer 2 for mean velocity measurements demonstrating a bias of -2.0 (SD 7.6) and 95% limits of 
agreement from -17 to 13.    
 
Figure 51: Shows the Bland-Altman analysis of the inter-observer reliability between observer 1 and 
observer 2 for measurements of the duration of calf squeeze demonstrating a bias of -0.099 (SD 0.63) and 
95% limits of agreement from -1.3 to 1.1.   
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Figure 52: Shows the Bland-Altman analysis of the inter-observer reliability between observer 1 and 
observer 2 for maximum velocity measurements demonstrating a bias of -2.9 (SD 16) and 95% limits of 
agreement from -34 to 28.  Figure 53: Shows the Bland-Altman analysis of the intra-observer reliability 
for observer 1 for maximum velocity measurements demonstrating a bias of -0.61 (SD 1.1) and 95% 
limits of agreement from -2.8 to 1.5.    
 
Figure 50: Shows the Bland-Altman analysis of the inter-observer reliability between observer 1 and 
observer 2 for mean velocity measurements 
 
 
 
 
 
Figure 51: Shows the Bland-Altman analysis of the inter-observer reliability between observer 1 and observer 2 for 
measurements of the duration of calf squeeze 
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Figure 52: Shows the Bland-Altman analysis of the inter-observer reliability between observer 1 and observer 2 for 
maximum velocity measurements 
 
 
 
Figure 53: Shows the Bland-Altman analysis of the intra-observer reliability for observer 1 for maximum velocity 
measurements 
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The maximum velocities obtained in the lying position ranged from 51.43-127.06 cm/s and in the 
standing positions from 29.37-59.00 cm/s.  The average of all the maximum velocities 2cm distal to the 
valve, within the valve and 2cm proximal to the valve are shown in Figure 54.  Using a one-way Anova 
test to compare the three values there was no significant difference (p=0.401), and an unpaired student t-
test demonstrated no significant difference between each of the three columns.  The average of all the 
mean velocities 2cm distal to the valve, within the valve and 2cm proximal to the valve are shown in 
Figure 55.  Using a one-way Anova test to compare the three values there was no significant difference 
(p=0.217), and an unpaired student t-test demonstrated no significant difference between each of the 
three columns, however the difference between the mean velocity measurements 2cm distal to the valve 
compared with the mean velocity measurements within the valve and 2cm proximal to the valve to the 
valve approached significance with p=0.131 and p=0.119 respectively.   
 
 
Figure 54: Shows the average of the maximum velocity for the 7 subjects relative to the valve leaflets using 
ultrasound 
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Figure 55: Shows the average of the mean velocities for each of the 7 subjects relative to the valve leaflets using 
ultrasound 
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6.3.4 Discussion 
This study investigated the use of ultrasound imaging to provide the flow profile around the femoral vein 
valve distal to the confluence of FV and DFV in normal subjects.  The mean duration of calf squeeze was 
2.32s.  Although the velocities were very variable between subjects, the average maximum velocity and 
the average mean velocity increases as blood flows through the valve leaflets.  The information obtained 
can be compared to other imaging modalities to assess its reliability.  Given the good inter and intra 
observer reliability obtained, this information can be used to develop computational models and 
laboratory flow models 
 
 
 
6.4 MAGNETIC RESONANCE IMAGING OF DEEP VEIN 
VALVES 
 
6.4.1 Introduction 
 
Magnetic Resonance (MR) Venography is increasingly used to obtain information on the deep veins that 
are less accessible to ultrasound, for example, the pelvic veins.  It is able to give accurate anatomical data 
and information on obstruction of the deep venous system278, 325 and confers an advantage over 
Computed Tomography Venography as it does not involve the use of ionising radiation.  The use of 
dynamic MRI has expanded in many clinical areas recently as real-time imaging can be obtained of 
vessels.  Contrast is not required as the blood acts as a contrast as it is moving.  MR Velocity Mapping has 
been previously used predominantly in arterial system, when it is gated with the cardiac cycle to build up 
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the acquired images.  It is not however, often used in the venous system.  More recently it has been used 
to measure flow in the deep veins of the calf in volunteers with and without compression hosiery, or with 
intermittent pneumatic compression344, 345.  It confers advantage as it is able to give simultaneous 
anatomical and velocity mapping.  One of the major disadvantages, however, is that it is not possible to 
image valves directly using MR due to spatial resolution restrictions and incredibly thin valve leaflets, 
however high resolution ultrasound can achieve this as shown in Figure 48.   
This part of the study aimed to image the same subjects who had been assessed with ultrasound and 
obtain dynamic MR images across the same segment of vein to obtain accurate velocity data. 
 
6.4.2  Methods 
IPC Device 
AS for the ultrasound study, the same IPC device, Kendall SCD EXPRESS Compression System, was 
used to drive an impulse of venous blood through the deep veins of the leg.  The device delivers 
45mmHg through a cuff consisting of an airbladder with non-elastic Velcro strapping transferring the 
pressure over the whole circumference of the leg.  The device inflates separate air bladders sequentially; 
however the cuff was attached so that only the first bladder inflation would have a compression effect on 
the leg, and this was applied to the widest point of the calf. 
 
Subject setup 
The same 7 normal subjects that were scanned using ultrasound to locate the first venous valve in the 
common femoral vein in the right leg and to confirm the competency of the valve were imaged.  The 
distance from the confluence of the femoral vein with the deep femoral vein to the base of the first valve 
was measured and used as a marker for centring the MR imaging volume, this was performed in the same 
subject positioning as used for MR scanning to reduce any anatomical movement and allow approximate 
location with a pen mark drawn on the subjects skin.   
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The subjects were set up for the MR scan as follows; Using a 1.5T Avanto Siemens scanner the subject 
lay supine on the MR table with a foam support (~ 10 cm high) beneath the ankles, this allowed the calf 
to remain above the table reducing any unwanted compression of the leg and also allowed the application 
of the compression cuff around the muscle mass of the calf without causing excessive motion of the leg 
during inflation. A further foam support (generally used for knee and lower leg support) was used with 
pillows to raise the subject into a low semi-recumbent position, this increased hydrostatic pressure acting 
on the veins in the leg increasing vein size and improving venous filling between compressions.  A small 
surface coil, Carotid Coil, Machnet, was then taped over the pen mark of the valve location, near the 
proximal inner thigh.  This set up is shown in Figure 56. 
Figure 56: Shows a volunteer ready for MRI, showing clockwise from top left; expiratory breath hold, Kendal SCD 
express system calf pump, heel raised slightly from the bed to prevent calf compression and surface coil.  
Then, bSSFP multi-slice localisers allowed visualisation of the bifurcation and, using the distance 
measured from the ultrasound scan, the estimated location of the valve was moved to the scanner iso-
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centre.  A high resolution 3D bSSFP scan allowed further confirmation of the imaging region.  This is 
shown in Figure 57. 
 
Figure 57: Shows a transverse slice from the bSSFP 3D volume within the imaging region used, with 
vessels labelled, also noted are the femur and testicle for orientation.  An artefact from the carotid coil 
can be seen above the anterior surface of the leg and the coil sensitivity can also be observed. 
 
 
 
 
The 3D images also allowed a check of the trajectory of the vein through the imaging slice, fortunately 
the vein in this location tends to run axially through the leg, major offsets were corrected by repositioning 
the subject.  The subject was asked to perform an end expiratory breath-hold, to reduce any respiratory 
induced venous flow variations between scans, with the IPC device activated during the breath-hold 
instructions as it had a delay of approximately 15s from turning on to first inflation. The RV spiral 
sequence was then run continuously over the compression period.  A preparation scan allowed a check of 
172 
 
the RV spiral setup and image reconstruction, but also flushed any excess blood in the venous reservoir 
and therefore reduced variance between the initial scans.  This was repeated for 10 slices through the 
isocentre with Z offsets within the range +25 mm to -25 mm with 5 mm slice separation with 
approximately 45 s between scans to further regularise the venous blood reservoir filling. After a short 
break the same 10 slice were repeated again.  The parameters for the sequence are shown in Table 16 
below. 
 
Table 16: Shows the RV spiral scan parameters 
Parameter Value 
FOV 150  
Resolution (acquired/reconstructed) 1 x 1 -> 0.5 x 0.5 mm 
Slice Thickness 4 mm 
VENC 85 cm/s 
Water Excitation / flip angle  (1,1) / 30 °  
Interleaves  4 
No. Ref scans 3 
 
 
 
RV Spiral Scanning Parameters 
The RV spiral sequence at 1 x 1 mm spatial resolution was used to achieve maximum temporal resolution.   
The fixed design of the FOV and the imaging location presented a problem of wrap artefact in the 
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images; the small carotid coil reduces this artefact with its sensitivity.  The slice thickness was reduced to 4 
mm to reduce partial volume effects.  A large VENC range was chosen such that all velocity maps could 
be resolved with no phase wrap around due to the number of slices being acquired and the lack of an off-
line reconstruction, pilot scans agreed with preliminary Doppler ultrasound measurements showing a 
peak venous velocity ~50 – 70 cm/s over the flow impulse.  
Images were reconstructed using modelling of the background muscle signal for the phase subtraction 
because of vessel size and shape changes over the flow impulse from compression; also because of 
potential variance between scans a separate reference scan subtraction could not be used.  ROIs for 
modelling of the muscle signal were drawn, independently for each of the 2 elements in the carotid coils, 
on a magnitude image averaged from 3 Ref scans at the beginning of each RV spiral acquisition, avoiding 
any residual fat signal and leaving room around vessels for shape changes.  The same ROI was used 
throughout each acquisition applied to each velocity image for an individual background phase map 
subtraction.  This sequence was developed by Dr Pierce and Dr Gatehouse at the Royal Brompton 
Hospital, optimised there by with Dr Pierce for imaging the FV / DFV confluence and all scanning was 
carried out at Charing Cross Hospital, with Dr Pierce and with the help of Anastasia Papadaki and Lesley 
Honeyfield.  
 
Image analysis 
 
Images were loaded into CMR Tools for inspection and analysis.  Using SPIN (signal processing in NMR) 
software, obtained from Professor Mark Haake, The MRI Institute, Detroit, USA, the images were 
analysed.  Briefly, both the phase and magnitude images are opened within the software.  Using flow 
mode, the vessel to be assessed was defined as a region of interest by one observer and the software then 
follows this through the images. The VENC and R-R intervals are then manually inputted and the 
software calculates the velocity data for the images across the defined vessel.   The maximum velocity 
during the calf squeeze was recorded by the software.    
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 6.4.3 Results 
 
Velocity data from MRI  
Images have been reconstructed using modelling of the background muscle signal for the phase 
subtraction as the vessel size and shape changes over the flow impulse.  An early problem with the 
reconstruction sequence on Matlab and the selection of the region of interest for digital subtraction 
meant that alternative software was chosen.  The reconstruction was performed by the SPIN software.  A 
region of interest for modelling of the muscle signal was drawn by one observer.  The software then 
produces a graph of the average velocity across the femoral vein as against time.  The coefficient of 
variation for 5 readings taken was 3.21%.  Data was acquired to excel and the mean velocity waveform 
was used to identify the frame with the temporal peak mean velocity for each slice, an example of this is 
shown in Figure 58.  
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Figure 58: Shows the average velocity across the femoral vein during a calf squeeze 
  
 
Figure 59: Shows the average of the maximum velocity for the 7 subjects relative to the valve leaflets using MRI 
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 The maximum velocities for each subject during the calf squeeze were recorded 2cm distal to the valve, 
within the valve and 2cm proximal to the valve.  Using a one-way Anova test to compare the three values 
there was a significant difference (p=0.013), and an unpaired student t-test demonstrated a significant 
difference (p=0.004) between the maximum velocity 2cm distal to the valve and the maximum velocity 
within the valve and a significant difference (p=0.013) between the maximum velocity 2cm distal to the 
valve and the maximum velocity 2cm proximal to the valve.  There was no significant difference 
(p=0.887) between the maximum velocity within and 2cm proximal to the valve.  This demonstrates that 
the maximum velocity of blood increases as it passes through the valve leaflets.   
 
Comparison of Ultrasound and MRI Results 
The data regarding the maximum velocities from both the ultrasound and MRI data was compared by 
Bland-Altman analysis.  Figure 60: Shows a comparison of the maximum velocity in the femoral vein 
measured by both MRI and ultrasound in the form of a Bland-Altman analysis.  This shows a bias of -50 
(SD 22) and 95% limits of agreement from -93 to -7.8.  The velocities obtained from MRI were lower 
than those obtained from ultrasound in all cases.     
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Figure 60: Shows a comparison of the maximum velocity in the femoral vein measured by both MRI and ultrasound 
in the form of a Bland-Altman analysis 
 
 
 
6.4.4 Discussion 
This study investigated the potential of both Ultrasound imaging with and without contrast and real-time 
spiral MR image sequences to provide the flow profile around the first femoral vein valve distal to the 
confluence of femoral and deep femoral vein in normal subjects.  The information obtained from these 
seven patients has been further analysed and used to contribute to the development of both the 
computational and laboratory flow models described later in this Chapter and in chapter 8.  Data 
obtained from both US and MRI demonstrates that the velocity of blood flow increases as it passes from 
distal to the valve, through the valve and then proximally towards the heart.  This did not reach 
significance for the US modality, however.   
There are limitations to this study.  The US and MRI data was obtained from the same subjects but on 
different days and at different times.  Venous haemodynamics can vary with time and physiological 
status346  The accuracy of US is limited not only by the equipment and software but also to operator 
related problem such as identification of the correct vessel, correct insonation angle relative to vessel 
cross section and ability to replicate this over multiple scans.   
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The MRI used here also had significant limitations.  The valves themselves were not visible using MRI, 
therefore the location was estimated using the measurements obtained from US, measuring the distance 
distally from the confluence of the femoral vein and deep femoral vein.  The subjects used for the 
experiment had to breath hold in expiration for the duration of the study, relying on their compliance.  In 
addition, a 1.5T MRI scanner was used for this study.  Sacrifices between temporal and spatial resolution 
that were made could have been minimised by using higher field strength, such a 3T scanner.   
 
 
6.5 COMPUTATIONAL MODELLING OF DEEP VEIN 
VALVES 
 
6.5.1 Introduction 
 
Background 
There have been few previous studies to develop computational models of the venous system with and 
without a venous valve, in comparison to the studies of the arterial system, the work is very limited.  Basic 
venous models require a resistor to represent viscosity of the blood, a capacitor to incorporate the vessel 
wall compliance and an inductor347.  Pressure and flow data, as well as the tendency for smaller venules to 
collapse is harder to incorporate into these models.  The model must also be changed with posture of the 
subject, as gravity will have an impact on all factors incorporated348.  Other venous models have focussed 
on modelling the cardiopulmonary vasculature.  Using the assumption that blood is a Newtonian fluid, a 
model of cardiopulmonary bypass was developed349, but this is not applicable to the lower limb venous 
system.  Only one study focussed specifically on the modelling of a venous valve, however, the tubes 
were rigid, and no experimental subject data was used350.  Zervides et al351 and Diaz-Zuccarini et al352 have 
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further advance this work and are developed a model into which a valve can be incorporated and have 
studies the venous haemodynamics around the valve, but they did not include the valve sinuses.    
Experience gained in computational analysis of large vessel haemodynamics combined with patient-
specific images from a previous study of the effect of external compression on the deformation and wall 
shear stress in the superficial and deep veins in the lower limb 353, 354 laid a solid foundation for further 
development of the computational model to incorporate the deep vein valves. Using computational fluid 
dynamics, more information on the haemodynamics around the venous valve can be understood, 
including the velocity, wall shear stress and flow patterns.  Computational Fluid Dynamics (CFD) is a 
method which uses algorithms to solve a system of partial differential equations by discretisation in order 
to describe fluid flow355.  Using CFD in blood flow studies can reduce the number of experiments on 
patients which are time consuming, and costly in terms of resources, as well as exposing patients to 
unnecessary radiation if CT is used.  There have been great improvements in computing power and speed 
which have allowed more advanced calculations and therefore more comprehensive analysis of data.  For 
flow data, this has allowed more comprehensive analysis of flow condition at in the vascular system. 
 
Biofluid Mechanics 
Viscosity is an inherent property that determines the fluid’s resistance to flow and is affected by factors 
such as density (mass per unit volume) and shear rate (the velocity gradient across the diameter of the 
vessel)356.  When viscosity remains constant irrespective of the shear rate, the fluid is termed a 
Newtonian’ fluid and when it changes with the shear rate, the fluid is termed ‘Non-Newtonian’. Non-
Newtonian fluids may be ‘shear thinning’, where the viscosity decreases at higher shear rates or ‘shear 
thickening’ where viscosity increases at higher shear rates. Water is a Newtonian fluid while blood and 
aqueous foams are examples of Non-Newtonian shear thinning fluids357.  
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Aims 
This part of the project aims to develop a computer model of venous flow in normal deep venous 
function and validate the computational model using data obtained from ultrasound scanning. 
 
6.5.2 Methods 
Governing Equations 
Assuming that blood is a Newtonian fluid, the model was governed by 2 equations.  The first is the 
continuity equation, which derives as it is assumed that energy is neither lost nor gained, but conserved 
locally within a system, so any energy entering, must leave the system at the end.  Therefore in this case:   
 
Δρ + ∇ . (ρu)   =  0 
Δt 
Where: 
∇ = Divergence 
ρ = fluid density, assumed to be 1.60g/cm3 for blood 
t = time 
u = flow velocity vector field 
As we have made the assumption that ρ is constant, as we have assumed incompressible flow, then the 
equation is simplified to: 
   ∇  .  u   =  0 
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The second is the Navier-Stokes equation describing the motion of fluid substances simplified for 
incompressible fluid355, which is: 
 
 ρ   Δv  +  v . ∇v   =  -∇p  +  µ∇2v  
  Δt 
 
Where: 
v = flow velocity 
p = pressure 
µ = viscosity of blood, assumed to be 0.035g/cm/s for blood 
 
Ultrasound Imaging 
The ultrasound imaging obtained in section 6.3 was used.  One subject was excluded as the valve leaflets 
could not be visualised throughout the complete process of opening and closing.  Therefore 6 normal 
subjects, all male, mean age 32 were included.  AVI Videos of B-mode ultrasound images of the first 
valve distal to the confluence of the femoral vein and deep femoral vein obtained while the subjects were 
standing during normal respiration were used.  If both leaflets could not be visualised, the imaging 
acquired focussed on one leaflet, and geometry was duplicated.  The averaged cross sectional velocity 
from the velocity waveforms at the locations, 2cm distal to the valve, within the valve leaflets, and 2cm 
proximal to the valve were used. 
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Geometry classification 
DICOM images of the ultrasound scans were used.  MATLAB (Mathworks), was used to open the 
images and extract the geometry.  As discussed, one of the limitations of the ultrasound imaging is that 
both valve leaflets cannot be visualised at all times, however, where one leaflet was visible, symmetry 
between the two leaflets was assumed, in terms of both length and movement, and symmetry of the valve 
sinus was assumed.  The valve was open for the majority of the time 
 
Meshing 
Once the geometry was obtained, models of the valve leaflet positions were created.  A mesh was 
generated for each model, as part of the pre-processing of CFD, which ensures the discretisation of the 
geometric domain of the venous valve.  This results in the formation of finite elements using the finite 
element method (FEM).  In view of the geometric issue characterised, the components inside the grid 
comprise of partial differential equations (PDEs) that could predict haemodynamic variables.  FEM 
transform, by discretisation, can then be approximated with algebraic equations. For this simulation, 
PDEs are governed by the 2D Navier-Stokes comparison for incompressible liquid.  
The denser the mesh, the more accurate the fluid behaviour will be, however, this will result in a longer 
computational time.  Therefore a compromise must be reached.  The mesh density can be changed at 
different locations within the vein and valve.  In this case, it was increased around the valve leaflets and 
within the valve sinus to obtain more accurate results.  Both quadrilateral and triangle mesh structures 
were employed.  A grid dependency test was performed to ensure mesh quality.  A mesh size of 9307 
elements, which gave a change of <0.41 cm/s relative to the 17961 element mesh was chosen, as a mesh 
size of 5135 elements gave a velocity change of 1.33 cm/s. 
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Boundary conditions 
Reliable boundary conditions are essential for reproducible and accurate results, as they provide the 
solution to the PDEs.  The inlet and outlet location of the models were defined to ensure the model was 
directional.  Other conditions that were applied include: a no-slip condition to the interior of the vessel, 
that is it was assumed that the velocity at the wall was 0cm/s, flow was laminar, and at the outlet the 
pressure was 0.  Subject-specific velocity was initially applied at the inlet, however, no difference in the 
spatial distribution of the variables was found between subjects, an average velocity of 7.83 cm/s was 
applied at the inlet for all models, unless specified. 
 
Steady-flow simulation 
The dynamic viscosity of blood was 0.035 g/(cm/s) and the density was 1.60 g/cm3 respectively.  The 
Reynolds number ranges between 34.43 and 344.33 depending on the flow rate in the deep vein and 
therefore laminar flow could be assumed354. 
ADINA (Automatic Dynamic Incremental Non-Linear Analysis, v 8.8, ADINA R&D Inc., USA), finite 
analysis software was used to create the model.  This is able to analyse slid, fluids and fluid-structure 
interactions for both linear and non-linear systems, and each CFD model was created and meshed using 
this. 
 
Summary of Methods 
To summarise the methods: 
1. The geometry of the vein and valve leaflets was extracted from the ultrasound imaging. 
2. The geometry was reconstructed for different valve leaflet positions, that is closed, minimal 
opening, intermediate opening and maximal opening. 
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3. A mesh was generated using the Adina software, boundary conditions applied and a model 
constructed.  
This work was done in collaboration with Patrizia Lee, as part of her MSc project, under the supervision 
of Professor Yun Xu.  
 
6.5.3 Results 
Valve, Sinus and Vein Wall Geometry  
The measurements taken from the ultrasound imaging including the diameter of the vein proximal to the 
valve, at the base of the valve leaflets, at the widest point of the valve sinus and distal to the valve, as well 
as the visible length of valve leaflet are described in Table 17.  These represent the mean values from all 
of the subjects, except subject 2 who was not included as the valve leaflets could not be seen adequately 
to establish the valve geometry. 
Table 17: Shows the diameter of vein, sinus and length of the valve leaflets 
 Diameter 
proximal to 
valve (cm) 
Diameter at 
valve sinus 
(cm) 
Length of 
sinus (cm) 
Leaflet basal 
length (cm) 
Length of 
valve leaflet 
(cm) 
Median 0.93 1.06 1.41 0.14 0.83 
Average 0.94 1.07 1.45 0.13 0.88 
Standard error 
of mean 
0.05 0.04 0.10 0.02 0.12 
Percentage 
difference (%) 
9.61 6.95 13.34 27.14 27.64 
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Using this information and the assumptions previously made, Adina finite analysis software was used.  A 
mesh was overlain onto structures with the geometry of the subjects’ veins as described above.  There is a 
difference of up to 27% between individuals.     
 
Valve motion 
The AVI videos of the ultrasound of real-time flow through the valve demonstrate the stages of the 
“valve cycle” previously described by Lurie et al, 2002224.  They described the valve passing through 
closed, opening, equilibrium and closing phase.  In the standing position with normal respiration, the 
majority of the time the valve is in at the maximal opening stage.  The valve closes only occasional and 
usually for less than 2 seconds.  One of the issues with this study is that the valve leaflets are dynamic and 
during the valve cycle can move into and out of the visual plane.   
Velocity profile 
Derived from Ultrasound Imaging 
The velocity waveforms observed on the ultrasound during relaxed respiration are similar to those 
demonstrated previously in other studies of lower limb veins using other imaging modalities354, 358.  The 
velocity waveforms do appear to have a very low magnitude pulsatility, which was observed in the 
ultrasound imaging, and given its frequency seemed to represent changes caused by respiration.     During 
inspiration, the changes in intrathoracic and intra-abdominal pressures contribute to flow in the deep vein 
of the lower limbs. 
 
Steady-state flow analysis 
Although blood flow through the body is not constant, as in the venous system it varies with respiration, 
this study assumes that a state of steady flow exists in the deep veins.  Between respirations, this is the 
case, and therefore the model is that of venous flow during this steady state flow.   
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CFD simulation for each of the six included subjects was performed.  This is shown in Table 18.   No 
spatial changes in flow, pressure and WSS patterns were found.  The model was therefore computed from 
during the different stages of the valve cycle as previously discussed:  
• minimal opening 
• intermediate opening 
• maximal opening 
with an averaged maximum velocity load of 7.83±0.98 cm/s. 
 
Velocity profile 
The contour plots represent the different velocities of blood flow across the vessel.  These are shown in 
Figure 61.  These are comparable with those found by Lurie et al224, who showed that the velocity of 
blood flow in the femoral vein increases close to the valve, demonstrated in the contour plots by he 
change in colour moving through the valve.  The maximum velocity is achieved just proximal to the apex 
of the leaflets, and this is further increased when the valve is in the minimal opening phase, when the 
maximum velocity at this point is 162 cm/s, gradually decreasing to a maximum velocity of 12.89 cm/s at 
this point in the maximal opening phase.  In the contour plots, the lowest velocities are seen in the 
venous valve pocket, between the base of the valve leaflet and the sinus.  
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Figure 61: Shows the contour plots of velocity distribution (cm/s) 
a) 
b) 
c) 
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Flow pattern 
Vector plots of the velocity profile were developed for the different stages of the valve cycle, as shown in 
Figure 62.  As shown, blood flow follows the wall, but at the apices of the leaflets, separates resulting in a 
flow void in the area behind the valve leaflet, in the venous valve pocket.  Some distance beyond the 
leaflets, the flow resumes the original velocity profile.  To further evaluate the venous valve pocket, the 
vector plots in these areas were replotted.  This is shown in Figure 63.  Three separate vortices were 
observable within a single venous pocket.  This could be relevant as if the valves are damaged these 
mechanisms will fail. 
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Figure 62: Shows the vector plots (vector size scaled to magnitude) for the velocity profile along the vein (cm/s) 
b 
a 
c 
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Figure 63: Shows the vector plot of flow pattern for a) minimal opening of valve, b) maximum opening of valve; 
arrows indicate the location of vortices in one side of the pocket. 
 
a 
b 
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Wall Shear Stress (WSS) 
The distribution of wall shear stress in the model is shown in Figure 64, and it varies at different points in 
the valve cycle.  During minimal opening, the maximum WSS is at the apex of the leaflets and then shifts 
as the valve leaflets open further along the leaflets.  There was decrease in maximum WSS when 
comparing minimum to maximum opening of the valve by 97.1%. The WSS in the venous valve pocket 
was close to 0 g/cm/s2).   
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Figure 64: Shows the contour plot of Wall Shear Stress (dyne/cm2) 
 
b 
a 
c 
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Model validation 
Table 18: Shows the comparison between subject-specific experimental and computed velocity values ascertained at 
different positions relative to the deep vein valve 
Subject 
No. 
Inlet 
Velocity 
Velocity (cm/s) taken from between 
leaflets 
Velocity (cm/s) taken from 2cm 
proximal to leaflets 
Experi-
mental 
Computed % Diff. Experi-
mental 
Computed % Diff. 
1 5 8.5 8.32 2.16 7.5 6.8 9.33 
3 10 17.5 16.2 8.02 18 14.3 20.6 
4 10 19 16.2 17.3 18 14.3 20.6 
5 10 12 16.2 -25.9 20 14.3 28.5 
6 6 10 9.89 1.11 17 8.3 51.2 
7 6 12 9.89 21.3 12 8.3 30.8 
Median 8 12 13.0 8.02 17.5 11.3 24.5 
Mean 7.83 14.1 12.8 3.99* 15.4 11.1 26.8* 
SEM 0.980 1.60 1.55 7.63 1.93 1.47 5.76 
 
 
The velocities from the computational model were compared with those from the ultrasound images of 
the six subjects’ deep vein.  The ultrasound image velocities taken between the leaflets and 2 cm proximal 
to the valve leaflets were compared with the computed values.  This is shown in Table 18. There is some 
discrepancy, but the maximum measurable velocity for each subject was applied to the model, which 
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could allow for this.  Therefore, the comparison was made between this value and the maximum value on 
the computational model.  These differences are small and do not reach significance, for the 
measurements between the leaflets p=0.75 and proximal to the valve p=0.25.    
 
6.5.4 Discussion 
A “typical” model of the femoral vein including the valve sinus and a pair of crescent shaped flexible 
leaflets attached at a point to the vein wall has been constructed. A model to simulate the dynamic 
movement of the valve leaflets has been developed and incorporated into the venous flow model.  The 
geometry was extracted from the ultrasound imaging carried out on normal subjects and the model based 
on average dimensions measured from these subjects, all of which have normal deep venous function.  
Fluid-structure interaction (FSI) simulations of venous flow in the typical normal vein model has been 
performed and analysed to establish flow patterns in the venous valve pocket (VVP) where thrombi are 
likely to form.  There are several considerations that have been accounted for: 
 
 The valves have flexible leaflets  
 Blood consists of cells, platelets and plasma, making it behave in a non-Newtonian way, however, 
for this model it is assumed that blood behaves as an incompressible Newtonian fluid 
 Flow is turbulent, especially around special areas such as valves and bifurcations 
 
This is the first study that has used CFD analysis based on realistic geometry extraction and velocity data 
from ultrasound images of the femoral vein in human subjects to demonstrate flow dynamics around the 
valve and valve sinus, the distribution of velocity changes and WSS exerted by the flow.  The findings are 
consistent with previous flow patterns in other veins, both ex vivo and in vivo224, 359.  The vortices in the 
venous valve pocket as well as the acceleration of the blood as it passes through the valve leaflets, which 
act as a relative stenosis.  This keeps the valve leaflets separate from the wall of the vein.   
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The model developed here differs from a previous study which showed that the separated part of the 
flow should reach the sinus wall, followed by vortex formation359, however, this study was based on dog 
at post mortem.  This model demonstrates the flow forms vortices further downstream.  
The valvular motion can thus be described according to Bernoulli’s principle, that is an increase in the 
speed of the fluid occurs simultaneously with a decrease in pressure or a decrease in the fluids potential 
energy.   When the valves are minimally open, the pressure gradient is at its highest, as is the velocity 
gradient.  This exerts a pressure against the luminal surface of the leaflet, forcing the valve to open.  The 
vortices are formed once the valve is maximally open, which increases the pressure within the sinus, 
resulting in closing of the valve. 
The vector plots revealed three vortices in the venous valve pocket.  This could result in cell aggregation 
and if this gets isolated from the flow in the vein then  this could be a potential site for the initiation of 
thrombus formation within the vein360. 
This study has many limitations.  It corresponded well with the data obtained from the ultrasound 
imaging, however, the assumptions that were made initially will affect the results.   The fluid properties 
and geometry of the valves that were obtained from the ultrasound imaging will lead to inaccuracies.  
Ultrasound imaging itself has limitations, there is inherent user variability.  Out images were all performed 
by the same experienced vascular scientist to make an attempt to overcome this.  The model was 
developed under the assumption of steady state flow, thus providing a snapshot of flow through the vein 
valve, however this could be further developed to incorporate respiration and the action of the calf 
squeeze, which was not incorporated into this model.   
In summary, by utilising CFD and FSI, computational models could potentially provide more data to 
guide the design of a valve or be used to develop patient specific models to accurately calculate the size 
and location that the valves developed should be sited.    
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7. DEVELOPMENT OF A NOVEL 
MATERIAL FOR USE IN THE VENOUS 
SYSTEM 
 
7.1 CARDIAC VALVE & VASCULAR GRAFT 
ENGINEERING: PREVIOUS WORK 
Introduction 
To date, no material is suitable ideal for use in the venous system, as it is a low flow, low velocity, and 
therefore high thrombogenicity system.  As demonstrated in Section 3.2, there is a paucity of literature on 
the use of bioengineered or synthetic materials in the venous system.  However, there has been similar 
work done in the cardiac valve and vascular graft engineering fields.  This section will review this 
literature as well as the literature available on a novel material which is considered may be of sufficiently 
low thrombogenicity for use in the venous system. 
Cardiac valve disease is a major worldwide health issue and cardiac valve replacement using metallic or 
tissue valves is common.  Each has its advantages and disadvantages, but neither provides the ideal 
solution, therefore research has continued to try to develop an alternative valve which would provide the 
answer.  Increasing work has also been carried out in the field of tissue engineering of vascular grafts, as 
atherosclerosis continues to increase, and if autologous vein graft is not available for bypass, the 
expanded PTFE, first introduced in 1973361, remains the most commonly used synthetic prosthesis.  In 
the medium term it develops intimal hyperplasia and eventually graft occlusion.  The previous work done 
in these fields, not including these common practices, is discussed here. 
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Methods 
Relevant papers were identified through systematic searches of Pubmed (1966 to August 2013). The 
search terms “cardiac valve”, “heart valve”, “aortic valve”, “mitral valve”,  “vascular graft” AND 
“polymer”, “tissue engineer”, “scaffold” were used.  Article titles and abstracts were screened for 
inclusion. A manual reference list search was also carried out for further appropriate studies to be 
considered for inclusion, ensuring relevant papers published before 1966 were included. Relevant full text 
articles were scrutinised and all studies reporting details of tissue engineered cardiac valves at any stage 
were included. Articles concerning native cardiac valves, peri-operative outcomes, aortic stenosis, 
superficial vein valves and deep venous valves were excluded.  
 
Results 
Although the initial search strategy yielded 1039 results, with 4 articles included from elsewhere, following 
exclusion of non-relevant publications, a total of 25 articles were included, as shown in Figure 65.  
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Figure 65: Shows a summary of the search strategy for previous cardiac valve and vascular graft engineering 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
           
Cardiac Valves 
Records identified through database 
searching  
(n = 1039 publications 
between 1963 and 2013) 
Additional records identified through 
other sources  
(n = 4) 
Records screened (title)  
(n = 1043) 
Records excluded  
(n = 1003) 
Exclusion criteria: Articles on 
native cardiac valves, peri-
operative outcomes, aortic 
stenosis, superficial vein valves 
and deep venous valves title of 
paper not within scope of 
review 
Abstracts and full-text 
articles assessed for 
eligibility (n = 40) 
Records excluded  
(n = 15) 
Excluded: duplicate records, 
conventional open surgical 
techniques,                                                                                                                                                                                                                                                 
venous valve studies  
 
 
 
 
 
Studies included (n = 25) 
Search terms entered: 
(((((cardiac valve[Title]) OR heart valve[Title]) OR aortic valve[Title]) OR mitral valve[Title])) AND 
(((polymer) OR tissue engineer) OR scaffold) 
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Biological Work 
Badylak et al362 in 2009 noted that at that time there did not appear to be a commercially available vessel 
biological scaffold and carried out some of the most extensive work with several published studies using 
ECM as a scaffold for a tissue engineered cardiac valve.  These include a study by Reing et al363 to assess 
the effects of processing methods on the mechanical and biological properties of porcine dermal 
extracellular matrix scaffolds, including growth factor content, glycosaminoglycan content, the ability to 
support cell growth in vitro and the mechanical strength.  Different decellularisation protocols are 
successful, but have different effects on detectable VEGF, TGF-beta1, glycosaminoglycans, ball-burst 
strength, and the ability of the ECM to support cell growth in vitro.  Further work by the same group by 
Tottey et al364 demonstrated differences in the properties of the scaffold depending on the age of the 
source animal, using porcine SIS.  They found that SIS from 3 week old animals failed at lower stress, 52 
week old SIS failed at higher strain and both 3 week and 52 week SIS had a lower elastic modulus.  It is 
known that SIS becomes thicker with age, and age increases the resistance to enzymatic degradation 
(collagenase), which could provide an explanation for this.  Brown et al365 characterised the surface 
properties of extracellular matrix scaffolds using SEM and ToF-SIMS, to include the luminal and 
abluminal surfaces (luminal sides relatively smooth) of urinary bladder matrix and SIS, which were found 
to be different and liver ECM, which showed no difference.  It is possible that source of ECM, as well as 
the surface used may modulate the phenotype of cells that are seeded onto it.  It was also found that the 
presence of a basement membrane also affects growth of cells.   When undergoing the reseeding process 
Tottey et al 366 found that using perivascular stem cells harvested from foetal muscle tissue by flow 
cytometry and  ECM harvested from porcine urinary bladder matrix, that ECM degradation products and 
low oxygen conditions (6% rather than 21%) enhance the regenerative potential of perivascular stem cells.  
Cells cultured in 6%  oxygen had 7 times  more DNA synthesised and 8 times more cells in number, 
possibly due to higher intracellular reactive oxygen species and higher superoxide dismutase. 
When utilising biological material as a scaffold many other factors are involved and have an effect on the 
cells growth and differentiaton.  Chiu et al367 determined via in situ hybridisation and antisense RNA 
probes that TGF-β, BMP-2 and VEGFA was expressed in chick embryo valvulogenesis at different times 
and that TGF-β and VEGFA modulate migration of AV valvular progenitor cells but BMP2 does not.  
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TGF-β 3 and BMP2 increase cushion invasion and different growth factors differentially regulate valve 
progenitor phenotype.  Gwanmesia et al368 found that TGF-beta1 and VEGF had opposite effects on the 
degeneration of aortic valvular interstitial cell, which could be modified by the ECM protein fibronectin.  
VEGF inhibited calcific nodule formation independent of ECM protein coating, where as TGF-β1 
increased calcific nodules if the ECM protein was coated with collagen, laminin or was uncoated, but a 
fibronectin coating caused reduced nodule formation.  
 Sacks et al369 considered the aortic valve cellular and ECM components: Endothelial cells are important 
for thromboresistance and mediation of inflammation, interstitial cells modulate durability and synthesis 
of the ECM and express enzymes including MMPs and elastin, and in the ventricularis layer have a  
mechanical role, glycosaminoglycans in the spongiosa layer cushion against shock and have a mechanical 
role, collagen  provides strength and stiffness and is the most important structural component.   Valentin 
et al370 studied the effect of macrophage depletion by injection of clodronate encapsulated in liposomes 
on porcine SIS crosslinked by CDI, and not crosslinked, placed in rat abdominal wall.   They found that 
cross-linking increases resistance to degradation by collagenase by depletion of macrophages at the site.  
Brown et al371 using porcine urinary bladder ECM, found different subgroups of macrophages present 
will also modify the phenotype of the cells.  
 
Polymer work 
There has been extensive work on the development of a cardiac valve using a polymer.  A review by 
Ghanbari et al372 in 2009 reviewed the literature to date regarding polymeric cardiac valves.  Required 
characteristics of the material to be used for the valve that were essential were; the need for the same 
durability of a mechanical valve, combined with the haemocompatibility and low thrombogenicity of a 
tissue valve.  Flexible polyurethane was not sufficiently durable.   Silicone demonstrated good flexibility 
and biocompatibility, but a short durability with early structural failure.  PTFE resulted in 
thromboembolism and major complications.  PEU and PCU were susceptible to biodegradation and 
calcification, as the soft segment of the polymer degrades quickly.  PVA, SIBS, polydimethylsoloxane – 
polyhexamethylene oxide PU and PDS-PCU nanocomposite all need further assessment for biostability.  
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In addition, the effect of incorporating anti-calcific agents or heparin needs further investigation.  
Paediatric patients have additional complex requirements for cardiac valve replacement, as they will grow 
over the lifetime of the valve.  Sachweh and Daebritz373 noted that manufacturing methods were very 
relevant when considering Silicone, PTFE, Dacron, PVC and PU to be used as polymeric heart valves, 
and when they tested PU valves in the aortic and mitral valve positions found them to be comparable 
with existing metallic and tissue valves used.  Christenson et al carried out both in vivo studies on 
degradation374 and in vivo and in vitro correlations on the oxidative mechanisms of PCU and PEU375.  
They found that PEU and PCU had different soft and hard segments, and different mechanical 
properties, and that PCU was more susceptible to degradation.  However, PCU undergoes less 
degradation when subjected to hydrogen peroxide and cobalt chloride solution.  Kannan et al376 found 
that the resistance of PU to degradation could be improved by the incorporation of a polyhedral 
oligomeric silsesquioxane nanocore and in this case the addition of carbonate improved the resistance to 
degradation when compared to bovine pericardium.  Silsesquioxane nanocomposite polymer was also 
found to have anti-calcification potential in in-vitro conditions by Ghanbari et al377.  Calcification is due 
to reaction between aldehyde groups of phospholipids and circulating calcium ions causing calcium 
phosphate, which causes cracking.  Modification of polyurethane with covalently attached 
bisphosphonate diethylamino moieties reduces calcification and reduces mechanical stress.  Incorporating 
POSS into the backbone gives reduced hydrophilicity, improving surface integrity, and reducing 
thrombogenicity, that is reducing platelet and protein adsorption.   
Poly(SIBS) is a biostable thermoplastic elastomer, which has been extensively investigated for use in many 
biomedical applications including cardiac valves378.  It was considered suitable for use in the vascular 
system as it does not substantially activate platelets, has few polymorphonuclear implants and 
myofibroblasts, embrittlement was not observed over time, neither was calcification or degradation.  
However, it was susceptible to stress cracking with organic solvents, had a tensile strength less than 
polyurethane and sterilisation was very difficult due to poor gas permeability.  After early promising 
studies of SIBS by Gallocher et al379, Wang et al380 further studied SIBS as a trileaflet heart valve in an in-
vivo sheep model, however, it exhibited cracking and severe tissue reactions, after becoming calcified and 
the material failed.  
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After earlier work, Schmidt et al381 used a minimally invasive method of implantation of trileaflet tissue 
engineered heart valves consisting of a scaffold of non-woven polyglycolic acid mesh coated with poly-4-
hydroxybutyrate, fixed in nitinol stent, seeded with myofibroblasts and endothelial cells into 16 sheep.  
The valves functioned, but became rapidly thickened. 
  
Vascular Grafts 
Much of the work on vascular grafts has focussed on the development of grafts which are pre-seeded 
with cells prior to implantation.  L’Heureux et al382 used a tissue engineered blood vessel utilising 
autologous fibroblasts and endothelial cells harvested from small biopsies of the skin and superficial 
veins.  Sheets of living fibroblasts were wrapped around a stainless steel mandrel, after 10 weeks of 
culture, and after a further 10 weeks, the luminal surface was devitalised by air drying and the endothelial 
cells seeded and conditioned to flow and pressure for 7 days. Of the 6 patients, 1 thrombosed and 5 
remained patent, however, this method is costly and time consuming and unlikely to become widely 
adopted.  McAllister et al383 demonstrated that these tissue engineered sheets could be used effectively for 
haemodialysis access in 10 patients, however, although most remained patent, the grafts failed due to 
aneurysm.  Teebken et al384 used ECM from decellularised vessels such as pig aortas, and reseeded them 
in vitro using endothelial cells harvested with collagenase from saphenous vein and smooth muscle cells 
harvested from saphenous vein using collagenase A and elastase.  Cells were seeded and the construct was 
inserted into a perfusion circuit.   This was successful in that endothelial cells formed a single layer, where 
as myofibroblasts showed a tendency to build more than one cell layer.   
Other groups focussed more on the use of polymers to develop a vascular graft.  Sun et al385  studied a 
material which is thermoplastically similar to polyethylene, with a strength and strain suitable for vascular 
tissues, namely Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate).   It has a good affinity for vascular 
smooth muscle cells and endothelial cells and after modification with silk fibroin showed an improved call 
affinity.  Other materials have been investigated for use as biodegradeable coronary stents, including Poly-
L-Lactide386, tyrosine poly(desaminotyrosyl_tyrosineethyl ester) carbonate, and  poly(anhydride ester) 
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salicylic acid, but all have shown issues with restenosis and intimal hyperplasia and therefore will not be 
considered for the development of vascular grafts.  
Discussion 
Polymers provide consistent, reproducible material from which to manufacture the valve, in contrast to 
biological scaffolds which are much more variable in their properties.  ECM for example varies with the 
age of the source donor, different methods of decelularisation, residual MMPs, elastin, collagen, growth 
factors and other constituents.  Once implanted, it is important to consider the effect cells, such as 
macrophages, cytokines and other circulating factors from the recipient patient and the effect that these 
will have.  When developing a suitable polymer, its properties must be fully optimised and characterised 
to include; thrombogenicity, haemocompatibility, biocompatibility, mechanical properties and the effect 
of the material on host cells.  Also, surface and structural modifications can improve the properties of the 
polymer, ensuring that these do not adversely affect the other properties. 
 
 
7.2 SELECTION OF POLYMER 
 
Any patient who undergoes deep venous surgery or intervention requires a period of anticoagulation with 
heparin or warfarin387, and if a foreign material is implanted, this can sometimes be a lifelong requirement. 
A material for use in the venous system as a valve should ideally have the following properties: 
• Flexible – to allow for leaflet movement 
• Non-biodegradable – in order that it remains in situ for full endothelialisation and 
maintains the properties of the valve over time 
• non-thrombogenic  - to prevent early or late occlusion  
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• Biocompatible – to prevent excessive tissue reaction, which may cause thrombosis 
• Support cell growth - allow growth of 1-2 layers of vascular endothelial cells only 
• non-fatigable and non calcifying – to maintain its mechanical properties and flexibility 
over time 
• have option for drug releasing component e.g. heparin – reducing the need for the 
patient to take systemic anticoagulation 
• potential for dip coating in decellularised vascular endothelium extracellular matrix – to 
promote endothelialisation in vivo 
• Ability to expand and contract with the vein, which can change its diameter two-fold 
with postural changes, to prevent a relative stenosis and alteration in haemodynamics 
 
Presently, polymers and polymer coated metal stents, used in the vascular system have several problems: 
they are very thrombogenic and they lack haemocompatibilty and biocompatibility. In addition they lack 
the required mechanical properties.  A non-thrombogenic material would have implications not only for 
the valve, but also for a venous stent to treat patients with deep venous obstruction and potential uses in 
the arterial system as well. 
MPC has been demonstrated be biocompatible and to have antifouling and antithrombogenic properties. 
It has been shown to reduce the non specific absorption of plasma proteins and cells and for proteins 
that are immobilised on it, appears to improve their longevity and stability388.  MPC copolymers are 
compatible with cell growth and have been suggested they would be beneficial for cell and tissue 
engineering, in this study when it was polymerised with butylmethacrylate389. 
In vitro studies demonstrated the ability of MPC to reduce platelet adhesion onto surfaces after contact 
with ovine blood, as shown in Figure 66. Recently, there have been further studies looking at 
methacrylolyoxyethyl phosphorylcholine (MPC) and its use in arterial stents 390, 391.  Its haemocompatibilty 
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has been demonstrated in several studies392, 393.  Modifying surfaces of other polymers with MPC 
polymers has been demonstrated to protect from thrombus formation when blood is passed over these 
surfaces394.   
   
Figure 66: Shows that MPC reduces platelet adhesion, reproduced from Ye et al, 2003 395 
 
 
 
Therefore MPC was chosen as the main polymer on which to base this novel copolymer from which to 
develop a novel deep vein valve replacement.  The other monomers selected were Hydroxypropyl 
methacrylate (HPMA), which was selected as it is very hydrophilic, and has some crosslinking sites. 
Methacrylate based polymers are biocompatible and Hydroxypropyl methacrylate is hydrophilic, non 
toxic and non-immunogenic, and has been documented to be useful for developing polymers for drug 
delivery396-398.  Trimethylsilylpropylmethacrylate (TMSPMA) will hydrolyse in the presence of acid or base 
through the Si-OH group, creating a stable insoluble polymer.   During the crosslinking process, this will 
form a backbone and if fibres are formed, will move towards the centre of the fibre forcing the more 
hydrophilic biocompatible MPC to the surface of the fibres, thus improving the haemocompatibility of 
the final polymer.   
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7.3 AIMS 
This part of the project aims to synthesise and investigate this novel biocompatible polymer, MPC-
HPMA-TMSPMA, for use in the venous system and develop a scaffold from which a valve could 
subsequently be made.  
 
7.4 PATENT SEARCH 
A full patent search was carried out to ensure that there were no issues with intellectual property.  The 
results of this are described below: A freedom-to-operate search on “MPC coated implantable valve” for 
all in-force patent documents filed since 01/01/1990 was executed. The search yielded 10 patent 
documents pertaining to MPC coated implantable valve: 
• EP2326283 A1 BIOABSORBABLE BLEND FOR TEMPORARY SCAFFOLDING OF THE 
BLOOD VESSEL WALL  
• US20100003303 A1 POLYMERS OF FLUORINATED MONOMERS AND 
HYDROCARBON MONOMERS 
• US20090238854 A1 PLASTICIZERS FOR COATING COMPOSITIONS 
• US20050208093 A1 PHOSPHORYLCHOLINE COATING COMPOSITIONS 
• EP1784434 A1 POLYMERS OF FLUORINATED MONOMERS AND HYDROPHILIC 
MONOMERS 
• WO2006025858A2MICROFABRICATED CELLULAR TRAPS BASED ON THREE-
DIMENSIONAL MICROSCALE FLOW GEOMETRIES 
• WO2007005253A1 BIODEGRADABLE POLYMER FOR COATING 
• WO2006118808A1 AMORPHOUS POLY (D,L-LACTIDE) COATING 
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• WO2005118018A1 HEPARIN CONTAINING BLOCK COPOLYMERS COATED ON 
IMPLANTS LIKE STENTS 
• WO2006026325A2 IMPLANTABLE TISSUE COMPOSITIONS AND METHOD 
 
Patent Document “US20100003303 A1” discloses a method of treating a disorder in a patient comprising 
implanting in the patient an implantable device not limited to artificial vein grafts. The implantable device 
includes a coating comprising at least one biocompatible polymer not limited to 2- Methacryloyloxyethyl 
phosphorylcholine (MPC). 
Patent Document “EP1784434 A1”discloses a biocompatible polymer blend comprising a biocompatible 
polymer selected from 2-methacryloyloxyethylphosphorylcholine (MPC), coated on an implantable device 
used for the treatment of disorders such as anastomotic proliferation for vein and artificial grafts. 
Patent Document “WO2006025858 A2” discloses a method of cross-linking an implantable tissue 
comprising steps of treating the tissue under effective cross-linking conditions with a monomer capable 
of polymerization being selected from the group of sulfonate or phosphorylcholine group. The tissue 
prepared includes vascular patch, heart valve, venous valve bioprosthesis and vascular grafts etc. 
These are being taken into consideration in the development of the polymer, and an Invention Disclosure 
Form has been submitted to Imperial Innovations, who are continuing the search. 
 
 
 
 
7.5 POLYMER SYNTHESIS 
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7.5.1 Introduction 
The monomers were selected as previously described.  Free radical polymerisation is a method of forming 
a polymer by the progressive addition of free radicals which are formed by the addition of an initiator.  
The building blocks of monomers are then added to the polymer as the radicals are transferred from the 
initiator to the monomers.   
 
7.5.2 Methods 
 
Monomers 
The materials used are, MPC, Hydroxypropyl methacrylate (HPMA) and Trimethoxysilyl propyl 
methacrylate (TMSPMA).  The structure of these is shown below in Figure 67, Figure 68 and Figure 69 
below.  These were drawn using ChemDraw®, PerkinElmer. 
 
Figure 67: Shows the structure of MPC 
 
 
 
Figure 68: Shows the structure of HPMA 
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Figure 69: Shows the structure of TMSPMA 
 
 
Both linear and branched versions of the polymer have been synthesised.  In order to do this the 
monomers above are combined with EGDMA (the branching agent) and DDT (the termination agent) 
for the branched version of the polymer and with DDT only for the linear version.  In order to vary the 
degree of branching, the amount of EGDMA can be varied and to vary the molecular weight of the 
polymer, the amount of DDT added can be varied, which reduces the chance of the polymerisation being 
terminated early.  If the amount of DDT is reduced, the molecular weight of the polymer should increase.  
The following ratios have been tried in the synthesis of the polymer, as shown in the Table 19 below: 
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Table 19: Shows the ratios of monomers combined to make both linear and branched versions of MPC-HPMA-
TMSPMA 
Sample MPC HPMA TMSPMA EGDMA DDT 
Linear 
1 50 25 25 - 2 
2 50 25 25 - 1 
3 50 25 25 - - 
4 50 15 35 - - 
5 50 5 45 - - 
Branched 
1 50 25 25 10 10 
2 50 25 25 10 7.5 
3 50 25 25 10 5 
 
 
Free Radical Polymerisation 
Free radical polymerisation is a method of forming a polymer by the progressive addition of free radicals, 
which in this case are formed by the monomers. The free radicals are formed by the addition of an 
initiator, which in this case was AIBN.  The building blocks of monomers are then added to the polymer 
as the radicals are transferred from the initiator to the monomers.  The radical in this case is created by 
heating the initiator so that it produces a radical.   
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The materials were purchased as follows: 
• 2-Methacryloyloxyethyl phosphorylcholine, 730115 Aldrich 
• Hydroxypropyl methacrylate, 268542, Aldrich 
• 3-(Trimethoxysilyl) propyl methacrylate, M6514, Sigma  
• Ethylene glycol dimethacrylate, 335681, Aldrich 
• 1-Dodecanethiol, 471364, Aldrich  
• Methanol, anhydrous, 322415, Sigma-Aldrich 
• Azobisisobutyronitrile, 441090, Aldrich 
 
Prior to the free radical polymerisation process, the monomers are prepared to remove stabilising agents.  
The MPC was placed in a 500ml volume round bottom flask in powder form with a magnetic stirrer and 
the anhydrous methanol added, under anhydrous conditions.  All monomers are passed in their liquid 
form through an aluminium oxide column prior to use to remove any impurities or inhibitors.  These 
liquid monomers are then added to the flask while maintaining anhydrous conditions, without oxygen, 
under nitrogen gas only, to make a 10% solution, according to the ratios described in Table 19, with the 
molar weights and volumes calculated, as shown in the results section.  After adding the dry MPC, the 
anhydrous methanol is added next, followed by the HPMA, TMSPMA and the branching and termination 
agent, ensuring anhydrous conditions at all times.  The initiator, AIBN, dissolved in anhydrous methanol 
under anhydrous conditions and then added to the monomer solution and the mixture is heated to 70°C 
in an oil bath, with “burping” to ensure the pressure inside the flask is released at 45°C and 60°C.  This 
temperature is then maintained for 48 hours and the mixture is stirred constantly with the magnetic stirrer 
inside the flask.   This process is free radical polymerisation. The set up is shown in Figure 70 below.   
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Figure 70:  Shows the laboratory set up for free radical polymerisation  
 
 
Once this process is complete at 48 hours, the heat is turned off and the resulting polymer solution is 
allowed to cool for 24 hours.  If anhydrous conditions are maintained, this solution can be stored in the 
flask at room temperature for up to 1 month before the next stage is carried out.  The methanol solvent is 
evaporated using a rotary evaporator, which combines heat and a vacuum to evaporate the solvent.  This 
was required to form a viscous solution ready for electrospinning.  
The final polymer solutions underwent NMR spectroscopy in anhydrous deuterated methanol (methanol-
d4), 569534 Aldrich, to determine the rates of conversion of the monomers to the final polymer.  This 
was performed in the Cross-faculty NMR Centre, using the Avance II 800 spectrometer.  5mg of the 
polymer was dissolved in 700ml of methanol-d4 and placed in an NMR analysis tube, and analysis was 
performed using Topspin software.  Subsequently, MestReNova analytical chemistry software was used to 
perform the integration and calculations from the NMR spectra. 
213 
 
7.5.3 Results 
Monomers 
The molecular weights and densities of the monomers are shown in Table 20. 
 
Table 20: Shows the known molecular weights and densities of the monomers used, provided in the product 
specification information 
 
Monomer Molecular Weight Density (g/ml) 
MPC 295.27 N/A - Solid 
HPMA 144.17 1.066 
TMSPMA 248.35 1.045 
EGDMA 198.22 1.051 
DDT 202.40 0.845 
 
 
Using these molecular weights, the volume of the liquid monomers required for each of the syntheses 
described in Table 19, as well as the total solid, volume of anhydrous methanol, weight of AIBN and 
volume of methanol used to dissolve the AIBN is shown in Table 21.  2g of MPC was always used for 
each synthesis. 
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Table 21: Shows the weights and volumes of monomers, anhydrous methanol and initiator used for each synthesis 
Sample MPC (g) HPMA (ml) TMSPMA 
(ml) 
EGDMA 
(ml) 
DDT (ml) Total weight 
of solid (g) 
Methanol 
polymer 
solution (ml) 
AIBN (g) Methanol for 
AIBN (ml) 
Linear 
1 2 0.458 0.805 - 0.065 3.384 33.84 0.034 3.38 
2 2 0.458 0.805 - 0.032 3.357 33.57 0.034 3.36 
3 2 0.458 0.805 - - 3.329 33.29 0.033 3.33 
4 2 0.275 1.127 - - 3.471 34.71 0.035 3.47 
5 2 0.092 1.449 - - 3.612 36.12 0.036 3.61 
Branched 
1 2 0.458 0.805 0.256 0.324 3.872 38.72 0.039 3.87 
2 2 0.458 0.805 0.256 0.243 3.804 38.04 0.038 3.80 
3 2 0.458 0.805 0.256 0.162 3.735 37.35 0.037 3.74 
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Free Radical Polymerisation 
The resulting polymer, MPC-HPMA-TMSPMA, should be a clear solution as shown below in Figure 71.  
However, the branched polymer, whenever the EGDMA was introduced became cloudy, and this did not 
resolve as the polymerisation process progressed.  A second batch of EGDMA was purchased and this 
did not resolve the issue.  Branched versions of the polymer were therefore not used for electrospinning 
or for further development of the valve. 
 
Figure 71: Shows the clear polymer solution 
 
 
 
 
The predicted structure of the resulting polymer is shown in the Figure 72 below.  The polymerisation 
process should stop by either combination or disproportionation. Both involve the combining of 2 free 
radicals and the cessation of the polymerisation process.     
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Figure 72: Shows the predicted structure of the polymer MPC-HPMA-TMSPMA 
 
 
 
Nuclear magnetic resonance (NMR) spectroscopy was carried out for the monomers MPC, HPMA, 
TMSPMA and the linear versions of the polymer.   All were performed in methanol-d4.  The branched 
version was not further investigated due to the cloudiness of the polymer solutions.   The resulting NMR 
spectra are shown in Figure 73, Figure 74, Figure 75, and Figure 76 below.  The structure of the 
monomers are shown on the NMR spectra, and labelled with letters which correspond to the peaks in the 
spectra, which are labelled in each NMR spectra with the same letter.  Figure 74 shows the spectra for 
HPMA.  This is, in fact, a mixture of Hydroxypropyl and hydroxyisopropyl methacrylate.   “d”, “e” and 
“f” apply to the hydroxypropyl methacrylate and “d*”, “e*” and “f*” apply to the hydroxyisopropyl 
methacrylate. 
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Figure 73: Shows the NMR spectrum for the monomer MPC 
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Figure 74: Shows the NMR spectrum for the monomer HPMA 
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 Figure 75: Shows the NMR spectrum for the monomer TMSPMA 
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Figure 76: Shows the NMR spectrum for the linear version of the polymer MPC-HPMA-TMSPMA 
MPC-HPMA-TMSPMA (Linear)
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The relevant peaks are circled in blue.  Due to the complexity of the polymer, however, it was not 
possible to fully characterise the exact structure of the polymer, however, based on resulting weight, the 
conversion of the monomers to polymer was >99% for all the linear versions of the polymer.  It was 
therefore assumed that the resulting polymer had all the monomers combined in the rations that were put 
into the solution for synthesis. 
The linear versions of the polymer in solution were then prepared ready for electrospinning.   This 
involved removal of the solvent to create a viscous solution using a Rotary Evaporator or “Rotovap”. 
The solvent could only be partially evaporated, as if it was fully evaporated, the dry polymer could not be 
dissolved in either methanol or HFIP for electrospinning.  Samples of the linear polymer solution 1 and 
2, that is those containing the termination agent DDT did not form an adequately viscous solution until 
more than 95% of the solvent was evaporated.  This suggests that the molecular weight of the resulting 
polymer is too low.  This did not leave sufficient polymer solution for electrospinning.  Therefore, Linear 
samples 3, 4 and 5 were used for further evaluation for creating electrospun fibres.   
 
 
7.6 ELECTROSPINNING MPC-HPMA-TMSPMA 
 
7.6.1 Scanning Electron Microscopy Imaging of  Deep Vein 
Valves 
Background 
There are many techniques that can be employed to vary the microstructure of a scaffold, including 
electrospinning and micropatterning.  If the native valve structure itself can be mimicked then this may 
reduce the thrombogenicity of the material by reducing flow variation as blood passes through the valve, 
preventing platelet adhesion or stasis of blood.  If the microstructure is known, this may guide 
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manufacturing techniques.  This study aims to determine the underlying microstructure of a deep vein 
valve using scanning electron microscopy techniques.    
 
Methods 
Fresh bovine veins were obtained from a 2 whole calves aged 2 weeks and 6 weeks harvested and 
processed within 12 hours of death.  The calves had died of natural causes; one due to a chest infection 
and one having been trampled by its mother.  4 legs were removed from the calf at Lye Cross Farm, 
Bristol, packed in ice and returned to the laboratory.  10 cm of deep vein were harvested from each of the 
4 legs.  Aseptic technique was used and a 2-0 braided suture was used to tie all tributaries.  Samples were 
stored in phosphate-buffered saline (PBS) at 4° C for 2 hours.  The vein was opened along its length so 
the valves inside the lumen were exposed.  The vein was cut so that only the segment containing the 
leaflet remained.  Each sample was approximately 9mm x 4mm in size.  The samples were fixed in 4% 
Formalin for 1 hour.  6 concentrations of ethanol were prepared by diluting by volume 100% ethanol 
with deionised water, to allow serial dehydration of the samples.  Each of the samples was placed 
sequentially for 1 hour, in 30%, 45%, 60%, 75%, 90% and 100% ethanol.  Finally each sample was placed 
in HMDS for 1 hour, then left to dry in the open air for 48 hours.  They were then stored in uncoated 
tissue culture well plates.  Scanning Electron Microscopy was then carried out of the dried samples.    
Results 
All valves seen were macroscopically bicuspid.  An example of the images obtained of the luminal surface 
of the valves is shown in Figure 77. The surface appears to have a fibrous structure with the fibres 
running parallel to the direction of flow of blood.  A few red blood cells can be seen on the surface of the 
valve, as they were not all washed off at the time of preparation.  
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Figure 77: Shows the scanning electron microscopy image of a bovine vein valve (luminal surface) 
 
.                              
     
The sizes of the fibres were measured on the x3000 images using ImageJ software. The mean size of the 
fibres was 1.13µm, the measurements are shown in Table 22 below. 
 
 
 
 
 
 
 
 
 
 
5µm 
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Table 22: Shows the diameter of fibres seen on the luminal surface of a bovine vein valve 
 
Sample number Fibre diameter 
(µm) 
1 1.305 
2 1.092 
3 1.331 
4 0.984 
5 0.946 
6 0.941 
7 1.421 
8 1.083 
9 1.114 
10 1.068 
 
 
 
7.6.2 Optimisation of Electrospinning the Polymer  
 
Background 
I have already demonstrated the microstructure of the valve suggesting that there is an alignment of a 
fibrous structure.  Perhaps this is generated by the flow of blood.  By simulating this with a material it 
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may be possible to optimise cell growth and the haemodynamics.  The process of electrospinning 
generates fibres which can be aligned in a similar fashion to recreate this micropatterning structure. 
Electrospinning is a process by which a voltage is applied across a polymer in solution.  The polymer, in a 
syringe, is expelled using a syringe pump, and a positive charge is applied across the needle.  A negatively 
charged collecting plate is placed at a set distance from the needle.  Once the voltage is applied, the 
solution is drawn from the tip of the needle towards the collecting plate to make a fibre.  This is shown in 
Figure 78 below. 
 
Figure 78: Shows a diagrammatic representation of the electrospinning set up 
 
 
 
Methods 
The polymer solution made by free radical polymerisation is dehydrated using a Rotary Evaporator or 
“Rotovap” to a known concentration of solution ready for electrospinning.  A concentration of solution 
which yields consistent fibres of approximately 1.1µm in diameter without beading is required.  The 
variables in the electrospinning process include; the solvent, the concentration of solution, the needle 
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gauge, the distance of collection plate from needle tip, the rate of syringe pump, and voltage applied 
across the needle are listed in the tables below.  Only the linear version of the polymer was used as 
previously discussed.  The polymer was dissolved in solvent, to a known concentration.  The solution was 
then loaded into a syringe and onto a programmable syringe pump (KD Scientific model KDS 100, 
Sandback, Cheshire), which was set to expel a known volume of solution per hour.  A hypodermic needle 
of known gauge, which was varied to change the fibre size, was attached to the syringe.  The voltage 
power supply (Glassman high voltage power supply series WR, Bramley, Hampshire) was connected to 
the needle.  The collecting plate can be in the form of either a plate, or a rotating mandrill, but for the 
optimisation process a static metallic plate to collect randomly aligned fibre scaffolds. Electrospinning 
was carried out under standard laboratory conditions of 20 ± 3 °C and relative humidity of 50 ± 5%.  
Scanning electron microscopy images of each of the samples were then obtained and then the diameter of 
the fibres was measured using Image J software as previously described. 
  
Results 
A viscous solution of polymer was obtained once 30-40% of the original weight of the polymer solution 
dissolved in methanol remained.  It was not possible to completely evaporate all of the solvent to a dry 
polymer as it would then not dissolve back into solution.  Further assessment between these values 
demonstrated that it was optimum to evaporate the solvent so that 35% of the initial weight of polymer 
and solvent was remaining.  A lower concentration that this resulted in beading of the fibres and a higher 
concentration resulted in sputtering of the solution during the electrospinning process.  This consistently 
provided a solution of polymer and solvent which could be used for the subsequent electrospinning 
process.  The addition of other solvents to the polymer solution, including HFIP resulted in the solution 
becoming cloudy, therefore all further electrospinning was performed from anhydrous methanol only.  
The variables that were changed for optimisation of the electrospinning process are shown in Table 23, 
alongside the x3000 SEM images of the resulting electrospun polymer.  All were performed with the plate 
at a distance of 10cm from the needle tip and at the same concentration of polymer solution from 
methanol. 
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Table 23: Shows the variables for electrospinning polymer in methanol 
 
Needle (G)  Rate (ml/h)  Voltage (Kv)  X3000 SEM image Mean fibre size 
(µm) 
16 
 
 
1 10 
 
0.566 
16 1 12 
 
0.814 
16 1 15 
 
0.540 
16 1 20 
 
0.676 
16 2 10 
 
0.696 
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Needle (G)  Rate (ml/h)  Voltage (Kv)  X3000 SEM image Mean fibre size 
(µm) 
16 2 12 
 
0.955 
16 2 15 
 
0.825 
16 2 20 
 
0.752 
19 1 10 
 
0.478 
19 1 12 
 
0.515 
9 1 15 
 
0.696 
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 Needle (G)  Rate (ml/h)  Voltage (Kv)  X3000 SEM image Mean fibre size 
(µm) 
19 1 20 
 
0.623 
19 2 10 
 
0.814 
19 2 12 
 
0.846 
19 2 15 
 
1.013 
19 2 20 
 
1.092 
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Fibres electrospun with all variables using a 23G needle showed marked beading and therefore are not 
included in the table and the fibre sizes were not measured.  An example of this beading is shown in 
Figure 79. 
 
Figure 79: Shows the MPC-HPMA-TMSPMA fibres electrospun with 23G needle showing beading 
 
 
The variables which resulted in the fibres which were the most uniform and of mean fibre size 1.092µm 
used the variables: 19G needle, 10cm from the plate, with 20kV applied across the needle and the pump 
at a rate of 2ml/hour.  These were used for all subsequent experiments.   
 
 
 
7.6.3 Electrospinning a Bicuspid Valve Shape 
 
A bicuspid valve shape that could be attached to the rotating mandrill for electrospinning was designed 
according to the dimensions measured in Section 6.5.  This was made by the Blackett Laboratory, 
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Imperial College.  The design sketches for this are shown in Appendix 5.  Using the parameters described 
above, the valve shape was spun, with the mandrill rotating at 100 rotations per minute.  The resulting 
shape is shown in Figure 80. 
 
Figure 80: Shows the electrospun bicuspid valve shape 
        
 
 
 
 
 
 
 
 
 
7.7 HAEMOCOMPATIBILITY TESTING 
 
7.7.1 Thrombogenicity Testing of MPC-HPMA-TMSPMA 
 
Background 
Materials which come into contact with the blood must be biocompatible, non thrombogenic and not 
cause haemolysis.  Any material to be implanted into the vascular system must undergo tests to ensure it 
fulfils these criteria.  Thrombin is an enzyme involved in the coagulation of blood and it can be measured 
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in laboratory conditions.  This will provide information on the thrombogenicity of the material tested.  In 
vivo, thrombin is rapidly inactivated as soon as it is captured in the fibrin mesh by antithrombin III, 
making it difficult to accurately measure.  A thrombin generation assay (TGA) kit developed by 
HaemoScan® determines the level of thrombin activity in the medium following exposure to the tested 
material and compares this to other materials, or reference materials, of known thrombogenicity399.  This 
part of the project aims to test the haemocompatibility of MPC-HPMA-TMSPMA, both MPC50-
HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 and establish whether the length of time the 
material was left in the crosslinking solvent TEA and subsequently in water had any effect.   
 
Methods 
The electrospun scaffold of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 were 
cross linked to form the Si backbone to ensure insolubility.  This was done by placing the electrospun 
samples in TEA for 1hour, 24 hours or 48 hours.  These samples were then either not placed in water, 
placed in water for 1 day or for 7 days.  The hydrophilic monomers should over time migrate to the 
surface of the electrospun fibres.  The samples under the various conditions are described in Table 24.   
Thrombogenicity of the materials was tested using a thrombin generation assay (TGA), which is a plasma 
product that will enable the determination of thrombin activity in a sample after it has been exposed to a 
material.   The concentration of thrombin is determined by enzymatic reaction with a thrombin-specific 
chromogenic substrate, which yields a yellow colored product proportional to the amount of thrombin.   
This can be compared to other reference materials of known high and low thrombogenicity, in this case 
one type of metal and two types of polymers.  A TGA kit was obtained from HaemoScan®. 
In the first instance, a calibration curve was developed using known concentrations of thrombin dissolved 
in buffer solution. The materials to be tested were cut by hand to a size of 5mm x 5mm to ensure it was 
of the same size as the reference materials included in the kit.   
The reference and test materials were placed in micro-centrifuge vials and fixed between the walls of the 
vials to prevent floating.  An empty vial without material was used as a negative control.   For each vial, 4 
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labelled micro-centrifuge vials were prepared and labelled SPL1-4.  Into each 490µl of Buffer B was 
placed and the vials were placed on ice.  350µl of TGA plasma was added to each of the vials containing 
the reference material, material to be tested or the negative control vial ensuring that the materials were 
completely immersed in the plasma.  The vials were then incubated for 15 minutes in a water bath at 
37°C.  At 11 minutes, a vial containing 450µl of TGA Reagent A was placed in the water bath at 37 °C 
and at 14 minutes, 50µl of TGA Reagent B was added to the vial containing TGA Reagent A and mixed.  
At 15 minutes, 175µl of the mixture of TGA Reagent A and B was added to the vial containing plasma 
and mixed.  At 16 minutes, a sample of 10µl was taken out of the reaction mixture after mixing it, and 
placed into the vial labelled SPL1, vortexed and store on ice.  This sampling procedure was repeated at 2 
minutes, 4 minutes and 6 minutes and placed into the vials labelled SPL2, SPL3 and SPL4, respectively.  
All calibrators and diluted samples collected in Buffer B were then removed from the ice, vortexed and 
placed at room temperature.  150µl of each of the calibrator and diluted samples was then transferred to a 
96-well plate and incubated for 2 minutes in an incubator at 37 °C.  50µl of diluted Substrate solution was 
added to each well of the plate, the plate was covered with foil and incubated for 20 minutes at 37 °C.  
50µl of Stop Solution was added to each well, and the optical density was measured using a plate reader at 
405 nm, using 540 nm as a reference wavelength.  The thrombin concentration of all diluted samples and 
then the velocity of thrombin generation for each test material, reference material and negative control 
were then calculated.  The material samples tested, the length of time spent in TEA and the time left in 
water subsequently are listed in Table 24. 
 
 
 
 
 
 
232 
 
Table 24: Shows the samples tested with TGA assay, material, time in TEA and time in water 
Sample Number Material  Time in TEA (hours) Time in water (days) 
1 MPC50-HPMA15-TMSPMA35 1 0 
2 MPC50-HPMA15-TMSPMA35 24 0 
3 MPC50-HPMA15-TMSPMA35 48 0 
4 MPC50-HPMA15-TMSPMA35 1 1 
5 MPC50-HPMA15-TMSPMA35 24 1 
6 MPC50-HPMA15-TMSPMA35 48 1 
7 MPC50-HPMA15-TMSPMA35 1 7 
8 MPC50-HPMA15-TMSPMA35 24 7 
9 MPC50-HPMA15-TMSPMA35 48 7 
10 MPC50-HPMA5-TMSPMA45 1 0 
11 MPC50-HPMA5-TMSPMA45 24 0 
12 MPC50-HPMA5-TMSPMA45 48 0 
13 MPC50-HPMA5-TMSPMA45 1 1 
14 MPC50-HPMA5-TMSPMA45 24 1 
15 MPC50-HPMA5-TMSPMA45 48 1 
16 MPC50-HPMA5-TMSPMA45 1 7 
17 MPC50-HPMA5-TMSPMA45 24 7 
18 MPC50-HPMA5-TMSPMA45 48 7 
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Results 
The optical density (OD) was plotted for OD405, corrected for OD540 as this was used as the reference 
wavelength, against the thrombin concentrations of the calibrators. The calibration curve is shown in 
Figure 81.  The resulting straight line indicates that the kit is working to detect increasing thrombin 
concentrations.  The correlation coefficient value was 0.9962, the slope 0.0037 and the intercept 0.0113.  
This allowed the calculation of the thrombin concentration for each of the materials.    
 
Figure 81: Shows the calibration curve of thrombin concentrations of the calibrators against the OD405  
 
At each time point, samples of each material were tested and the mean calculated.  The mean thrombin 
concentrations for the reference material, the negative control, and the material samples at each of the 
time points 1,2,4 and 6 minutes is shown in Table 25, and represented by a line graph in Figure 82.  The 
resulting curves demonstrate that MPC-HPMA-TMSPMA is comparable with the lowest thrombogenicity 
reference material sent with the kit, LDPE.   
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Table 25: Shows the thrombin concentrations at 1, 2, 4 and 6 minutes corrected for negative controls 
 
 
In
cu
ba
tio
n 
tim
e 
(m
in
) 
N
eg
at
iv
e 
Co
nt
ro
l Reference Materials Sample Number 
LD
PE
 
PD
M
S MS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
1 27.9 0.0 7.5 -6.9 -6.6 -5.0 -6.2 -6.3 -5.6 -3.0 -1.7 -0.1 7.4 0.3 -3.6 -2.6 -17.3 -3.0 -3.0 -30.9 -3.1 -0.5 
2 26.9 -4.6 3.4 48.0 -2.3 -2.8 -4.3 -4.3 -5.2 0.1 -0.3 0.4 -2.3 -1.1 1.5 -3.2 -16.7 19.2 -1.2 -30.0 3.9 -2.0 
4 22.1 3.4 77.5 96.8 3.8 2.2 3.5 1.5 0.8 5.1 3.0 3.6 7.0 4.0 3.1 5.4 -10.2 27.0 3.1 -25.1 3.6 3.5 
6 26.8 23.2 174 66.0 28.4 17.2 27.7 21.4 11.0 36.0 4.6 12.1 5.0 23.8 22.7 22.3 22.0 97.4 24.1 -29.8 18.8 12.4 
 
 
 
235 
 
Figure 82: Shows a line graph of thrombin concentrations at 1, 2, 4 and 6 minutes corrected for negative controls 
 
The thrombin generation curve for each of the samples is shown in Figure 82, by plotting the mean 
thrombin concentration at each sampling time points 1,2,4 and 6 minutes, corrected for the thrombin 
concentration of the negative control.  The highest velocity of thrombin generation in between any 2 
measured time points, that is the point of the steepest slope on the curve, was calculated and this was 
corrected for the dilution factor of the assay, and hence the thrombin generation for each material and 
reference material was calculated.  No correction for surface area was required as all materials tested has a 
surface area of 1cm2.  The thrombin generation for each of the samples and reference materials is shown 
in Table 26 and Figure 83.  The sample numbers correspond to those shown in Table 24. 
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Table 26: Shows the thrombin generation of the reference samples and sample materials 
Sample Surface Area Thrombin Generation 
(mU/ml/min) 
Corrected Thrombin 
Generation 
(mU/ml/min/cm2) 
LDPE 1.00 497 497 
PDMS 1.00 2402 2402 
MS 1.00 2741 2741 
1 1.00 615 615 
2 1.00 376 376 
3 1.00 605 605 
4 1.00 497 497 
5 1.00 255 255 
6 1.00 773 773 
7 1.00 81 81 
8 1.00 212 212 
9 1.00 232 232 
10 1.00 494 494 
11 1.00 490 490 
12 1.00 423 423 
13 1.00 806 806 
14 1.00 1760 1760 
15 1.00 524 524 
16 1.00 121 121 
17 1.00 380 380 
18 1.00 222 222 
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Figure 83: Shows the thrombin generation of reference samples and materials 
 
 
Further comparisons were then made between the thrombin generation of the reference materials and all 
samples of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45.  The error bars show the 
95% confidence interval.  For MPC50-HPMA15-TMSPMA35 the corrected mean thrombin generation 
was 405mU/ml/min/cm2 (SD 230.1, 95% CI; 228.2-581.9) and for MPC50-HPMA5-TMSPMA45 the 
corrected mean thrombin generation was 580mU/ml/min/cm2 (SD 483.1, 95% CI; 208.8-951.4).  Using 
an unpaired t-test, there was no significant difference between these groups, p=0.3409.  The material 
MPC-HPMA-TMSPMA is less thrombogenic than the reference materials MS and PDMS, and 
comparable with the lowest thrombogenicity material in the assay LDPE.  These results are shown in 
Figure 84. 
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Figure 84: Shows the comparison of the thrombin generation of the reference materials and MPC50-HPMA15-
TMSPMA35 and  MPC50-HPMA5-TMSPMA45 
 
 
 
Comparison between the thrombin generation of the all samples of MPC-HPMA-TMSPMA depending 
on the time left for crosslinking in TEA, for 1 hour, 24 hours or 48 hours was performed.  These results 
are shown in Figure 85.  The error bars shown are the 95% confidence interval.  For MPC-HPMA-
TMSPMA in TEA for 1 hour the corrected mean thrombin generation was 435.7mU/ml/min/cm2 (SD 
283.3, 95% CI; 138.4-733.0), for MPC-HPMA-TMSPMA in TEA for 24 hours the corrected mean 
thrombin generation was 578.8mU/ml/min/cm2 (SD 587.1, 95% CI; -37.24-1195) and for MPC-HPMA-
TMSPMA in TEA for 48 hours the corrected mean thrombin generation was 463.2mU/ml/min/cm2 (SD 
215.9, 95% CI; 236.6-689.7).  Using an ANOVA one-way analysis of variance to compare the three 
groups, there was no significant difference between these groups, p=0.8048.   
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Figure 85: Shows the comparison of the thrombin generation of MPC-HPMA-TMSPMA cross-linked in TEA for 1 
hour, 24 hours and 48 hours 
 
 
 
 
Comparison between the thrombin generation of the all samples of MPC-HPMA-TMSPMA depending 
on the time left in water following crosslinking in TEA, for 0 days, 1 day or 7 days was performed.  These 
results are shown in Figure 86.  The error bars shown are the 95% confidence interval.  For MPC-
HPMA-TMSPMA not placed in water the corrected mean thrombin generation was 
500.5mU/ml/min/cm2 (SD 95.59, 95% CI; 400.2-600.8), for MPC-HPMA-TMSPMA in water for 1 day 
the corrected mean thrombin generation was 769.2mU/ml/min/cm2 (SD 525.7, 95% CI; 217.5-1321) and 
for MPC-HPMA-TMSPMA in water for 7 days the corrected mean thrombin generation was 
208.0mU/ml/min/cm2 (SD 104.0, 95% CI; 98.87-317.1).  Using an ANOVA one-way analysis of 
variance to compare the three groups, there was a significant difference between these groups, p=0.0247, 
and using the unpaired t-test to compare each of the groups, there was a significant difference between 
MPC-HPMA-TMSPMA in no water and in water for 7 days (p=0.0005) and between MPC-HPMA-
TMSPMA in water for 1 day and in water for 7 days (p=0.0281).    
240 
 
 Figure 86: Shows the comparison of the thrombin generation of MPC-HPMA-TMSPMA left in water for 0 days, 1 
day or 7 days after cross-linking in TEA 
 
 
 
7.7.2 Complement Convertase Assay 
Background 
Materials that have contact with blood will activate the complement system, which is part of the innate 
immune system.  Activation of complement proteins amplifies the immune response which can have a 
detrimental effect to the patient.  It results in the attraction of white blood cells, which release proteases 
than cleave proteins to produce cytokines, which in turn lead to an exaggerated inflammatory response 
within tissue.  Any foreign material implanted into the body can cause instability of the enzymes and 
uncontrolled activation resulting in a foreign body reaction.  Therefore, testing of complement convertase 
activity by materials used for the construction of medical devices is needed to ensure the use of materials 
with as low complement activation as possible.   
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Measurement of complement convertase determines the  complement activation by biomaterials.  By 
incubating the material with plasma, complement factors which bind the surface of the material result in 
the formation of a complement convertase complex.  This can cleave a chromogenic substrate, which in 
turn can be quantified by measuring the optical density.  This can be compared to a negative control and 
reference materials.   
 
Methods 
A Complement Convertase Assay Kit was obtained from HaemoScan®, The Netherlands.  Samples were 
prepared as described in Table 24 and cut to size 10x5mm.  The reference and test materials were placed 
in micro-centrifuge vials using forceps, and fixed vertically between the walls of the vials to prevent 
floating.  650 µl of CCA plasma to each vial containing the material, and 650 µl of 0.9% sodium chloride 
solution was added to the negative control.  The vials were incubated for 15 minutes at room temperature 
after which 1ml of wash buffer was added.  The materials were then removed, blotted dry and each 
placed in separate vial containing 1.5ml of wash buffer.  The materials were then placed in micro-
centrifuge vials containing 0.5ml of substrate solution and incubated for 24 hours at room temperature.  
The rate of colour development depends on how much convertase has been generated on the surface of 
the biomaterial.  225 µl from each vial was transferred to a 96-well plate and the optical density read with 
a plate reader at 405 nm (OD405).   
 
Results 
CCA results are described in OD45/24h/cm2 and are corrected for the negative control as shown in 
Table 27.  CCA results are classified as Inactive: OD405/24 h/cm2 ≤ 0.06, Low:  0.06 < OD405/24 
h/cm2 ≤ 0.20, Medium: 0.20 < OD405/24 h/cm2 ≤ 0.60, High: OD405/24 h/cm2 > 0.60. 
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Table 27: Shows the CCA results for reference materials and sample materials 
Sample Mean CCA Result 
(OD405/24h/cm2)  
Corrected CCA Result 
(OD405/24h/cm2) 
LDPE 0.393 0.320 
PDMS 0.792 0.719 
Negative Control 0.073 - 
 1 0.744 0.671 
 2 0.643 0.570 
 3 0.598 0.525 
 4 0.652 0.579 
 5 0.629 0.556 
 6 0.616 0.543 
 7 0.713 0.64 
 8 0.670 0.597 
 9 0.613 0.540 
 10 0.664 0.591 
 11 0.667 0.594 
 12 0.719 0.646 
 13 0.578 0.505 
 14 0.649 0.576 
 15 0.679 0.606 
 16 0.690 0.617 
 17 0.718 0.645 
 18 0.733 0.660 
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Comparisons were made between the CCA results of the reference materials and all samples of MPC50-
HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45.  The error bars show the 95% confidence 
interval.  For MPC50-HPMA15-TMSPMA35 the corrected mean CCA result was 0.580 OD405/24 
h/cm2 (SD 0.081, 95% CI; 0.540-0.620) and for MPC50-HPMA5-TMSPMA45 the corrected mean CCA 
result was 0.610 OD405/24 h/cm2 (SD 0.0760, 95% CI; 0.571-0.650).  Using a one-way ANOVA test 
there was a significant difference between the columns and with Bonferroni’s Multiple Comparison Test, 
this reached significance p<0.05 for LDPE vs. MPC50-HPMA15-TMSPMA35 and LDPE vs. MPC50-
HPMA5-TMSPMA45.  There was no significant difference between PDMS and the sample materials.   
Using an unpaired t-test, there was no significant difference between MPC50-HPMA15-TMSPMA35 and 
MPC50-HPMA5-TMSPMA45, p=0.266.  The material MPC-HPMA-TMSPMA has no significant 
difference in complement activation to the reference material PDMS and has a medium complement 
convertase activation overall according to this assay.  These results are shown in Figure 87.  
 
Figure 87: Shows the comparison of the CCA results of the reference materials and MPC50-HPMA15-TMSPMA35 
and  MPC50-HPMA5-TMSPMA45 
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 Comparison between the CCA results of the all samples of MPC-HPMA-TMSPMA depending on the 
time left for crosslinking in TEA, for 1 hour, 24 hours or 48 hours was performed.  These results are 
shown in Figure 88.  The error bars shown are the 95% confidence interval.  For MPC-HPMA-TMSPMA 
in TEA for 1 hour the corrected CCA results were 0.609 OD405/24 h/cm2 (SD 0.070, 95% CI; 0.562-
0.656), for MPC-HPMA-TMSPMA in TEA for 24 hours the corrected CCA results were 0.589 
OD405/24 h/cm2 (SD 0.073, 95% CI; 0.5473-0.636) and for MPC-HPMA-TMSPMA in TEA for 48 
hours the mean corrected CCA results were 0.586 OD405/24 h/cm2 (SD 0.096, 95% CI; 0.526-0.647).  
Using an ANOVA one-way analysis of variance to compare the three groups, there was no significant 
difference between these groups, p=0.771.   
 
Figure 88: Shows the comparison of the CCA results of MPC-HPMA-TMSPMA cross-linked in TEA for 1 hour, 24 
hours and 48 hours 
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Comparison between the CCA results of the all samples of MPC-HPMA-TMSPMA depending on the 
time left in water for 0 days, 1 day or 7 days following crosslinking in TEA, was performed.  These results 
are shown in Figure 89.  The error bars shown are the 95% confidence interval.  For MPC-HPMA-
TMSPMA not placed in water the corrected mean CCA results were 0.599 OD405/24 h/cm2 (SD 0.067, 
95% CI; 0.557-0.642), for MPC-HPMA-TMSPMA in water for 1 day the corrected mean CCA results  
were 0.566 OD405/24 h/cm2 (SD 0.079, 95% CI; 0.512-0.619) and for MPC-HPMA-TMSPMA in water 
for 7 days the corrected mean CCA results were 0.616 OD405/24 h/cm2 (SD 0.088, 95% CI; 0.561-
0.672).  Using an ANOVA one-way analysis of variance to compare the three groups, there was no 
significant difference between these groups, p=0.303.      
 
Figure 89: Shows the comparison of the CCA results of MPC-HPMA-TMSPMA left in water for 0 days, 1 day or 7 
days after cross-linking in TEA 
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7.7.3 Haemolytic Assay 
 
Background 
Erythrocytes that come into contact with toxins, metal ions and materials can haemolyse, therefore the 
haemolytic activity of materials that will come into contact with blood is essential, particularly when the 
contact will be prolonged as is the case with a venous valve.  Excess haemolysis would induce anaemia 
and the release of iron.   Optimal conditions to perform a haemolysis assay have been described400 
previously using diluted human blood in an erythrocyte suspension incubated with the test material.   
 
Methods 
A biomaterial haemolytic assay was obtained from Haemoscan®, The Netherlands.  Samples were 
prepared as described in Table 24 and cut to size 5x5mm, giving a total surface area of 0.5cm2.  5ml of 
was buffer was added to the erythrocyte suspension and mixed, then centrifuged for 10 minutes at 400g.  
The supernatant was removed and the procedure repeated.  The same wash procedure was performed 
with 5ml of the dilution buffer.  The final pellet was then resuspended in 5ml of the dilution buffer.  The 
test materials were placed in a 2ml syringe and the erythrocyte suspension added and the air removed 
from the syringe and sealed with parafilm.  The negative control is a syringe without any material.  The 
haemoglobin calibrators were prepared according to the manufacturer’s instructions by diluting with lysis 
fluid.   The materials to be tested including the reference materials were placed in 2ml syringes and 0.5ml 
of erythrocyte suspension was added to each, air expelled and the outlet closed with parafilm.  10µl of 
erythrocyte suspension was added to 1ml of lysis fluid to ascertain the total haemoglobin concentration.  
The vials were then incubated with end-over end rotating at 37°C for 24 hours.  The erythrocyte 
suspension was then transferred to an eppendorf tube and centrifuged at 4000g for 1 minute.  20µl of 
supernatant from the sample was added to the well plate, and 180µl of assay buffer was added and mixed 
on a plate shaker.  The OD was measured at 415 nm.  The haemoglobin concentration for all test and 
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reference materials was corrected for the haemoglobin concentration of the negative control and 
calculated per 1cm2.    
 
Results 
The mean haemoglobin concentrations are described in mg/cm2 and are corrected for the negative 
control as shown in Table 28.   
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Table 28: Shows the haemoglobin concentration for reference materials and sample materials 
Sample Mean Haemoglobin 
Concentration (mg/cm2)  
Corrected Haemoglobin 
Concentration (mg/cm2) 
Silicon Elastomer 0.638 0.076 
Buna-N 0.685 0.123 
Negative Control 0.562 - 
 1 0.763 0.201 
 2 0.725 0.163 
 3 0.923 0.361 
 4 1.071 0.508 
 5 0.778 0.215 
 6 0.703 0.141 
 7 0.921 0.359 
 8 0.833 0.270 
 9 0.850 0.288 
 10 0.826 0.264 
 11 0.764 0.202 
 12 0.756 0.194 
 13 0.826 0.264 
 14 1.205 0.642 
 15 0.867 0.305 
 16 0.916 0.354 
 17 1.075 0.513 
 18 1.022 0.460 
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Comparisons were made between the haemoglobin concentrations of the reference materials and all 
samples of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45, corrected for the negative 
control.  The error bars show the 95% confidence interval.  For MPC50-HPMA15-TMSPMA35 the 
corrected mean haemoglobin concentration was 0.281 mg/cm2 (SD 0.175, 95% CI; 0.194-0.367) and for 
MPC50-HPMA5-TMSPMA45 the corrected mean haemoglobin concentration was 0.359 mg/cm2 (SD 
0.184, 95% CI; 0.264-0.454).  Using a one-way ANOVA test there was no significant difference between 
the reference materials and sample materials, although significance was approached, p=0.080.  Using an 
unpaired t-test, there was no significant difference between MPC50-HPMA15-TMSPMA35 and MPC50-
HPMA5-TMSPMA45, p=0.206.  These results are shown in Figure 90.  
 
Figure 90: Shows the comparison of the haemoglobin concentration of the reference materials and MPC50-
HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 
 
 
 
250 
 
Comparison between the haemoglobin concentration of the all samples of MPC-HPMA-TMSPMA 
depending on the time left for crosslinking in TEA, for 1 hour, 24 hours or 48 hours was performed.  
These results are shown in Figure 91.  The error bars shown are the 95% confidence interval.  For MPC-
HPMA-TMSPMA in TEA for 1 hour the corrected mean haemoglobin concentration was 0.327 mg/cm2 
(SD 0.177, 95% CI; 0.209-0.446), for MPC-HPMA-TMSPMA in TEA for 24 hours the corrected mean 
haemoglobin concentration was 0.337 mg/cm2 (SD 0.211, 95% CI; 0.203-0.470) and for MPC-HPMA-
TMSPMA in TEA for 48 hours the corrected mean haemoglobin concentration was 0.293 mg/cm2 (SD 
0.166, 95% CI; 0.187-0.398).  Using an ANOVA one-way analysis of variance to compare the three 
groups, there was no significant difference between these groups, p=0.830.   
 
Figure 91: Shows the comparison of the haemoglobin concentrations of MPC-HPMA-TMSPMA cross-linked in 
TEA for 1 hour, 24 hours and 48 hours 
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Comparison between the haemoglobin concentrations of the all samples of MPC-HPMA-TMSPMA 
depending on the time left in water for 0 days, 1 day or 7 days following crosslinking in TEA, was 
performed.  These results are shown in Figure 92.  The error bars shown are the 95% confidence interval.  
For MPC-HPMA-TMSPMA not placed in water the corrected mean haemoglobin concentration was 
0.233 mg/cm2 (SD 0.163, 95% CI; 0.129-0.336), for MPC-HPMA-TMSPMA in water for 1 day the 
corrected mean haemoglobin concentration was 0.348 mg/cm2 (SD 0.214, 95% CI; 0.211-0.484) and for 
MPC-HPMA-TMSPMA in water for 7 days the corrected mean haemoglobin concentration was 0.381 
mg/cm2 (SD 0.133, 95% CI; 0.292-0.470).  Using an ANOVA one-way analysis of variance to compare 
the three groups, there was no significant difference between these groups, p=0.114.      
 
Figure 92: Shows the comparison of the haemoglobin concentrations of MPC-HPMA-TMSPMA left in water for 0 
days, 1 day or 7 days after cross-linking in TEA 
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7.8 FOURIER TRANSFORM INFRARED SPECTROSCOPY 
 
7.8.1 Background 
Fourier Transform Infrared Spectroscopy (FTIR) is a method used to collect data on a solid, liquid or gas 
regarding its functional groups and surface characteristics.  The FTIR spectrometer produces a light in the 
infrared spectrum and the sample placed in its path absorbs the light according to its chemical properties.  
This data is collected by a detector and compared to a reference energy source.  The measured signal is 
sent to the computer and undergoes Fourier transformation, producing an infrared spectrum which can 
be interpreted.  In this part of the study, by using FTIR spectroscopy the aim is to gain further 
information about MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 and the effects of 
cross-linking with TEA and effect of water on the samples. 
     
7.8.2 Methods 
Electrospun scaffolds of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 were 
prepared as previously described.  Samples were then placed in TEA for 1hour, 24 hours or 48 hours and 
placed in water for 1 day or for 7 days.  The samples under the various conditions are described in Table 
24.   FTIR spectroscopy was performed using an FTIR Spectrometer, Bruker Optics.  Spectra were 
collected and plotted as absorption. 
 
7.8.3 Results 
FTIR analysis was carried out on the electrospun scaffolds of the samples in Table 24.  None of the 
results are significant an therefore no graphs are included here, however, the images contribute towards 
establishing the differences between MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 
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and the different amounts of time spent in TEA and water.  The spectra obtained are shown in Figure 93 
and Figure 94. 
 
The peaks were assigned as follows:  
• 1715 cm-1: C=O 
• 1480 cm-1: CH2 
• 1230 cm-1: C-O 
• 1160 cm-1: C-O + C-C (backbone of the polymer)  
• 1080 cm-1: O=P-O- 
• 1050 cm-1: Si-O-Si 
• 1020 cm-1: Si-O-CH3 
• 960 cm-1: Si-O- (non- bridging oxygen) 
• 925 cm-1: Si-OH (Silanol)  
• 870 cm-1: Si-C  
• 770 cm-1: CH3 (Rocking backbone of the polymer)  
 
Figure 93: Shows the effect of TEA on MPC50-HPMA15-TMSPMA35 (A) and MPC50-HPMA5-TMSPMA45 (B) 
A      B 
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Figure 94: Shows the effect of water on MPC50-HPMA15-TMSPMA35 (A) and MPC50-HPMA5-TMSPMA45 (B) 
A      B 
 
 
Immersion of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 in TEA appears to 
result in a change in the spectra overt time, with more crosslinking of the Si-O-Si groups with increased 
time in TEA.  At 48 hours there was more crosslinking of these groups which should result in a more 
stable polymer.    
With regard to the immersion of the MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 
that was cross-linked in TEA for 48 hours, it was expected that MPC50-HPMA5-TMSPMA45 would be 
more stable as there are more Si-O-SI groups, however, the converse was the case.  MPC50-HPMA5-
TMSPMA45 demonstrated a desorption of TEA after 1 day in water, which was further demonstrated at 
7 days, resulting in a disruption of the silica network as the peak Si-O-Si decreased and the Si-O- peak 
increase.  For MPC50-HPMA15-TMSPMA35 there is an initial same desorption but the effect, but only 
of the Si-OH peaks, followed by a condensation of the silica network.  This results in a scaffold which is 
more stable than before immersion in water.    
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7.9 MECHANICAL PROPERTY TESTING OF MATERIALS 
 
7.9.1 Background 
Mechanical properties of materials that will be implanted as part of a medical device must be considered.  
Particularly for the case of a valve leaflet, the material should be flexible and have a similar strength to 
that of the native tissue.  There are several ways of testing the mechanical properties of materials, and in 
the laboratory setting to test the stress-strain relationships of materials, a tensiometer is commonly used.  
Several studies have been carried out to establish the behaviour of blood vessels under tension with a 
tensiometer.  The majority of studies have assessed arteries, including carotid401, aorta402 and coronary 
arteries403, and Rossmann et al, 2010404, assessed jugular and bovine veins.  However, there is a paucity of 
literature regarding the mechanical properties of the deep veins.  This study aims to compare the 
mechanical properties of deep veins with those of the material MPC-HPMA-TMSPMA.   
 
7.9.2 Methods 
Bovine Vein 
Fresh bovine veins were obtained from a whole calf aged 6 weeks harvested and processed within 12 
hours of death.  The calf had died of natural causes having been trampled by its mother.4 legs were 
removed from the calf at Lye Cross Farm, Bristol, packed in ice and returned to the laboratory.  10cm of 
superficial vein and 10 cm of deep vein were harvested from each of the 4 legs.  Aseptic technique was 
used, 2-0 braided suture was used to ties all tributaries.  Samples were stored in phosphate-buffered saline 
(PBS) at 4° C overnight.    The segments of vein were opened along their length to form a flat sheet 
50mm in length.  The cross-sectional height of each sample, that is the height of the vein wall was 
measured in 3 different places across the length of vein, using an electronic digital calliper, and a mean 
obtained.  Samples were mounted in the Instron, Model 5540, testing machine with a 50N load cell at 
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crosshead speed of 10mm/min.  10mm at each end of the 50mm vein lengths was held fixed in the 
machine, hence a testing length of approximately 30mm was used, then after slack was removed from the 
sample, the gauge length was set.  From the results obtained, the breakpoint stress was calculated by 
observing the maximum load that could be tolerated and the modulus was calculated using the equation: 
 
 Modulus (E) =  Stress (σ) 
   Strain (ε) 
where: 
 Stress (σ) =  Force / N 
   Area / mm2 
And: 
 Strain (ε) =  Change in length (ΔL) 
   Initial length (Li) 
 
 This was then normalised to the mean of 3 cross sectional measurements for each segment of vein and 
compared to the same mechanical property testing of the material MPC-HPMA-TMSPMA materials. 
 
Electrospun MPC-HPMA-TMSPMA 
Randomly aligned electrospun scaffolds of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-
TMSPMA5 were made, as described in Section 7.6.2.  These were mechanically tested in tension to failure 
using an Instron Model 5540 testing machine, equipped with a 50 N load cell at a crosshead speed of 10 
mm/min.  Samples were cut to size 50mm x 10mm.  The cross-sectional height of each sample was 
measured in 3 different places across the length of the sample, using an electronic digital calliper, and a 
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mean obtained.  Samples were mounted in the Instron, Model 5540, testing machine with a 50N load cell 
at crosshead speed of 10mm/min.  10mm at each end of the 50mm samples was held fixed in the 
machine, hence a testing length of approximately 30mm was used, then after slack was removed from the 
sample, the gauge length was set.  From the results obtained, the breakpoint stress and modulus was 
calculated as described above and normalised to the mean of 3 cross sectional measurements.  
 
7.9.3 Results 
 
The mean tensile modulus of vein was 4.66 N/mm2 (SD 1.87, 95% CI; 1.69-7.63).  This was compared 
with the tensile modulus of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 
normalised to the diameter of the samples.    The results are shown in Figure 95.  The error bars show the 
95% confidence interval.  For MPC50-HPMA15-TMSPMA35 the tensile modulus was 0.13 N/mm2 (SD 
0.02, 95% CI; 0.10-0.16) and for MPC50-HPMA5-TMSPMA45 the tensile modulus was 0.12 N/mm2 
(SD 0.06, 95% CI; 0.03-0.21).  Using a one-way ANOVA test there was a significant difference between 
the three groups, p=0.0003 and using an unpaired t-test, there was a significant difference between vein 
and MPC50-HPMA15-TMSPMA35 (p=0.003) and vein and MPC50-HPMA5-TMSPMA45 (p=0.003).  
Using an unpaired t-test, there was no significant difference between MPC50-HPMA15-TMSPMA35 and 
MPC50-HPMA5-TMSPMA45, p=0.665. 
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Figure 95: Shows the tensile modulus of vein and MPC-HPMA-TMSPMA   
 
 
 
The mean breakpoint stress of vein was 7.05 N/mm2 (SD 4.07, 95% CI; 0.58-8.33).  This was compared 
with the breakpoint stress of MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 
normalised to the diameter of the samples.    The results are shown in Figure 96.  The error bars show the 
95% confidence interval.  For MPC50-HPMA15-TMSPMA35 the mean breakpoint stress was 5.11 
N/mm2 (SD 2.03, 95% CI; 1.88-8.33) and for MPC50-HPMA5-TMSPMA45 the mean breakpoint stress  
was 7.89 N/mm2 (SD 5.29, 95% CI; -0.53-16.30).  Using a one-way ANOVA test there was no significant 
difference between the three groups, p=0.621.    
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Figure 96: Breakpoint stress of vein and MPC-HPMA-TMSPMA   
 
 
 
 
   
7.10 DISCUSSION 
 
The venous system is a low flow, low velocity, system and therefore highly thrombogenic.  Previous work 
on materials in other parts of the vascular system, such as for cardiac valves or vascular graft, can be 
utilised to guide further research in developing a material for use in the venous system.   Autologous 
tissue remains the gold standard for grafts but if it is not available then an optimised prosthetic material 
with low thrombogenicity would be ideal.  In the biological scaffold field ECM has been extensively 
studied362, with different properties363 depending upon the processing methods and origin of the ECM364.   
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There has been extensive work on the development of a cardiac valve using a polymer, stressing the need 
for durability haemocompatibility and low thrombogenicity372.   PEU, PCU, silicone, PTFE, Dacron, 
PVC and PU have been extensively investigated373, as well as Silsesquioxane nanocomposite polymer377 
and Poly(SIBS)378.  Much of the work on vascular grafts has focussed on the development of grafts which 
are pre-seeded with cells, such as epithelial cells382 prior to implantation.   Polymers provide consistent, 
reproducible material from which to manufacture the valve, in contrast to biological scaffolds which are 
much more variable in their properties.  ECM for example varies with the age of the source donor, 
different methods of decelularisation, residual MMPs, elastin, collagen, growth factors and other 
constituents.  Once implanted, it is important to consider the effect cells, such as macrophages, cytokines 
and other circulating factors from the recipient patient and the effect that these will have.  When 
developing a suitable polymer, its properties must be fully optimised and characterised to include; 
thrombogenicity, haemocompatibility, biocompatibility, mechanical properties and the effect of the 
material on host cells.  Also, surface and structural modifications can improve the properties of the 
polymer, ensuring that these do not adversely affect the other properties. 
 
A material for use in the venous system as a valve should be flexible, non-biodegradable, be of low 
thrombogenicity and be biocompatible.  Presently, polymers and polymer coated metal stents are 
thrombogenic and they lack haemocompatibilty and biocompatibility.  MPC has been demonstrated be 
biocompatible and to have antifouling and antithrombogenic properties in previous studies388  and 
copolymers of MPC have been suggested to be beneficial for cell and tissue engineering389.  Its 
haemocompatibilty has been demonstrated in several studies392, 393 and its use reduces the 
thrombogenicity of other polymers394 .  This has been further demonstrated in this study.     
 
2 polymers of MPC-HPMA-TMSPMA have been synthesised in this study by free radical polymerisation, 
and the ratios of HPMA and TMSPMA were varied for further experiments.  The conversion of the 
monomers to polymer was >99% for all the linear versions of the polymer.  Scanning electron 
microscopy images of bovine vein valves demonstrated a fibrous underlying microstructure with a mean 
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fibre diameter of 1.13µm.  The material developed has tried to mimic the structure using the technique of 
electrospinning which to form a fibrous scaffold.  The linear versions of the polymer in solution were 
then electrospun to make this fibrous scaffold, which underwent cross-linking in TEA.  The variables 
which resulted in the fibres which were the most uniform and of mean fibre size 1.092µm used the 
variables: 19G needle, 10cm from the plate, with 20kV applied across the needle and the pump at a rate 
of 2ml/hour.  These variables were then used to create a bicuspid valve shape by electrospinning directly 
onto a shaped mandrill.   
 
The thrombogenicity, haemocompatibility and biocompatibility of the material were further tested.  
Materials which come into contact with the blood must be biocompatible, non thrombogenic and not 
cause haemolysis.  The haemocompatibility of MPC-HPMA-TMSPMA, both MPC50-HPMA15-
TMSPMA35 and MPC50-HPMA5-TMSPMA45 was further tested.  For MPC50-HPMA15-TMSPMA35 
the corrected mean thrombin generation was 405mU/ml/min/cm2 (SD 230.1, 95% CI; 228.2-581.9) and 
for MPC50-HPMA5-TMSPMA45 the corrected mean thrombin generation was 580mU/ml/min/cm2 
(SD 483.1, 95% CI; 208.8-951.4), but the difference is not significant, however, MPC-HPMA-TMSPMA 
is less thrombogenic than the reference materials MS and PDMS, and comparable with the lowest 
thrombogenicity material in the assay LDPE.  There was no significant difference between the thrombin 
generation of the all samples of MPC-HPMA-TMSPMA depending on the time left for crosslinking in 
TEA, for 1 hour, 24 hours or 48 hours.   However, there was a significant difference between MPC-
HPMA-TMSPMA in no water and in water for 7 days (p=0.0005) and between MPC-HPMA-TMSPMA 
in water for 1 day and in water for 7 days (p=0.0281), suggesting that the more haemocompatible 
monomers may migrate to the surface of the fibres.  The biocompatibility of the material MPC-HPMA-
TMSPMA, tested with a complement convertase assay demonstrated no significant difference in 
complement activation to the reference material PDMS and has a medium complement convertase 
activation overall according to this assay.  Comparison between the CCA results of the all samples of 
MPC-HPMA-TMSPMA depending on the time left for crosslinking in TEA, for 1 hour, 24 hours or 48 
hours and the time left in water for 0 days, 1 day or 7 days following crosslinking in TEA showed no 
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significant difference between these groups.   With regard to haemolysis of erythrocytes in contact with 
MPC-HPMA-TMSPMA, there was no significant difference between the reference materials and sample 
materials, and no significant difference between MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-
TMSPMA45.  These studies demonstrate that the thrombogenicity, biocompatibility and 
haemocompatibility of MPC-HPMA-TMSPMA is good, and improves once the material is left in water 
for 7 days.   
 
FTIR analysis of the electrospun scaffolds, although it did not give any statistically significant data, did 
demonstrate that immersion of both MPC50-HPMA15-TMSPMA35 and MPC50-HPMA5-TMSPMA45 
in TEA appears to result in a change in the spectra overt time, with more crosslinking of the Si-O-Si 
groups at 48 hours which should result in a more stable polymer.   Immersing cross-linked MPC50-
HPMA5-TMSPMA45 in water, resulted in a decomposition of the silica network upon immersion, but in 
the case of the MPC50-HPMA15-TMSPMA35 the immersion in water actually reinforced the silica 
network, resulting in increased stability.     
 
The mean tensile modulus of vein was 4.66 N/mm2 (SD 1.87, 95% CI; 1.69-7.63), compared to 0.13 
N/mm2 (SD 0.02, 95% CI; 0.10-0.16) for MPC50-HPMA15-TMSPMA35 and 0.12 N/mm2 (SD 0.06, 
95% CI; 0.03-0.21) for MPC50-HPMA5-TMSPMA45.  The mean breakpoint stress of vein was 7.05 
N/mm2 (SD 4.07, 95% CI; 0.58-8.33), compared with 5.11 N/mm2 (SD 2.03, 95% CI; 1.88-8.33) for 
MPC50-HPMA15-TMSPMA35 and 7.89 N/mm2 (SD 5.29, 95% CI; -0.53-16.30) for MPC50-HPMA5-
TMSPMA45.   The tensile modulus of vein is different from the material tested, howeer, the breakpoit 
stress is consistently in the correct range.  Vein has a relatively low stiffness but high upper limit of tensile 
strength.   
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8. DEVELOPMENT OF A LABORATORY 
VENOUS FLOW MODEL 
8.1 INTRODUCTION 
A laboratory model of deep venous function, in the form of a flow rig, would be a useful dynamic 
assessment rig for the simulation of deep venous flow.  Once developed, the conduit to be evaluated 
could be easily assessed by ultrasound in order to obtain detailed flow dynamic measurements to compare 
to in-vivo observations, or to provide further information on the behaviour of a valve and its longevity.   
Although there are many in vitro models of arterial flow, arterialised great saphenous vein and models of 
venous thrombosis, there is a paucity of literature regarding lower limb venous flow models.  In vitro 
models of venous flow have been used in previous studies.  Wang et al, 1992405 used a flow loop which 
functioned by adjusting the height of the head tank and outflow chamber with a sinusoidal pressure pump 
to simulate respiratory function, but this was not a validated model.  There is no validated in vitro flow 
model in the literature of lower limb venous flow. 
This part of the study aims to develop and validate a laboratory flow model of venous flow. 
 
8.2 METHODS 
8.2.1 Set up of Laboratory Flow Model 
Flow Meter Calibration 
Before setting up the complete flow model, the various components were calibrated to ensure that the 
output voltages received by the computer could be translated to relevant flow and pressure data.  The 
flow meter, Transonic TS410, was connected to the MCP-Z Standard gear pump, Ismatec with  Z-120 
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pump head, Ismatec.  Both the pump and the flow meter were connected to a PC via the Data 
Acquisition System (DAQ), National Instruments, through Labview software, to control the pump and 
receive voltage information from the flow meter.  The rate of flow was measured manually in millilitres 
per minute, by collecting the liquid passing through the pump and flow meter for 1 minute, using a 
measuring flask.  The flow medium used was water.   
 
Pressure Gauge Calibration 
Two compound pressure transducers, Ashcroft G2, Cole-Parmer, UK were used.  These were calibrated 
manually.  A vertical column containing a known height of water was attached above the pressure 
transducer.  The height of the column of water was gradually increased in a stepwise manner from 5cm to 
135cm, in 5cm increments.  The voltage reading from each pressure transducer was detected by the 
computer via the Data Acquisition System (DAQ), National Instruments, through Labview software.   
 
Laboratory Flow Model 
The laboratory flow model was set up as shown schematically in Figure 97, below.   
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Figure 97: Shows a schematic diagram of the laboratory flow model: Data Acquisition Assistant (DAQ); 
Pressure Gauge (PG); Ultrasound (US) 
Direction of Flow
  
 
In summary an MCP-Z Standard gear pump, Ismatec with  Z-120 pump head, Ismatec, was connected to 
a reservoir containing water by 1/4" silicon tubing.  The pump was controlled using Labview software 
and Data Acquisition System (DAQ), National Instruments.  An example of the DAQ assistant is shown 
in Figure 98. 
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Figure 98: Shows an example of the DAQ assistant system which controls and collects data from the model 
 
 
 
The flow of water then passed through ¼” silicon tubing passing through the first pressure gauge, 
Ashcroft G2, Cole-Parmer, the flow meter, Transonic TS410, then the second pressure gauge, Ashcroft 
G2, Cole-Parmer.  This then passed through a pulse dampener.  This was made by drilling three holes 
into a rubber bung fitted tightly on a glass beaker.  A 1/8" to 1/4" male luer adaptor attached to the 
silicon tubing was inserted through the bung.   A second 1/8" to 1/4" male luer adaptor attached to 
another length of silicon tubing was inserted through another hole in the bung. The tubing inside the 
dampener reached the bottom of the liquid.  The third hole in the bung is an air vent.  The tubing leaving 
the dampener then passes to the reservoir, thus completing the flow circuit.  The actual laboratory set up 
is shown below in Figure 99. 
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Figure 99: Shows the flow model set up in the laboratory 
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8.2.2 Validation of Laboratory Flow Model 
 The velocity data obtained by ultrasound for each subject, described in Section 6.3 was used to validate 
the flow model.  The MCP-Z Standard gear pump, Ismatec with Z-120 pump head, Ismatec, was 
calibrated so that the input voltage, RPM and flow rate were known.  Subject specific simulations were 
performed.  The velocities obtained from the ultrasound images, those taken distal to the valves were 
used, and the voltage input to the gear pump calculated.  As such an input voltage which changed with 
time was given to the pump via the DAQ assistant.  An example of the voltage input in graphical form is 
shown in Figure 100. 
 
 
 
Figure 100: Shows an example of the voltage input in graphical form.  This represents subject 4, in the standing 
position with a calf squeeze and breath hold. 
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The actual flow velocity in the segment of the flow model was measured using a CX50 Philips ultrasound 
machine with a linear transducer with venous protocol.  The pressure gauges and flow meter collected 
data regarding the pressure and flow velocities in the subject specific models.  The voltage readings from 
both the pressure gauges and the flow meter were detected by the computer via the Data Acquisition 
System (DAQ), National Instruments, through Labview software.  These measured readings were then 
compared to the actual readings from the original subjects.   
  
8.3 RESULTS 
8.3.1 Flow Meter Calibration 
The flow meter, Transonic TS410, was calibrated to ensure that the output voltages received by the 
computer could be translated to the relevant flow data.  The RPM of the gear pump was generated by an 
input voltage from the computer through Labview software.  The voltage from the flow meter was 
received via the Data Acquisition System (DAQ), National Instruments, through Labview software. And 
the rate of flow was measured manually in millilitres per minute.  These values were compared as shown 
in Figure 101 and Figure 102 below.  The derived equations that were subsequently inputted to the 
labview software to calculate the measured velocity data are shown in each figure.  The R2 values for all 3 
measurements were >0.97 demonstrating consistent data readings. 
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Figure 101: Shows the flow meter calibration results comparing the pump RPM and the measured flow rate in 
ml/min 
 
 
 
Figure 102: Shows the flow meter calibration results comparing the measured flow rate in ml/min and the RPM of 
output voltage of the flow meter 
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8.3.2 Pressure Gauge Calibration 
 
The pressure gauge, Ashcroft G2, Cole-Parmer, was calibrated to ensure that the output voltages received 
by the computer could be translated to the relevant pressure data.  The vertical column containing a 
known height of water, attached above the pressure transducer, was measured.  This was compared to the 
the voltage reading from each pressure transducer, detected by the computer via the Data Acquisition 
System (DAQ), National Instruments, through Labview software.  These values were compared as shown 
in Figure 103 and Figure 104 below.  The derived equations that were subsequently inputted to the 
labview software to calculate the measured velocity data are shown in each figure.  The R2 values for the 
measurements were >0.99 demonstrating consistent data readings. 
 
Figure 103: Shows the calibration results for Pressure Gauge 1 showing the output voltage compared to the known 
pressure generated by the column of water 
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Figure 104: Shows the calibration results for Pressure Gauge 2 showing the output voltage compared to the known 
pressure generated by the column of water 
 
 
 
 
8.3.3 Validation of the Laboratory Flow Model 
 
The velocity data obtained by ultrasound for each subject, described in Section 6.3 was used to validate 
the flow model.  The MCP-Z Standard gear pump, Ismatec with Z-120 pump head, Ismatec, was 
calibrated so that the input voltage, RPM and flow rate were known.  These results are shown in Figure 
105. 
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Figure 105: Shows the calibration of the flow meter for voltage and RPM 
 
 
 
The subject specific simulations were performed.  The actual flow velocity in the segment of the flow 
model was measured using a CX50 Philips ultrasound machine with a linear transducer with venous 
protocol.  These were repeated five times by one observer.  The coefficient of variation for the maximum 
velocity measurements was 5.51% and for the mean velocity measurements was 6.67%.  These measured 
readings were then compared to the actual readings from the original subjects.  These have been 
compared with the data obtained from patients by Bland-Altman analysis.  Figure 106: Shows a Bland-
Altman analysis of maximum velocity measurements comparing the ultrasound data obtained from the 
subjects and the flow model demonstrating a bias of -25 (SD 34) and 95% limits of agreement from -92 
to 42.  Figure 107: Shows a Bland-Altman analysis of the mean velocity during the calf squeeze 
measurements comparing the ultrasound data obtained from the subjects and the flow model 
demonstrating a bias of -12.34 (SD 23) and 95% limits of agreement from -57.41 to 23.  Figure 108: 
Shows a Bland-Altman analysis of the mean velocity measurements comparing the ultrasound data 
obtained from the subjects and the flow model demonstrating a bias of -8.2 (SD 12) and 95% limits of 
agreement from -32 to 16.   
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 Figure 106: Shows a Bland-Altman analysis of maximum velocity measurements comparing the ultrasound data 
obtained from the subjects and the flow model 
 
 
 
 
Figure 107: Shows a Bland-Altman analysis of the mean velocity during the calf squeeze measurements comparing 
the ultrasound data obtained from the subjects and the flow model 
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Figure 108: Shows a Bland-Altman analysis of the mean velocity measurements comparing the ultrasound data 
obtained from the subjects and the flow model 
 
 
Figure 109: Shows a graph of the maximum velocity from the subject data and the flow model showing 
the mean and 95% confidence intervals demonstrating a Spearman correlation r=0.7, with p<0.0001 
reaching statistical significance.  This demonstrates that the agreement between the data obtained 
experimentally from subjects and frm the flow model regarding maximum velocity is good.   
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Figure 109: Shows a graph of the maximum velocity from the subject data and the flow model showing the mean 
and 95% confidence intervals demonstrating a Spearman correlation r=0.7 
 
 
 
Figure 110: Shows a graph of the mean velocity from the subject data and the flow model showing the 
mean and 95% confidence intervals demonstrating a Spearman correlation r=0.38, with p=0.04 reaching 
statistical significance.  This demonstrates that there is agreement between the data obtained 
experimentally from subjects and from the flow model, however this is less than the maximum velocity. 
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Figure 110: Shows a graph of the mean velocity from the subject data and the flow model showing the mean and 
95% confidence intervals demonstrating a Spearman correlation r=0.38 
 
 
 
 
8.3.4 Discussion 
Using readily available flow generators and variables obtained from in Chapter 6, a rig for the simulation 
of deep venous flow has been been developed. It includes a segment into which the conduit or implant to 
be tested may be incorporated into the circuit.  An image of the valve in the flow model is shown in the 
discussion regarding future work.  The subject specific simulations performed showed good consistency 
for the observer obtaiing the ultrasound images from the flow model.  When the measurements obtained 
from ultrasound of the subjects were then compared to the readings taken from the flow model, it was 
demonstrated that there was good agreement for the maximum and mean velocities, but there was a 
consistent bias whereby the data from the flow model seemed to overestimate the velocity when 
compared to the subject data.  This may be an inhernet error in the system as in the subjects, the velocity 
of blood was occasionally 0 cm/s, however, in our flow model, the minimum input voltage to the pump 
was 0.06 which generated slow flow in the model and therefore the velocity was never 0cm/s.  The 
278 
 
accuracy of the US is limited as two different US machines were used.  The patient data was obtained 
using a Phillips IU22, however, it was not possible to transport this to the laboratory and the smaller 
more mobile CX50 Philips ultrasound machine was used.  The standardised venous protocols on these 
machine were used, which may differ between the machines.  The operators were differwnt in both cases, 
which can lead to error.  In addition the readings taken by the flow model were taken directly from the 
tubing in the flow model.  In patients there are layers of skin, fat and muscle, the varying depth of which 
can have an impact on the results.   
This study has developed a laborator model of deep venous flow which has been validated using 
ultrasound and compared to subject specific data from subjects with normal deep venous function.   
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9. FUTURE WORK 
At each stage of the project there is further work that could be considered, and the results have 
demonstrated new avenues for further research. 
 
9.1 IMAGING OF THE VENOUS SYSTEM  
This study has used normal subjects to model deep venous function.  This project could be repeated with 
patients with deep venous disease.  The optimised US and MRI protocols could be repeated and used in 
the laboratory flow model.  This information could be used in the computational model and flow model 
to give further information about the management and even the pathophysiology of venous disease.  In 
addition, it was observed that the background venous flow when neither a calf squeeze nor respiration 
were playing a part, was pulsatile. This will be further studied in the literature and from the imaging 
performed in this study. 
 
9.2   DEVELOPMENT OF A COMPUTATIONAL MODEL 
OF VENOUS FLOW 
A computational flow model of deep vein valve function has been completed but further work is needed 
to develop a 3-dimensional model which will account for movements of the vein wall.  Further 
experiments can then begin by varying the valve structure and function of valves to assess the effect on 
flow dynamics.  Further collaboration will begin with Professor Jean-Francois Uhl, Paris Descartes 
University, France, who has extensive experience in CT venography, and utilising this for 3-Dimensional 
modelling of the venous system.  There is potential to combine the two models for further work.  The 
computational model developed can be extended to incorporate patients with abnormal deep veins to 
develop a “typical” model of the femoral vein with an incompetent valve to simulate abnormal venous 
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function.  Further patient-specific simulations could then be performed and deep venous reflux will be 
calculated and compared with ultrasound measurements for validation purpose. Differences in flow 
characteristics between normal and abnormal veins will be assessed in order to identify haemodynamic 
conditions that predispose to thrombus formation. This model will be developed into a 3-dimensional 
model.  Finally, prosthetic venous valves with a single cusp and double cusp leaflets will be built into a 
“typical” model of the femoral vein. Numerical experiments will be performed by varying the valve 
geometry (such as valve depth, leaflet to leaflet contact) and material properties and subsequently 
different valve-stent designs will be analysed. The first step involves simulation of stent deployment in 
deep veins using computational solid mechanics in order to predict the deformed configuration of the 
veins following stent insertion. A number of parameters will be examined; these include stent type and 
dimension, stent inflation pressure, and the way valve leaflets are attached to stent. The deformed 
configurations following stent deployment will then be used in the second step where haemodynamics 
analysis will be performed. The haemodynamic conditions identified as thrombus prone will be used to 
evaluate different stent designs and identify an optimal stent design that is likely to minimise the risk of 
thrombus formation can be determined.  This will require further funding and expertise in computational 
modelling to progress. 
 
9.3 DEVELOPMENT OF A LABORATORY FLOW MODEL 
The laboratory flow model can be further developed.  For example if it could be validated in the vertical 
position to incorporate the effects of gravity, this would further improve the study.  The image below 
shows the bicuspid valve of MPC-HPMA-TMSPMA in the flow model.  However the fixation into the 
model was problematic and further work is needed to improve its fixation into the model to allow it to be 
further investigated.   
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Figure 111: Shows the ultrasound image of the valve in the flow model 
 
 
 
 
9.4 DEVELOPMENT OF MPC-HPMA-TMSPMA 
 The material development will continue as it may be possible to further optimise it.  Its material 
properties could be improved, and its thrombogenicity may be further optimised, perhaps by 
incorporating a heparin into the material which would be slowly released over time.  Extracellular matrix 
could also be incorporated to encourage cell growth on the material.  Further cell studies are needed to 
ensure that the material can facilitate cell growth.   
282 
 
Once this has been completed, it is likely that industrial involvement will be necessary.  This will be to 
develop a valve stent device that can be deployed endovascularly.  This can be tested initially in the 
laboratory flow model and then animal studies can take place.  Following this, cell studies will be carried 
out to ensure that the material will support cell growth. 
 
9.5 POTENTIAL SECONDARY RESEARCH AVENUES 
In view of the huge incidence of chronic venous disease and deep vein valve failure, the potential future 
clinical impact of the work is significant. The development of a valve stent prosthesis as a minimally 
invasive clinical treatment modality will provide a treatment where few therapeutic options are currently 
available. There is immense potential to generate novel secondary research avenues as the subject of deep 
venous disease remains under researched. Some potential secondary research projects are listed below: 
• Identification of anatomical and other risk factors in patients with deep venous failure to develop 
clinical management algorithms 
• Adaptation of vein flow computer models to application in deep venous thrombosis 
• Exploration of new venous and arterial applications of materials developed for use in the valve 
stent prosthesis 
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Appendix 3 
Table 1: Subject 1 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 6.60 4.40 - 
Standing No Normal Within leaflets 17.46 4.92 - 
Standing No Normal 1cm distal 5.02 2.70 - 
Standing Yes Normal 2cm proximal 57.50 18.39 27.35 
Standing Yes Normal Within leaflets 53.50 18.20 27.88 
Standing Yes Normal 1cm distal 43.50 14.17 20.82 
Standing Yes Breath hold 2cm proximal 59.00 18.73 31.84 
Standing Yes Breath hold Within leaflets 48.50 16.69 27.94 
Standing Yes Breath hold 1cm distal 40.00 13.16 22.13 
Semi-recumbent No Normal 2cm proximal 21.91 15.14 - 
Semi-recumbent No Normal Within leaflets 21.43 12.65 - 
Semi-recumbent No Normal 1cm distal 20.48 10.33 - 
Semi-recumbent Yes Normal 2cm proximal 87.62 32.21 42.35 
Semi-recumbent Yes Normal Within leaflets 65.24 28.42 38.16 
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Semi-recumbent Yes Normal 1cm distal 74.76 25.51 40.75 
Semi-recumbent Yes Breath hold 2cm proximal 91.05 27.88 45.93 
Semi-recumbent Yes Breath hold Within leaflets 91.05 32.36 47.82 
Semi-recumbent Yes Breath hold 1cm distal 63.50 23.96 29.59 
 
Table 2: Subject 2 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 18.60 6.41 - 
Standing No Normal Within leaflets 15.44 7.16 - 
Standing No Normal 1cm distal 11.00 4.09 - 
Standing Yes Normal 2cm proximal 36.67 10.18 26.22 
Standing Yes Normal Within leaflets 40.35 9.96 21.39 
Standing Yes Normal 1cm distal 32.63 7.98 16.67 
Standing Yes Breath hold 2cm proximal 34.04 8.36 21.76 
Standing Yes Breath hold Within leaflets 37.54 10.99 23.37 
Standing Yes Breath hold 1cm distal 26.32 7.47 17.19 
Semi-recumbent No Normal 2cm proximal 26.32 12.08 - 
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Semi-recumbent No Normal Within leaflets 25.61 13.11 - 
Semi-recumbent No Normal 1cm distal 29.83 20.93 - 
Semi-recumbent Yes Normal 2cm proximal 58.95 22.28 35.48 
Semi-recumbent Yes Normal Within leaflets 54.74 17.32 29.62 
Semi-recumbent Yes Normal 1cm distal 42.81 16.10 26.14 
Semi-recumbent Yes Breath hold 2cm proximal 47.37 16.50 30.23 
Semi-recumbent Yes Breath hold Within leaflets 71.93 25.92 36.15 
Semi-recumbent Yes Breath hold 1cm distal 62.81 21.23 33.87 
 
Table 3: Subject 3 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 16.84 6.51 - 
Standing No Normal Within leaflets 18.11 8.72 - 
Standing No Normal 1cm distal 12.21 5.67 - 
Standing Yes Normal 2cm proximal 27.79 11.19 16.64 
Standing Yes Normal Within leaflets 41.68 17.36 25.89 
Standing Yes Normal 1cm distal 15.58 8.17 11.57 
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Standing Yes Breath hold 2cm proximal 28.63 9.87 13.08 
Standing Yes Breath hold Within leaflets 30.32 13.85 18.56 
Standing Yes Breath hold 1cm distal 21.77 9.88 1.65 
Semi-recumbent No Normal 2cm proximal 28.21 24.53 - 
Semi-recumbent No Normal Within leaflets 24.00 18.11 - 
Semi-recumbent No Normal 1cm distal 12.00 8.42 - 
Semi-recumbent Yes Normal 2cm proximal 76.50 29.83 47.85 
Semi-recumbent Yes Normal Within leaflets 60.00 22.29 32.19 
Semi-recumbent Yes Normal 1cm distal 36.00 17.05 21.16 
Semi-recumbent Yes Breath hold 2cm proximal 67.00 26.43 44.06 
Semi-recumbent Yes Breath hold Within leaflets 64.00 26.41 41.19 
Semi-recumbent Yes Breath hold 1cm distal 58.00 21.49 38.55 
 
Table 4: Subject 4 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 11.37 5.48 - 
Standing No Normal Within leaflets 12.94 7.99 - 
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Standing No Normal 1cm distal 18.43 3.12 - 
Standing Yes Normal 2cm proximal 54.90 6.83 25.63 
Standing Yes Normal Within leaflets 52.94 7.97 28.20 
Standing Yes Normal 1cm distal 49.41 7.47 22.32 
Standing Yes Breath hold 2cm proximal 51.77 5.92 23.16 
Standing Yes Breath hold Within leaflets 47.84 6.77 21.59 
Standing Yes Breath hold 1cm distal 42.69 6.03 20.40 
Semi-recumbent No Normal 2cm proximal 28.35 15.11 - 
Semi-recumbent No Normal Within leaflets 37.26 21.47 - 
Semi-recumbent No Normal 1cm distal 29.02 14.36 - 
Semi-recumbent Yes Normal 2cm proximal 100.39 22.14 45.57 
Semi-recumbent Yes Normal Within leaflets 102.75 24.27 46.46 
Semi-recumbent Yes Normal 1cm distal 85.49 27.59 48.21 
Semi-recumbent Yes Breath hold 2cm proximal 105.88 23.81 51.37 
Semi-recumbent Yes Breath hold Within leaflets 91.37 23.06 49.08 
Semi-recumbent Yes Breath hold 1cm distal 91.37 18.71 43.28 
 
Table 5: Subject 5 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
Maximum 
velocity 
Mean 
velocity 
Mean 
velocity in 
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valve  (cm/s) (cm/s) calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 16.86 8.28 - 
Standing No Normal Within leaflets 17.65 6.80 - 
Standing No Normal 1cm distal 11.77 4.07 - 
Standing Yes Normal 2cm proximal 36.03 11.97 17.80 
Standing Yes Normal Within leaflets 32.67 11.33 18.37 
Standing Yes Normal 1cm distal 17.60 4.08 10.19 
Standing Yes Breath hold 2cm proximal 41.11 10.80 23.07 
Standing Yes Breath hold Within leaflets 37.78 12.13 24.56 
Standing Yes Breath hold 1cm distal 25.30 6.44 14.35 
Semi-recumbent No Normal 2cm proximal 31.11 14.34 - 
Semi-recumbent No Normal Within leaflets 15.93 9.42 - 
Semi-recumbent No Normal 1cm distal 22.59 16.60 - 
Semi-recumbent Yes Normal 2cm proximal 93.23 39.24 61.32 
Semi-recumbent Yes Normal Within leaflets 85.85 32.79 44.65 
Semi-recumbent Yes Normal 1cm distal 80.00 27.46 50.25 
Semi-recumbent Yes Breath hold 2cm proximal 85.93 44.58 58.96 
Semi-recumbent Yes Breath hold Within leaflets 57.78 25.04 39.49 
Semi-recumbent Yes Breath hold 1cm distal 68.89 24.91 46.97 
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 Table 6: Subject 6 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 11.14 5.62 - 
Standing No Normal Within leaflets 13.17 6.14 - 
Standing No Normal 1cm distal 9.62 3.96 - 
Standing Yes Normal 2cm proximal 27.85 7.33 18.31 
Standing Yes Normal Within leaflets 29.00 11.91 19.99 
Standing Yes Normal 1cm distal 24.81 7.95 13.67 
Standing Yes Breath hold 2cm proximal 16.71 4.80 11.56 
Standing Yes Breath hold Within leaflets 29.37 8.55 19.58 
Standing Yes Breath hold 1cm distal 27.85 6.89 15.97 
Semi-recumbent No Normal 2cm proximal 16.20 9.67 - 
Semi-recumbent No Normal Within leaflets 18.73 9.03 - 
Semi-recumbent No Normal 1cm distal 17.72 8.89 - 
Semi-recumbent Yes Normal 2cm proximal 48.57 17.64 24.84 
Semi-recumbent Yes Normal Within leaflets 45.31 13.06 23.50 
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Semi-recumbent Yes Normal 1cm distal 34.69 13.34 21.33 
Semi-recumbent Yes Breath hold 2cm proximal 49.39 19.56 33.66 
Semi-recumbent Yes Breath hold Within leaflets 51.43 19.69 33.24 
Semi-recumbent Yes Breath hold 1cm distal 41.63 13.70 20.75 
 
Table 7: Subject 7 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 22.75 15.10 - 
Standing No Normal Within leaflets 15.69 10.42 - 
Standing No Normal 1cm distal 16.47 9.78 - 
Standing Yes Normal 2cm proximal 40.78 12.67 21.05 
Standing Yes Normal Within leaflets 34.90 11.04 18.03 
Standing Yes Normal 1cm distal 30.20 7.50 15.06 
Standing Yes Breath hold 2cm proximal 52.94 15.38 24.68 
Standing Yes Breath hold Within leaflets 33.73 11.04 17.78 
Standing Yes Breath hold 1cm distal 37.65 6.87 16.71 
Semi-recumbent No Normal 2cm proximal 18.43 12.30 - 
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Semi-recumbent No Normal Within leaflets 17.65 10.93 - 
Semi-recumbent No Normal 1cm distal 15.69 8.70 - 
Semi-recumbent Yes Normal 2cm proximal 100.00 26.13 54.57 
Semi-recumbent Yes Normal Within leaflets 101.57 29.73 53.34 
Semi-recumbent Yes Normal 1cm distal 94.51 24.27 48.48 
Semi-recumbent Yes Breath hold 2cm proximal 113.53 31.04 59.24 
Semi-recumbent Yes Breath hold Within leaflets 127.06 39.16 69.84 
Semi-recumbent Yes Breath hold 1cm distal 125.88 33.35 72.10 
 
 
Appendix 4 
Table 1: Subject 1 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 6.04 4.01 - 
Standing No Normal Within leaflets 17.12 4.99 - 
Standing No Normal 1cm distal 5.56 2.29 - 
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Standing Yes Normal 2cm proximal 55.12 20.70 26.12 
Standing Yes Normal Within leaflets 26.19 9.52 12.58 
Standing Yes Normal 1cm distal 41.95 19.07 22.67 
Standing Yes Breath hold 2cm proximal 59.51 20.13 32.58 
Standing Yes Breath hold Within leaflets 46.83 16.07 31.76 
Standing Yes Breath hold 1cm distal 38.05 17.88 24.22 
Semi-recumbent No Normal 2cm proximal 18.18 13.73 - 
Semi-recumbent No Normal Within leaflets 25.26 13.93 - 
Semi-recumbent No Normal 1cm distal 25.00 16.21 - 
Semi-recumbent Yes Normal 2cm proximal 73.68 32.95 48.00 
Semi-recumbent Yes Normal Within leaflets 71.80 32.75 44.51 
Semi-recumbent Yes Normal 1cm distal 85.41 31.60 46.77 
Semi-recumbent Yes Breath hold 2cm proximal 110.00 37.98 52.98 
Semi-recumbent Yes Breath hold Within leaflets 92.00 29.26 60.13 
Semi-recumbent Yes Breath hold 1cm distal 64.00 24.56 36.30 
 
Table 2: Subject 2 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
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(cm/s) 
Standing No Normal 2cm proximal 19.26 5.96 - 
Standing No Normal Within leaflets 17.36 10.79 - 
Standing No Normal 1cm distal 12.36 6.70 - 
Standing Yes Normal 2cm proximal 40.71 13.98 26.53 
Standing Yes Normal Within leaflets 31.34 11.51 14.72 
Standing Yes Normal 1cm distal 45.28 12.36 22.48 
Standing Yes Breath hold 2cm proximal 37.36 12.77 22.34 
Standing Yes Breath hold Within leaflets 40.00 14.85 24.93 
Standing Yes Breath hold 1cm distal 29.23 9.77 18.58 
Semi-recumbent No Normal 2cm proximal 29.06 16.26 - 
Semi-recumbent No Normal Within leaflets 23.64 13.61 - 
Semi-recumbent No Normal 1cm distal 32.22 22.68 - 
Semi-recumbent Yes Normal 2cm proximal 64.62 28.46 41.77 
Semi-recumbent Yes Normal Within leaflets 60.00 20.38 34.83 
Semi-recumbent Yes Normal 1cm distal 45.39 18.56 33.55 
Semi-recumbent Yes Breath hold 2cm proximal 49.81 19.00 33.30 
Semi-recumbent Yes Breath hold Within leaflets 78.49 28.07 51.38 
Semi-recumbent Yes Breath hold 1cm distal 70.77 23.12 44.61 
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Table 3: Subject 3 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 17.55 8.68 - 
Standing No Normal Within leaflets 19.57 7.77 - 
Standing No Normal 1cm distal 11.92 6.58 - 
Standing Yes Normal 2cm proximal 41.36 15.63 27.70 
Standing Yes Normal Within leaflets 34.43 15.34 24.35 
Standing Yes Normal 1cm distal 17.67 5.96 10.30 
Standing Yes Breath hold 2cm proximal 44.80 14.72 25.84 
Standing Yes Breath hold Within leaflets 40.40 15.11 27.78 
Standing Yes Breath hold 1cm distal 28.80 8.85 15.17 
Semi-recumbent No Normal 2cm proximal 23.20 16.01 - 
Semi-recumbent No Normal Within leaflets 17.20 9.00 - 
Semi-recumbent No Normal 1cm distal 23.92 17.57 - 
Semi-recumbent Yes Normal 2cm proximal 99.68 49.31 83.16 
Semi-recumbent Yes Normal Within leaflets 89.23 32.18 55.07 
Semi-recumbent Yes Normal 1cm distal 93.33 35.04 61.52 
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Semi-recumbent Yes Breath hold 2cm proximal 79.49 28.93 55.98 
Semi-recumbent Yes Breath hold Within leaflets 64.26 26.35 42.81 
Semi-recumbent Yes Breath hold 1cm distal 91.61 49.06 67.87 
 
Table 4: Subject 4 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 24.83 15.32 - 
Standing No Normal Within leaflets 16.21 10.48 - 
Standing No Normal 1cm distal 18.28 10.29 - 
Standing Yes Normal 2cm proximal 45.97 13.92 23.88 
Standing Yes Normal Within leaflets 37.90 11.94 21.66 
Standing Yes Normal 1cm distal 33.45 9.43 19.88 
Standing Yes Breath hold 2cm proximal 57.19 18.39 36.44 
Standing Yes Breath hold Within leaflets 35.00 11.50 19.22 
Standing Yes Breath hold 1cm distal 40.00 9.11 21.53 
Semi-recumbent No Normal 2cm proximal 19.31 12.89 - 
Semi-recumbent No Normal Within leaflets 17.00 11.83 - 
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Semi-recumbent No Normal 1cm distal 17.93 10.52 - 
Semi-recumbent Yes Normal 2cm proximal 109.31 29.86 64.94 
Semi-recumbent Yes Normal Within leaflets 112.98 36.83 65.16 
Semi-recumbent Yes Normal 1cm distal 100.00 24.83 52.54 
Semi-recumbent Yes Breath hold 2cm proximal 137.44 33.57 74.56 
Semi-recumbent Yes Breath hold Within leaflets 138.50 40.45 75.62 
Semi-recumbent Yes Breath hold 1cm distal 122.53 33.11 62.39 
 
Table 5: Subject 5 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 10.91 6.86 - 
Standing No Normal Within leaflets 13.33 6.15 - 
Standing No Normal 1cm distal 10.91 4.43 - 
Standing Yes Normal 2cm proximal 28.93 9.12 17.68 
Standing Yes Normal Within leaflets 32.00 12.81 23.37 
Standing Yes Normal 1cm distal 28.15 7.81 15.71 
Standing Yes Breath hold 2cm proximal 15.00 5.31 11.68 
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Standing Yes Breath hold Within leaflets 31.64 10.66 19.10 
Standing Yes Breath hold 1cm distal 29.29 8.26 15.64 
Semi-recumbent No Normal 2cm proximal 17.82 10.89 - 
Semi-recumbent No Normal Within leaflets 19.27 9.25 - 
Semi-recumbent No Normal 1cm distal 17.90 8.58 - 
Semi-recumbent Yes Normal 2cm proximal 52.17 18.58 29.86 
Semi-recumbent Yes Normal Within leaflets 50.59 14.86 25.79 
Semi-recumbent Yes Normal 1cm distal 36.06 14.40 22.59 
Semi-recumbent Yes Breath hold 2cm proximal 45.00 16.03 27.39 
Semi-recumbent Yes Breath hold Within leaflets 54.12 22.62 33.84 
Semi-recumbent Yes Breath hold 1cm distal 52.46 20.74 35.44 
 
Table 6: Subject 6 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
(cm/s) 
Standing No Normal 2cm proximal 18.31 9.95 - 
Standing No Normal Within leaflets 17.25 9.58 - 
Standing No Normal 1cm distal 11.93 5.61 - 
347 
 
Standing Yes Normal 2cm proximal 16.67 8.07 11.38 
Standing Yes Normal Within leaflets 44.14 18.65 28.79 
Standing Yes Normal 1cm distal 29.12 11.49 15.42 
Standing Yes Breath hold 2cm proximal 30.18 10.58 18.36 
Standing Yes Breath hold Within leaflets 30.69 15.00 19.59 
Standing Yes Breath hold 1cm distal 22.69 10.71 19.37 
Semi-recumbent No Normal 2cm proximal 28.00 25.82 - 
Semi-recumbent No Normal Within leaflets 26.43 19.11 - 
Semi-recumbent No Normal 1cm distal 12.36 9.10 - 
Semi-recumbent Yes Normal 2cm proximal 38.57 17.64 24.90 
Semi-recumbent Yes Normal Within leaflets 62.50 24.64 40.14 
Semi-recumbent Yes Normal 1cm distal 82.18 31.89 50.43 
Semi-recumbent Yes Breath hold 2cm proximal 74.18 31.13 47.49 
Semi-recumbent Yes Breath hold Within leaflets 71.43 29.71 44.60 
Semi-recumbent Yes Breath hold 1cm distal 63.27 24.99 40.74 
 
Table 7: Subject 7 maximum and mean velocities from ultrasound data 
Subject position Calf 
squeeze 
Respiration Position 
relative to 
valve  
Maximum 
velocity 
(cm/s) 
Mean 
velocity 
(cm/s) 
Mean 
velocity in 
calf squeeze 
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(cm/s) 
Standing No Normal 2cm proximal 12.542 5.83 - 
Standing No Normal Within leaflets 12.203 8.16 - 
Standing No Normal 1cm distal 19 5.33 - 
Standing Yes Normal 2cm proximal 49.84 9.80 23.56 
Standing Yes Normal Within leaflets 56.95 9.74 30.47 
Standing Yes Normal 1cm distal 61.03 10.30 24.57 
Standing Yes Breath hold 2cm proximal 56.21 11.43 25.22 
Standing Yes Breath hold Within leaflets 51.00 8.50 21.18 
Standing Yes Breath hold 1cm distal 53.22 8.20 22.63 
Semi-recumbent No Normal 2cm proximal 30.17 16.49 - 
Semi-recumbent No Normal Within leaflets 41.40 22.86 - 
Semi-recumbent No Normal 1cm distal 30.51 16.17 - 
Semi-recumbent Yes Normal 2cm proximal 92.54 29.49 53.45 
Semi-recumbent Yes Normal Within leaflets 112.54 27.40 52.21 
Semi-recumbent Yes Normal 1cm distal 110.69 28.69 50.42 
Semi-recumbent Yes Breath hold 2cm proximal 120.70 29.86 55.02 
Semi-recumbent Yes Breath hold Within leaflets 97.63 22.65 42.85 
Semi-recumbent Yes Breath hold 1cm distal 102.07 24.99 50.53 
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